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1.1 General Introduction 
 
Fungi are eukaryotic organisms that belong to the Kingdom Eumycota. Fungal diseases 
have gained much importance during the last decade due to the growing population of 
immunocompromised individuals with hematological malignances, solid organ 
transplants, hematopoietic stem cell transplants (HSCT), those receiving 
immunosuppressive therapy or broad-spectrum antibiotics or patients diagnosed with 
AIDS. Of the 50,000-250,000 species of fungi, only about 200 are associated with human 
disease, which is related to their ability to grow at body temperature. In general invasive 
infection is acquired from the environment by inhalation, ingestion or via traumatic 
inoculation. 
Prediction of in vivo outcome is difficult particularly with less common agents of disease. 
Only scattered information on antifungal susceptibility is available when rare fungal 
pathogens are involved. More importantly, taxonomic borderlines of such species may 
have been investigated insufficiently and may lack statistical support. Strains held under a 
particular name in a culture collection do not necessarily represent the core of that species 
as it exists in nature. Studies of its clinical behavior should therefore be preceded by a 
molecular verification of taxonomy and phylogeny of the entity to be studied. In many 
cases this will lead to significant taxonomic rearrangements, resulting in entities that 
consist of strains with the desired mutual resemblance in physiology, ecology and clinical 
potential. 
The most common invasive fungal infections are caused by yeasts such as Candida 
species or filamentous fungi such as Aspergillus species, other s are uncommon such as 
zygomycetes and Scedosporium species or rare such as Exophiala  and Cladophialophora 
species. 
Aspergillosis can be defined as damage to living tissue caused by species of Aspergillus. 
The damage may be caused by invasion of tissues, allergic mechanisms or colonization of 
cavities resulting in several diseases of which the severity depends on the state of the host 
defenses. Aspergillus is worldwide distributed and is abundant in the environment. The 
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conidia are frequently inhaled and therefore, the lung is the most frequently affected site. 
Individuals with normal defense mechanisms rarely  develop invasive disease. 
Neutropenia and the administration of high doses of corticosteroids are two major risk 
factors for the development of invasive aspergillosis (31). Invasive aspergillosis in 
transplant patients has a mortality of up to 90% depending on the patient group infected 
(37). The incidence of invasive aspergillosis is 20% in HSCT (38); 14 to18% in lung and 
heart-lung transplantation (23); 1.5 to14.7% in liver transplantation but can be as high as 
67% (7). The case-fatality rate was described as being 86.7% in HSCT (11) , 67.6% in 
liver and 62.5% in kidney transplant patients (20, 47).   
Members of the class zygomycetes also cause human disease. The main risk factors for 
developing invasive zygomycosis include diabetes with ketoacidosis, neutropenia, receipt 
of a transplant or administration of corticosteroids in patients with leukemia. The 
mortality in patients suffering from disseminated zygomycosis is 95% (2).Therapy failure 
may occur due to the divergent degrees of susceptibility of the fungus, therefore, accurate 
and rapid diagnosis are essential. Current treatment of invasive zygomycosis consists of 
high doses of amphotericin B and surgery. Other drugs such as the triazoles or the 
echinocandins appear not to be very active (21, 39). 
Dematiaceous fungi are characterized by the presence of melanin in the wall of hyphae 
and/or conidia. There are three orders of melanized fungi. The Pleosporales (e.g. 
Alternaria , Curvularia) are widely distributed in soil and on plant material. The Dothiales 
(e.g. Aureobasidium) are particularly found as colonizers of surfaces, such as stone, glass 
or plant leaves. Members of both orders are occasionally found as opportunistic on 
humans. The third order, the Chaetothryales, contain the pathogens black yeasts and their 
relatives, e.g. Exophiala, Cladophialophora and Fonsecaea. They are frequently involved 
in human mycoses, but their natural niche is hitherto insufficiently understood. These 
fungi may cause phaeohyphomycosis, chromoblastomycosis or black grain mycetoma 
(16, 30).They are widely distributed, particularly in wood, soil and other plant matter (36, 
41). In normal hosts, localized lesions of skin or subcutaneous tissues are involved. 
Sinusitis and pneumonia are being increasingly recognized and disseminated infections 
arise, particularly in immunocompromised patients including organ transplant recipients 
(43). Although rare, Exophiala spinifera is recognized as one of the most aggressive in 
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the group of black yeasts, with localized lesions in adults but disseminated infections in 
children or adolescents, always with a fatal outcome (10). 
Therapeutic measures used in cases of E. spinifera infection have been highly diverse and 
the optimal treatment is still in dispute (43). The efficacy of the currently used antifungal 
therapy regimens is variable since relapses have frequently been observed. (3, 18, 26, 32, 
35, 36). 
Scedosporium species are filamentous fungi with worldwide distribution and which may 
cause hyalohyphomycoses. They have been reported from white grain mycetoma, 
disseminated infections, CSF infection and subcutaneous infections (5, 9). With the 
increment of immunocompromised patients, the species can disseminate in patients such 
as those with hematological malignances (29) or organ transplant recipients (5). 
Particular ly, S. apiospermum has a predilection for the central nervous system (9).  
Given the poor responses to the above mentioned fungi novel approaches to improve 
outcome are clearly needed. Given the interaction between fungus, host and drug in 
relation to outcome (Figure), each can be used as target for novel approaches to 
management.  
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Antimicrobial agents 
 
The arsenal of agents used for antifungal therapy is limited compared with antibacterial 
drugs. The available drugs include polyenes, azoles and allylamines although new 
compounds are under investigation such as echinocandins, with exception of caspofungin 
that is already approved.  
Polyenes. The mechanism of action is the interaction of the antifungal with the 
membrane sterol, ergosterol, resulting in pores that form a channel, leading to altered 
permeability, leakage of vital cytoplasmic components and death of the microorganism. 
Amphotericin B represents the standard therapy for several systemic fungal infections. 
This drug is active against most Candida species, Cryptococcus neoformans, Aspergillus 
species, zygomycetes, dimorphic fungi and some dematiaceous fungi (28). 
Azoles. The target for azoles is the heme protein which catalyzes  cytochrome P-450 
dependent, 14a-demethylation of lanosterol. Inhibition of this enzyme leads to depletion 
of ergosterol and accumulation of precursors, resulting in the formation of a plasma 
membrane with altered structure and function (17). 
Itraconazole is a triazole used in humans with a broad spectrum of activity including 
Candida species, Aspergillus species, dimorphic and dematiaceous fungi. It is commonly 
used as prophylactic drug in patients at high risk for invasive aspergillosis. Since an 
intravenous formulation has become available, it is also used for primary treatment of 
invasive aspergillosis (6, 44, 45). 
Fluconazole is well absorbed and has a favorable toxicity profile but has a narrow 
spectrum of activity with reduced action against some non-albicans Candida species and 
moulds (19).  
Voriconazole a new triazole has a similar spectrum of activity as itraconazole. Other new 
azoles under investigation are ravuconazole and posaconazole that have been shown to be 
active against a broad range of yeasts and filamentous fungi (28).  
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Other antimicrobial drugs than antifungal agents 
Besides the currently used antifungal drugs , other agents have been shown to exhibit 
antifungal activity either alone or in combination with other drugs. 
Quinolones. These drugs have a broad spectrum of activity as inhibitors of a DNA 
gyrase, type II topoisomerase, that is present in prokaryotes and eukaryotes. The presence 
of high levels of topo-isomerase I and II was reported in pathogenic fungi (42). Although 
quinolones exhibit no antifungal activity, they have been shown to augment the activity 
of amphotericin B and azoles (33, 43). 
Phenotiazines. These compounds are antipsychotic agents that inhibit calmodulin 
leading to multiple cellular effects like modification of membranes, alteration of cyclic 
nucleotide metabolism and intercalation into DNA (24). Genetic studies suggest that 
calmodulin, is essential for growth of fungi (22). Phenotiazines have been reported to 
exhibit antibacterial and antifungal activity (1, 12, 44, 46). Of special interest is the 
observation that the cis-geometric stereoisomerism has antimicrobial and neuroleptic 
activity, whereas the trans-geometric stereoisomerism has only an antimicrobial effect 
(25) being an option for further investigation. 
 
 
Laboratory diagnosis 
 
The laboratory diagnosis of fungal infections includes standard techniques that include 
direct microscopic examination, culture, identification including macroscopic and 
microscopic examination, physiological characteristics, and molecular biological 
techniques such as genomic sequencing. Preferably microbiological identification of the 
fungal pathogen should be combined with histological examination of tissue in order to 
prove the fungal infection. 
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Correct and fast identification is very important in order to initiate treatment with the 
optimal drug promptly. Nevertheless, in neutropenic and transplant patients diagnosis of 
infections due to (uncommon) fungi may be difficult. In such cases therapy is given 
empirically or pre-emptively, awaiting the final diagnosis. 
For in vitro susceptibility testing  the National Committee for Clinical Laboratory 
Standards (NCCLS) provides a guideline for testing the activity of polyenes, flucytosine 
and azole antifungal agents against a number of conidium-forming filamentous fungi 
(34). The minimal fungicidal concentration (MFC) is in evaluation in order to find its role 
as a good parameter to predict the clinical outcome together with the MIC (15). 
In addition to testing the activity of single drugs, the study of drug interactions both in 
vitro and in vivo has gained interest given the increased arsenal of antifungal agents and 
the overall poor outcome of monotherapy. In vitro several tools are available including  
time kill methods, checquerboard techniques or E-tests (4, 27). 
The clinical usefulness of in vitro susceptibility testing results in treating fungal 
infections remains controversial, due to lack of correlation with clinical response for 
some drugs. Lack of correlat ion between in vitro and in-vivo results could be due to many 
factors. For instance, MIC is not a physical or chemical measurement, all in vitro tests are 
performed with conidial suspensions while hyphae are the form that is present in vivo , 
variation of pH or temperature, medium and incubation period might also have influence. 
Microorganisms are exposed to a constant level of the drug in in vitro systems while in 
vivo they are exposed to fluctuating levels of the antimicrobial agents, resulting in other 
possible factors for the observed lack of correlation. In addition, host factors are very 
important in determining clinical outcome. 
Therefore, in vitro tests do not always predict successful therapy in susceptible 
microorganisms. In bacteriology, the 90-60 rule has been put forward, indicating that 
90% of patients infected with a susceptible isolate will respond to appropriate therapy, 
whereas as much as 60% will respond when infected with an isolate resistant to the drug 
administered. It has been shown that this ratio is also applicable for yeasts (40).  
The post-drug-exposure effects are another point to take into consideration. This 
phenomenon was shown to be the cause for treatment success with certain drugs that 
were administered intermittently, even when the concentration of the drug fell below the 
MIC of the pathogen. The explanation was suggested to be the persistent suppression of 
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microbial growth after clearance of the drug. This effect was first described for bacteria 
and called post antibiotic effect (PAE), but was later also described for Candida species 
and C. neoformans where it was named as post-antifungal effect (PAFE) (8, 13, 14). The 
study of PAE provides additional information on the action of antimicrobial agents that 
can not be obtained from standard methods of susceptibility testing. 
The clinical significance of this effect has not been established, but could ha ve an impact 
on antimicrobial dosing regimens as was described for some antibiotics (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outline of the thesis 
 19 
 
 
References 
 
1. Amaral, L., and J. E. Kristiansen.  2000. Phenothiazines: an alternative to conventional 
therapy for the initial management of suspected multidrug resistant tuberculosis. A call for 
studies. Int. J. Antimicrob. Agents. 14:173-176. 
2. Anaissie, E. J., G. P. Bodey, and M. G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. 
Clin. Microbiol. Infect. Dis. 8:323-330. 
3. Barba-Gomez, J. F., J. Mayorga, M. R. McGinnis, and A. Gonzalez-Mendoza.  1992. 
Chromoblastomycosis caused by Exophiala spinifera. J. Am. Acad. Dermatol. 26:367-370. 
4. Berenbaum, M. C. 1989. What is synergy? Pharmacol Rev 41:93-141. 
5. Berenguer, J., J. L. Rodriguez-Tudela, C. Richard, M. Alvarez, M. A. Sanz, L. 
Gaztelurrutia, J. Ayats, and J. V. Martinez-Suarez. 1997. Deep infections caused by 
Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. 
Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore). 76:256-265. 
6. Boogaerts, M., J. Maertens, A. van Hoof, R. de Bock, G. Fillet, M. Peetermans, D. 
Selleslag, B. Vandercam, K. Vandewoude, P. Zachee, and K. De Beule. 2001. 
Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in 
neutropenic cancer patients. J. Antimicrob. Chemother. 48:97-103. 
7. Collins, L. A., M. H. Samore, M. S. Roberts, R. Luzzati, R. L. Jenkins, W. D. Lewis, and 
A. W. Karchmer. 1994. Risk factors for invasive fungal infections complicating orthotopic 
liver transplantation. J. Infect. Dis. 170:644-652. 
8. Craig, W. A., and S. Gudmunsson. 1991. Postantibiotic effect, p. 403-431. In M. E. Victor 
Lorian (ed.), Antibiotics in Laboratory Medicine., 3 ed. Williams & Wilkins., Baltimore. 
9. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic 
antifungal drugs. Clin. Pharmacokinet. 8:17-42. 
10. De Hoog, G. S., N. Poonwan, and A. H. G. Gerrits van den Ende. 1999. Taxonomy of 
Exophiala spinifera and its relationship to E. jeanselmei. Stud. Mycol. 43:133-142. 
11. Denning, D. W.  1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 
23:608-615. 
12. Eilam, Y., I. Polacheck, G. Ben-Gigi, and D. Chernichovsky. 1987. Activity of 
phenothiazines against medically important yeasts. Antimicrob. Agents Chemother. 31:834-
836. 
Chapter 1.2 
 20 
13. Ellepola, A. N., and L. P. Samaranayake. 1998. The postantifungal effect (PAFE) of 
antimycotics on oral C. albicans isolates and its impact on candidal adhesion. Oral Dis. 
4:260-267. 
14. Ernst, E. J., M. E. Klepser, and M. A. Pfaller. 2000. Postantifungal effects of 
echinocandin, azole, and polyene antifungal agents against Candida albicans and 
Cryptococcus neoformans.  Antimicrob. Agents Chemother. 44:1108-1111. 
15. Espinel-Ingroff, A., A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh. 2002. Testing 
conditions for determination of minimum fungicidal concentrations of new and established 
antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 
40:3204-3208. 
16. Fader, R. C., and M. R. McGinnis. 1988. Infections caused by dematiaceous fungi: 
chromoblastomycosis and phaeohyphomycosis. Infect. Dis. Clin. North. Am. 2:925-938. 
17. Ghannoum, M. A., and L. B. Rice. 1999. Antifungal agents: mode of action, mechanisms of 
resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. 
Rev. 12:501-517. 
18. Gold, W. L., H. Vellend, I. E. Salit, I. Campbell, R. Summerbell, M. Rinaldi, and A. E. 
Simor. 1994. Successful treatment of systemic and local infections due to Exophiala species. 
Clin. Infect. Dis. 19:339-341. 
19. Hughes, C. E., R. L. Bennett, I. C. Tuna, and W. H. Beggs. 1988. Activities of fluconazole 
(UK 49,858) and ketoconazole against ketoconazole -susceptible and -resistant Candida 
albicans. Antimicrob. Agents Chemother. 32:209-212. 
20. Husni, R. N., S. M. Gordon, D. L. Longworth, A. Arroliga, P. C. Stillwell, R. K. Avery, 
J. R. Maurer, A. Mehta, and T. Kirby. 1998. Cytomegalovirus infection is a risk factor for 
invasive aspergillosis in lung transplant recipients. Clin. Infect. Dis. 26:753-755. 
21. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, 
itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 
42:741-745. 
22. Joseph, J. D., and A. R. Means. 2002. Calcium binding is required for calmodulin function 
in Aspergillus nidulans. Eukaryot. Cell. 1:119-125. 
23. Kanj, S. S., K. Welty-Wolf, J. Madden, V. Tapson, M. A. Baz, R. D. Davis, and J. R. 
Perfect. 1996. Fungal infections in lung and heart-lung transplant recipients. Report of 9 
cases and review of the literature. Medicine (Baltimore). 75:142-156. 
24. Kantesaria, P., and P. Marfey. 1975. The effect of chlorpromazine on some properties 
DNA in solution. Physiol. Chem. Phys. 7:53-67. 
Outline of the thesis 
 21 
25. Kristiansen, J. E. 1990. The antimicrobial activity of psychotherapeutic drugs and stereo- 
isomeric analogues. Dan Med Bull 37:165-82. 
26. Lacroix, C., V. Barrazza, A. Levy, D. Brette, L. Dehen, C. De Bièvre, and M. Feuilhade 
de Chauvin. 1998. Lésions cutanées végétantes à Exophiala spinifera chez un patient 
immunodéprimé. Abstr. Réun. Soc. Fr. Mycol. Méd.:25. 
27. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser.  2002. 
Comparison of  Etest, checkerboard dilution and time-kill studies for the detection of synergy 
or antagonism between antifungal agents tested against Candida species. J Antimicrob 
Chemother 49:345-51. 
28. Loeffler, J., and D. A. Stevens. 2003. Antifungal drug resistance. Clin. Infect. Dis. 36:S31-
41. 
29. Marin, J., M. A. Sanz, G. F. Sanz, J. Guarro, M. L. Martinez, M. Prieto, E. Gueho, and 
J. L. Menezo. 1991. Disseminated Scedosporium inflatum infection in a patient with acute 
myeloblastic leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 10:759-761. 
30. McGinnis, M. R., and R. C. Fader. 1988. Mycetoma: a contemporary concept. Infect. Dis. 
Clin. North. Am. 2:939-954. 
31. Meyer, R. D., L. S. Young, D. Armstrong, and B. Yu. 1973. Aspergillosis complicating 
neoplastic disease. Am. J. Med. 54:6-15. 
32. Mirza, S. H., A. Hannan, A. Ahmad, and M. Ahmad. 1993. Subcutaneous 
phaeohyphomycosis. J. Infect. Dis. 27:75-78. 
33. Nakajima, R., A. Kitamura, K. Someya, M. Tanaka, and K. Sato. 1995. In vitro and in 
vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin 
B and fluconazole against pathogenic fungi. Antimicrob. Agents Chemother. 39:1517-1521. 
34. NCCLS. 2003. Reference method for broth dilution antifungal susceptibility testing of 
conidium-forming filamentous fungi; approved standard. Document M-38A. National 
Committee for Clinical Laboratory Standards, Wayne, PA. 
35. Padhye, A. A., L. Ajello, F. W. Chandler, J. E. Banos, E. Hernandez-Perez, J. Llerena, 
and L. M. Linares. 1983. Phaeohyphomycosis in El Salvador caused by Exophiala spinifera. 
Am. J. Trop. Med. Hyg. 32:799-803. 
36. Padhye, A. A., A. A. Hampton, M. T. Hampton, N. W. Hutton, E. Prevost-Smith, and M. 
S. Davis. 1996. Chromoblastomycosis caused by Exophiala spinifera. Clin. Infect. Dis. 
22:331-335. 
37. Paterson, D. L., and N. Singh. 1999. Invasive aspergillosis in transplant recipients. 
Medicine (Baltimore) 78:123-38. 
Chapter 1.2 
 22 
38. Peterson, P. K., P. McGlave, N. K. Ramsay, F. Rhame, E. Cohen, G. S. Perry, 3rd, A. I. 
Goldman, and J. Kersey.  1983. A prospective study of infectious diseases following bone 
marrow transplantation: emergence of Aspergillus and Cytomegalovirus as the major causes 
of mortality. Infect. Control. 4:81-89. 
39. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two 
echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of 
Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 
30:251-255. 
40. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. 
Infect. Dis. 35:982-989. 
41. Rossmann, S. N., P. L. Cernoch, and J. R. Davis. 1996. Dematiaceous fungi are an 
increasing cause of human disease. Clin. Infect. Dis. 22:73-80. 
42. Shen, L. L., and J. M. Fostel. 1994. DNA topoisomerase inhibitors as antifungal agents. 
Adv. Pharmacol. 29B:227-244. 
43. Singh, N., F. Y. Chang, T. Gayowski, and I. R. Marino. 1997. Infections due to 
dematiaceous fungi in organ transplant recipients: case report and review. Clin. Infect. Dis. 
24:369-374. 
44. Wang, D., R. Li, X. Wang, and W. Dai. 1987. Studies on three strains of Exophiala 
spinifera. Acta Mycol. Sin. 6:229-232.  
45. Wang, Y., and A. Casadevall. 1996. Susceptibility of melanized and nonmelanized 
Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and 
chloroquine. Antimicrob. Agents Chemother. 40:541-545. 
46. Wood, N. C., and K. M. Nugent. 1985. Inhibitory effects of chlorpromazine on Candida 
species. Antimicrob. Agents Chemother. 27:692-694. 
47. Yeldandi, V., F. Laghi, M. A. McCabe, R. Larson, P. O'Keefe, A. Husain, A. Montoya, and 
E. R. Garrity, Jr. 1995. Aspergillus and lung transplantation. J. Heart Lung Transplant. 
14:883-890. 
 
 
 
 
 
 
 
 
 
 
 
 
Outline of the thesis 
 23 
 
 
 
1.2 Outline of the thesis 
 
In order to gain more insight  in the potential of alternative approaches to the management 
of invasive mycoses, we investigated the in vitro activity of several drugs with antifungal 
activity against a selection of common and uncommon fungal pathogens.  
This study was carried out in terms of evaluation of the minimal inhibitory concentration 
(MIC), minimal fungicidal concentration (MFC) and drug interactions. Furthermore an in 
vitro  system was developed to study the post-drug-exposure effect of antifungal and non-
antifungal drugs against filamentous fungi and black yeasts. 
Since identification is very important as was highlighted above, we performed classic and 
molecular identification methods, using E. spinifera as a model, because the group of 
black yeasts are one of the most difficult to treat and to identify.  
The classical strategy against severe or resistant bacterial or viral infections has been 
combining different classes of antimicrobial agents. By analogy, the combination of 
antifungal drugs with other antifungal or antimicrobial agents could represent a promising 
approach. 
Chapter 2 is focused on the identification and susceptibility profile of the E. spinifera 
clade. In chapter 2-1 , identification was carried out using classic morphology, 
physiological profiles and molecular typing. Susceptibility profiles for sixteen clinical 
and environmental strains of E. spinifera were determined in chapter 2-2 , applying 
different incubation temperature regimens.  
Due to the long treatment needed and the often observed relapses of infections caused by 
black fungi combination of antimicrobial agents could represent a better approach than 
monotherapy. Therefore the in vitro combined effects of antifungal and antibiotic drugs 
using the checkerboard method was investigated in chapter 2-3. 
The standardized method to evaluate the activity of antifungal agents against filamentous 
fungi is static because the fungi are exposed to a constant level of drug. Given the fact 
that, in vivo , the organism is exposed to fluctua ting levels of antimicrobials  with drug 
levels that fall below the MIC , we simulated the in vivo situation in vitro by removing 
the drug by washing and determining if any effect persisted. PAFE is described in 
Chapter 1.2 
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chapter 2-2 for eleven clinical E. spinifera strains against four drugs and in chapter 3 for 
different antifungal and some other antimicrobial agents against different moulds. 
In chapter 3-1 , a method to evaluate PAFE against filamentous fungi is described and the 
effect of amphotericin B and itraconazole was evaluated against  fifteen clinical isolates 
of Aspergillus species. 
Based on this method, in chapter 3-2 , PAFE of amphotericin B and nystatin was 
evaluated in 30 clinical zygomycetes using two different media, RPMI -1640 and 
antibiotic medium 3 (AM3). 
In chapter 3-3 the activity and PAFE of chlorpromazine and trifluoroperazine was 
evaluated in species of Aspergillus , Scedosporium and zygomycetes. 
Since prophylaxis is often given to patients at risk of developing invasive aspergillosis, in 
chapter 3-4 Aspergillus species were pre-incubated up to eight weeks with sub-inhibitory 
concentrations of itraconazole, fluconazole and amphotericin B. Then, the MIC, MFC 
and PAFE was evaluated at each condition and was compared  with that of the wild-type 
strains. 
Finally, in chapter 4, a summarized conclusion of the results obtained in each chapter is 
given and possible future perspectives are addressed. 
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·  Molecular diversity, new species and antifungal susceptibilities in the 
Exophiala spinifera clade.  
·  In vitro activity of amphotericin B, itraconazole, terbinafine and 5-
fluorocytosine against Exophiala spinifera and evaluation of post 
antifungal effects.   
·  In vitro activity of amphotericin B and itraconazole in combination 
with flucytosine, sulfadiazine and quinolones against Exophiala 
spinifera.  
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Abstract 
 
 
Black yeasts morphologically identified as Exophiala cf. spinifera were re-analyzed on 
the basis of morphology, nutritional physiology and ITS rDNA sequencing data. 
Ribosomal small subunit (SSU) DNA sequence data confirmed that strains belonged to a 
clade containing the ex-type strain of E. spinifera. Variation in the Internal Transcribed 
Spacer (ITS) region of the rDNA was studied within this group. Five infraspecific groups 
were delineated. Phylogenetic analysis of the SSU rDNA data revealed that several of the 
strains analyzed were located at considerable evolutionary distance from the E. spinifera 
clade. ITS rDNA sequencing showed that the deviating strains could not be identified 
with any existing species. Two new species, E. attenuata and E. nishimurae, were 
therefore proposed. Antimycotic susceptibility data of the new species were compared 
with those obtained with members of the E. spinifera clade. 
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Introduction 
 
Black yeasts of the genus Exophiala are commonly found in association with 
environmental substrates, including soil as well as wood and other plant materials 
[1]. More often, however, they are encountered as agents of human mycoses in 
immunocompromised or debilitated patients [2], as well as in otherwise healthy hosts. 
The great majority of these infections are superficial, but rarely they may be devastating, 
fatal systemic infections [3]. In some species a predilection for particular patient groups 
seems to occur [4]. The pathology of the blackyeasts and their relatives is still poorly 
understood. 
Exophiala spinifera (Nielsen & Conant) McGinnis is among of the most 
aggressive species of the genus. Two types of mycoses caused by this taxon are apparent 
[5]. Adult patients reported thus far have generally had an underlying disease such as 
arthritis. Their lesions were of traumatic origin and remained localized with primary 
cutaneous or subcutaneous involvement [6,7]. In contrast, children and adolescent 
patients have lacked detectable constitutional disorders. Cases were disseminated and 
chronic, with severe secondary cutaneous lesions, and often took a fatal course after 3–6 
years [3,8,9]. 
This divergent clinical behaviour suggests taxonomic diversity within the species. 
However, only a limited number of voucher strains from published case reports are still 
available for study. De Hoog et al. [5] analyzed the E. spinifera complex by sequence 
comparison of the internal transcribed spacer (ITS) region of ribosomal DNA (rDNA). 
They also investigated nutritional physiology. In sequence dendrograms, E. spinifera was 
found to be flanked by a number of morphologically similar strains that were located at 
significant phylogenetic distance from the core group of the species. The present article 
aims to establish the identity of additional  clinical strains, including those matching the 
description of E. spinifera sensu stricto as well as deviating strains. The molecular 
variability within the E. spinifera complex was investigated and related taxonomic 
investigations were also performed.  
Haase et al. [10], using ribosomal small subunit (SSU) DNA phylogeny, 
described the E. spinifera complex as a statistically significantly supported monophyletic 
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group within the herpotrichiellaceous black yeasts. Most other species included in these 
authors’ tree showed insuficient resolution to be recognized separately. In principle, if all 
strains with an E. spinifera-like appearance turn out to be members of a single broad 
clade, they are likely to share a similar ecology and evolution and thus may have similar 
opportunistic potential. This is suficient reason to determine the SSU position of the 
deviating E. spinifera-like strains, in addition to using ITS sequences to resolve the 
species level disjunctions in the group.  
Since microscopic morphology alone is insufficient to allow routine laboratory 
identification of black yeasts and their relatives, we searched for additional key features 
in physiological profiles of the strains. In addition, susceptibility to six antifungal drugs 
was determined in order to compare the susceptibilities of deviating strains to patterns of 
susceptibility already recorded for E. spinifera [11]. 
 
Materials and Methods 
 
Fungal strains. The strains studied (Table 1) were grown on potato dextrose agar (PDA) 
at 24oC for 10 days.  
Morphology and physiology. Species names are attributed on the basis of preliminary 
morphological identification and corrected on the basis of molecular and physiological 
features. Microscopic morphology on Sabouraud’s glucose agar (SGA), malt extract agar 
(MEA) and PDA was verified before and after experimental data had been evaluated. 
Physiological methods applied have been described in detail by Untereiner et al. [12]. 
Thermotolerance was tested by incubation of freshly inoculated culture plates at 28, 37 
and 40oC. All tests were performed three times in duplicate. 
DNA extraction. About 1 cm2 of mycelium was transferred to a 2 ml Eppendorf tube 
containing a 2:1 (w/w) mixture of silica gel and Celite (silica gel H, Merck 7736 / 
Kieselguhr Celite 545, Machery) and 300 µl cetyltrimethylammonium bromide (CTAB) 
buffer [Tris HCl, 200 mM, pH 7.5, 200 mM Na-EDTA, 8.2% NaCl w/v, 2% CTAB w/v]. 
The mycelium was ground with a micropestle (Eppendorf, Hamburg, Germany) for 1–2 
min. Volume was adjusted by adding 200 µl CTAB buffer. After vigorous shaking, the 
sample was incubated at 65oC for 10 min. One volume (~500 µl) of chloroform was 
added and vortexed for 1–2 s. The samples were centrifuged at 14,000 rpm for 5 min. 
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After transferring the aqueous supernatant to a new Eppendorf tube, two volumes (~800 
ml) ethanol 96% -20oC were added and mixed gently. Samples were incuba ted at -20oC 
for 30 min or overnight and then centrifuged for 5 min at 14,000 rpm. The pellets were 
rinsed twice with 500 ml ice-cold ethanol 70%. After pellets were dried at room 
temperature they were resuspended in 48.5 µl TE-buffer (10 mM Tris, 10 mM Na-EDTA, 
pH 8.0) adding 1.5 µl RNAse solution (10 mg pancreatic RNAse in 1 ml 0.01 M 
Naacetate, pH 5.2). The pH was adjusted by adding 100 µl 1 M Tris HCl (pH 7.4). 
Samples were incubated 5–30 min at 37oC and refrigerated.   
 
DNA amplification. PCR was performed in 50 µl volumes of a reaction mixture 
containing 10 mM Tris HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2 *6H2O, 0.01% gelatin, 
200 µM of each deoxynucleotide triphosphate, 50 pmol of each primer, 10–100 ng rDNA 
and 0.5 U Taq DNA polymerase (Amplitherm, ITK Diagnostics, Maarssen, The 
Netherlands). 
Primers used were NS1, NS24, V9G and LS266 [2,13]. Forty amplification cycles were 
performed: denaturing 94oC, 30 s; annealing 58oC, 1 min; elongation 72oC, 30 s (with an 
initial delay of 1 min and a terminal delay of 2 min) in a GeneAmp 9600 thermocycler 
(Applied Biosystems, Nieuwerkerk a.d. IJssel, The Netherlands). If no amplicon was 
obtained the cycle was changed to 94oC, 1 min; 48oC, 1 min; 72oC, 2 min. Amplicons 
were cleaned using Microspin S-300 HR columns (Amersham Pharmacia, Roosendaal, 
The Netherlands). For sequencing, PCR conditions were as follows: 25 cycles with 
denaturing 96oC, 10 s; annealing 50oC, 5 s; elongation 60oC, 4 s, carried out with primers 
ITS1 or 5 and ITS 4. For SSU sequencing, primers NS1, Oli 1, 2, 7, 10, 11, 13, 14 and 
NS24 were used. Base compositions of all primers used are given by De Hoog et 
al. [2]. DNA was precipitated with ethanol and sequenced using an ABI PrismT M310 
Genetic Analyzer (Applied Biosystems).  
Alignment and phylogenetic analysis. Sequences obtained were adjusted using SeqMan II 
of Lasergene software (DNASTAR, Inc.) and aligned iteratively using Ward’s averaging 
in the BioNumerics package (Applied Maths, Kortrijk, Belgium). Nearest neighbours 
were found by local Blast searches. Distance trees were based on re-aligned files using 
the DCSE program [14] and calculated with the Neighbor-joining method of the 
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TREECON package [15] with Kimura correction. Bootstrap values 490 of 100 resampled 
datasets are shown. The inferred topology was verified using the same data in a 
phylogenetic tree constructed with PAUP version 4.0b8 [16] with heuristic search option 
(data not shown). 
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Antifungal susceptibility testing. Amphotericin B (AMB; Bristol-Myers Squibb, 
Woerden, The Netherlands), itraconazole (ITZ; Janssen-Cilag, Beerse, Belgium) and 
terbinafine (TBF; Novartis, Basel, Switzerland) were dissolved in dimethyl sulfoxide 
(DMSO), fluconazole (FLZ; Janssen-Cilag, Beerse, Belgium) and 5 fluorocytosine (5-
FC; Hoffman La Roche, Basel, Switzer land) in water and aliquots of the stock solutions  
were stored at -70oC until used. Solutions were diluted in RPMI 1640 medium with L-
glutamine and without bicarbonate (GIBCO BRL, Life Technologies, Woerden, The 
Netherlands) buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid (MOPS; 
Sigma-Aldrich, Steinheim, Germany). The range was 0.016–16 mg/ml for AMB, ITZ and 
TBF and 0.063–64 mg/ml for 5-FC and FLZ. 
Isolates were subcultured on PDA for 10 days at 28oC to obtain adequate 
sporulation. Conidia were collected with a cotton swab and suspended in saline with 
0.05% Tween 20. After the heavy particles had settled, 10 fold dilutions were made and 
conidial suspensions were adjusted microscopically by haemocytometer to 106 conidia 
per ml. Viability was conf irmed by plating serial dilutions on SGA culture plates. A broth 
microdilution method was performed according to NCCLS guidelines (M38-P [17]) using 
RPMI 1640 medium buffered to pH 7 with MOPS. The tests were performed in 96-well 
flat bottom microtitration plates (Corning, New York, NY, U.S.A) that were kept at   -
70oC until the day of testing. Conidial suspensions prepared as described above were 
diluted 1:50 in RPMI 1640 to obtain two times the desired inoculum. After the 
inoculation, the microtitration plates were incubated at 35oC and the MICs were read 
after at 72 and 96 h of incubation by a Rosys Anthos ht3 spectrophotometric reader 
(Anthos Labtex Instruments, Salzburg, Austria). The MIC for amphotericin B was 
defined as the lowest concentration of the drug that showed at least 95% reduction of 
growth compared with that of the growth control (MIC-0) by the following equation: 
[optical density (OD) 405 of wells that contained the drug / OD of the drug free well] X 
100%. For ITZ, TBF, FLZ and 5-FC the MIC was defined as the lowest concentration of 
the drug that showed 50% growth reduction when compared with the control (MIC-2). 
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Results 
 
Sequencing of 30 strains revealed five subgroups within E. spinifera (Table 2, Fig. 1).  
Informative variation was found in 14 of 196 positions (7.1%) in ITS1 and in 10 of 175 
positions (5.8%) in ITS2; the 157 positions of the 5.8S gene were identical in all strains. 
 
ITS sequences of strains IFM 41698, IFM 41700, IFM 41855, IFM 46115, IFM 
46117, UTMB 2670, UTMB 2674 and IP 2133.93, all morphologically identified as E. 
spinifera, were confirmed to deviate considerably from the E. spinifera ex-type strain, 
CBS 889.68. In order to establish the phylogenetic positions of these strains, SSU 
sequences were generated to determine the relationships of our strains with the previously 
established statistically supported E. spinifera clade [10]. 
In SSU sequence analysis, IFM 41698 was found to be located in the E. spinifera  
clade (data not shown), but its ITS sequence was too different from E. spinifera to allow 
meaningful alignment. The strain did not assimilate lactose and was weakly tolerant or 
intolerant to salts (5% MgCl2 or NaCl; Table 3).  
UTMB 2670 and 2674 were reidentified by ITS sequencing as E. jeanselmei 
(Langer.) McGinnis & A.A. Padhye (Fig. 1). IFM 41855 differed in 12 SSU sequence 
positions from the ex-type strain of E. spinifera, CBS 899.68 (data not shown). 
Physiologically it deviated from E. spinifera by being unable to assimilate meso-
erythritol and D-glucuronate (Table 3).  
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IFM 46115 was strongly divergent. A more conservative ribosomal region, the 
18S region, was sequenced. In this way, the strain was found to be located outside the E. 
spinifera clade, at a distance of 43 bases from the type strain, CBS 899.68 (data not 
shown). Two further strains, IP 2133.93 and UTMB 2905 had ITS sequences identical to 
that of IFM 46115.  
The ITS sequence of IFM 46117 (=CBS 101541) was found to be nearly identical 
to that of Capronia epimyces M.E. Barr (Fig. 1); seven ITS base substitutions and two 
length mutations were found in otherwise highly variable regions. This affinity was 
confirmed by showing sequence identify in the SSU (data not shown).  
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Discussion 
 
The molecular taxonomy of E. spinifera based on ITS rDNA analysis was outlined by De 
Hoog et al. [5]. These authors concluded that E. spinifera could be recognized as a 
relatively well-delimited species, but that a subgroup of three strains was discernible 
which differed from the ex-type strain, CBS 899.68, in 15 positions. This group 
contained the ex-type culture of Phaeococcomyces exophialae de Hoog, CBS 668.76. In 
the present study we noted considerable infraspecific variation within E. spinifera; the 
question is whether this is taxonomically significant. The degree of variability within ITS 
domains of fungal species is known to differ considerably. The ITS2 subunit within ITS 
may be somewhat less variable than the ITS1 subunit, as was noted by Lieckfeldt & 
Seifert [19] in some members of the Hypocreales. Matos et al. [18], studying 48 strains of 
E. dermatitidis (Kano) de Hoog, found that variability was found in 5 of 202 bases 
(2.5%) in ITS1 and 2 of 209 (0.9%) in ITS2. In the Microascaceae both ITS1 and 2 
showed very high, more or less equal rates of variability [20]. In contrast, in 
Aureobasidium pullulans (De Bary) Arnaud (Dothideales) ITS2 was 5 times more 
variable than ITS1 [21]. 
An explanation for these different degrees of variation is not available.  
In Table 1 the strains are arranged according to their sources of isolation, which 
can be categorized as (a) mammalian invasive disease, (b) dwelling sites of warmblooded 
animals, (c) environmental surfaces rich in polysaccharides, (d) decayed plant material, 
and (e) soil. There is no apparent correspondence between these ecological backgrounds 
and the different genotypes obtained. Hence we consider E. spinifera to be a unit, despite 
its intrinsic ITS variation. No distinction of infraspecific formal entities is necessary for 
any of its five subgroups, including the group containing the type of Phaeococcomyces 
exophialae (group 5). De Hoog et al. [5] hesitated about a possible varietal status of the 
latter because all the strains attributed to this group were yeast-like and lacked 
conidiophores. However, this can be ascribed to the more general phenomenon of 
predominance of particular synanamorphs within individual strains of E. spinifera (see 
below).  
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The SSU sequence of IFM 41698, a strain originating from soil in China, was 
found to be located in the E. spinifera clade, but the large differences in ITS sequences 
showed that a separate species was concerned. The isolate was slow -growing and 
consisted of yeast-like cells and very scant hyphae with intercalary conidiogenous cells; 
upon receipt for our study, no structures similar to E. spinifera conidiophores were 
detected. It had a characteristic physiological profile in that it was negative for lactose 
assimilation and weakly tolerant or intolerant to salts. Its identity as a new species is thus 
confirmed, but because of its nondescript morphology we prefer to wait for additional 
strains before formally introducing it as a new taxon. For similar reasons, IFM 41700 was 
excluded from further study.  
C. epimyces , a teleomorphic species with sequence similarity to our strain IFM 
46117 (=CBS 101541), is a member of the E. dermatitidis clade [18], clearly 
phylogenetically separate from the E. spinifera clade. The physiological profile of IFM 
46117 is similar to that of C. epimyces [12], but the former isolate is deviant in its ability 
to assimilate ribose and lactate. E. spinifera differs consistently from C. epimyces in its 
responses  to seven compounds (compare De Hoog et al. [5]). C. epimyces is known to 
have an Exophiala anamorph and may exhibit an additional Phialophora synanamorph 
[25], not found in the present strain. Morphologically the C. epimyces anamorph is 
reminiscent of Exophiala bergeri Haase & de Hoog but differs by the frequent 
occurrence of large chlamydospore-like structures that might be ascoma initials. It and E. 
bergeri are physiologically distinguishable by growth responses to Lrhamnose, sucrose, 
melibiose, raffinose, meso-erythritol, xylitol and D-gluconate (compare Table 3 with De 
Hoog et al. [2, 26]). Both are able to grow at 37oC [2]. 
IFM 41855, originating from tree bark in Venezuela, was found to be a separate 
member of the E. spinifera clade based on SSU sequence data. It was morphologically 
similar to E. jeanselmei [5]. The strain  was found to have a unique mtDNA profile [22]. 
Also it deviated physiologically from E. spinifera by being unable to assimilate meso-
erythritol and D-glucuronate. In the ITS tree (Fig. 1) IFM 41855 was located clearly 
separate from both E. jeanselmei and E. spinifera, and was well aligned (approx. 10% 
ITS difference) with CBS 725.88 (data notshown). The latter strain, originating from a 
cerebral infection and reported as ‘‘Exophiala sp.’’ by Tintelnot et al. [23] will described 
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as a new species in a forthcoming paper (G.S. de Hoog, unpublished results). IFM 41855 
is introduced below as a new species.  
Exophiala nishimurae Vitale & de Hoog, Sp. nov (Fig.2). Coloniae ad 7 mm 
diam. post 10 dies, atrae; microcoloniae confluentes radiatim sulcatae et in agaro modice 
submersae, siccae sed textura butyrosa. Cellulae germinantes et gemmantes absentes; 
mycelium torulosum paucissimum. Hyphae dense aggregatae, angulis acutis ramosae, 
aequaliter pallide olivaceae, 2–3 µm latae, ad intervalla 12–20 µm septatae. Cellulae 
conidiogenae houd differentes, sessiles, laterales vel terminales ramulis insidentes, 
anguste ellipsoideae, zona annellata brevissima. Conidia subhyalina, ellipsoidea, 3–4 x 
2.2–3.0 µm. Cellulae inflatae crassitunicatae, dilute olivaceo-brunneae, 
chlamydosporarum similes, ad 10 µm diam. partim formatae.  
Typus CBS 101538 in herb. CBS praeservatus.  
The following description is based on CBS 101538 (IFM 41855) after 10 d on 
SGA at 20–22oC:  
Colonies attaining a diameter of 7 mm, black, consisting of con•uent 
microcolonies leading to a soft felt with shallow radial fissures that are somewhat sunken 
into the agar, dry, with buttery texture. Germinating [27] and budding cells absent. 
Torulose mycelium nearly absent. Hyphae densely aggregated, branched at acute angles, 
evenly pale olivaceous, 2–3 µm wide, septate every 12–20 µm. Conidiogenous cells 
undifferentiated, sessile and lateral on hyphae, or terminal on short branches, narrow-
ellipsoidal, producing conidia from very short annellated zones. Conidia subhyaline, 
ellipsoidal, 3–4 - 2.2–3.0 µm. Locally thick-walled, pale olivaceous-brown 
chlamydospore-like cells up to 10 mm diam present in lateral or terminal position.  
Ex-type strain CBS 101538 = IFM 41855 (dried culture holotype in CBS 
herbarium), isolated from bark, Venezuela, K. Nishimura.  
E. nishimurae as well as E. bergeri are able to grow at 37oC [2]. The latter species 
is known from two strains, which both were isolated from subcutaneous mycoses in 
humans [24, 29]. It is likely that E. nishimurae will also prove to be able to cause 
infections in humans. The low incidence of the two species may partly be caused by 
underdiagnosis due to the difficulty of correctly identifying black yeasts.  
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IFM 46115, originating from soil in Colombia, was 18S-sequenced in the present 
study. The sequence was compared with others in a nearly complete 18S sequence 
database for all known black yeasts (a portion of these data were published by Haase et 
al. [10]). The isolate was found to fall outside the E. spinifera clade, clustering in a group 
with low bootstrap support along with Exophiala lecanii-corni (Benedek & Specht)  
 
Haase & De Hoog. De Hoog et al. [5] were unable to align much of the ITSdomain of 
IFM 46115 with that of E. spinifera, a problem that would be anticipated in organisms 
with this degree of SSU dissimilarity. These authors’ published tree containing these 
fungi was mainly based the 5.8S gene and small parts of the ITS domain. Further 
investigation in the present study revealed two more strains, IP2133.93 from a lesion on a 
cat’s nose [24] and UTMB 2905 from a human patient, with ITS sequences identical to 
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that of IFM 46115. These sequence data are surprising because at first sight the strains 
have the very characteristic morphology of E. spinifera, the only Exophiala species with 
large, erect and well-differentiated conidiophores. However, detailed morphological 
analysis of slide cultures showed that the deviating strains had conidiophores that were 
wide, thick- and dark-walled at the base and that tapered distinctly towards an apical 
region, terminating in a thin -walled, hyaline, very fragile conidiogenous cell. This cell 
had an inconspicuous annellated zone. In contrast, E. spinifera has cylindrical 
conidiophores with fusiform apical cells and very distinct annellated zones [2]. The 
atypical strains are physiologically different from E. spinifera in assimilating lactose and 
D-galacturonate but not myo-inositol (Table 3). The characters are judged sufficient to 
allow description of the strains as a new species, which will be introduced below. 
Exophiala attenuata Vitale & de Hoog, sp. nov (Fig. 3). Coloniae zymatoideae, ad 
12 mm diam. post 10 dies, minute cerebriformes, olivaceo-atrae, textura molli butyrosa; 
reversum olivaceo-atrum; coloniae hyphales ad 16 mm diam. post 10 dies, pulvinatae, in 
medio transverse sulcatae vel modice cerebriformes, deinde in medio diffractae et 
elevatae, locum aeratum sub agaro relinquentes, siccae, coactae, atro-griseae, marginem 
versus grisellae, reverso olivaceo-atro neque pigmentum exudantes. Cellulae gemmantes 
praesentes vel absentes, cellulae germinantes 7–9 x 4–7 mm; mycelium torulosum 
praesens vel absens. Hyphae obscurae et vulgo crassitunicatae, 2–4 m m latae, ad 
intervalla 12–20 µm septatae. Conidiophora erecta, ad basim 3 µm lata et crassitunicata, 
olivaceo-brunnea, sursum angustata et pallidiora, 70–100 µm alta, plerumque ter ad 
quinquies septata, saepe unum vel duos ramos vel cellulam conidiogenam ad quodque 
septum ferentia. Cellulae conidiogenae plerumque tenuitunicatae, subhyalinae, aculeatae 
vellageniformes, conidia e zona annellata brevi inconspicua proliferentes. Conidia 
(sub)hyalina, anguste ellipsoidea, 4–6 x 2–3 µm, deinde saepe inflata et dilute brunnea et 
crassitunicata. Phialides si praesentes ellipsoideae, collare terminale dilatatum e basi 
obscurata aperientes; phialoconidia hyalina, late ellipsoidea, minora quamannelloconidia, 
in capitulis densis adhaerentia. 
Typus CBS 101540 in herb. CBS praeservatus.  
The following description is based on CBS 101540 and CBS 101596 after 10 d on 
SGA at 20–22oC:  
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Yeast-like colonies attaining a diameter of 12 mm, finely cerebriform, olivaceous-
black, with a soft, buttery texture; reverse evenly olivaceous -black. Hyphal colonies 
attaining a diameter of 16 mm, cushion-shaped, evincing central transverse fissures or 
somewhat cerebriform, later centrally cracking, lifting up from the agar and building air 
spaces under the colony, dry, felty, blackish grey, dull grey towards the margin; reverse 
olivaceous-black. No blackish brown pigment exuded on any medium. Budding cells 
present or absent; germinating cells 7–9 x 4–7 µm. Torulose mycelium present or absent. 
Hyphae dark- and mostly thick-walled, 2–4 µm wide, septate every 12–20 µm. 
Conidiophores erect, 3 µmwide at the base, tapering towards the apex, basal part thick-
walled, olivaceous -brown, terminal part thinwalled, hyaline; conidiophores 70–100 µm 
high, mostly with 3–5 transverse septa, often bearing one or two lateral branches at acute 
angles at each septum, dark brown near the base, becoming (sub)hyaline at the tip. 
Conidiogenous cells mostly thin-walled, subhyaline, tapering or flask-shaped, producing 
conidia from inconspicuous annellated zones. Conidia (sub)hyaline, narrowly ellipsoidal, 
4–6 x 2–3 µm, later often swelling and becoming pale brown and thick-walled. Phialides, 
when present, ellipsoidal, each bearing a terminal, wide collarette with darkened basis; 
phialoconidia hyaline, broadly ellipsoidal, somewhat smaller than annelloconidia, 
adhering in dense clumps.  
 
Ex-type strain IFM 46115 = CBS 101540 (dried culture holotype in CBS 
herbarium), isolated from soil, Colombia; for additional strains, see Table 1.  
The E. attenuata  ITS domain deviates at 140 positions from that of E. spinifera. 
Morphologically, E. attenuata is distinct in having acicular conidiophores that are wide 
and thick-walled at the base, distinctly tapering towards the tip, with the upper half 
consisting of narrow, thinwalled and hyaline cells. In addition, the characteristic 
elongating annellated zones of E. spinifera are absent. Exophiala jeanselmei has single-
celled, rocket-shaped conidiophores. There is some superficial similarity to 
Phaeoacremonium [30], particularly in the acicular conidiophore shape, but 
Phaeoacremonium is phialidic. Kylindria and Xenokylindria [31] have robust 
conidiophores abruptly tapering in a terminal annellated zone; their phylogenetic position 
probably is among the Sordariales. 
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Two of our strains (UTMB 2905 and IFM 46115) converted into dry, filamentous 
growth with dark, thickwalled, strikingly curved cellular elements; the prevalent type of 
conidiogenesis in such cultures was phialidic rather than annellidic. Similar transition to 
preponderantly phialidic morphology is known in many black yeasts on nutritionally poor 
media [32,33]. The dry segregants were reminiscent of those described in E. jeanselmei 
as meristematic mutants [34]. In contrast, strain IP 2133.93 became more yeast-like with 
subculturing. This sudden preponderance of different types of growth and conidiation 
underlines the difficulties in morphological identification of black yeasts. Even the 
morphologically distinct species E. attenuata and E. spinifera can only be recognized 
when the annellidic anamorph is predominant.  
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The MICs of E. attenuata and E. nishimurae are summarized in Table 4; in Table 
5 the geometric means and ranges are compared with those of E. spinifera and P. 
exophialae. ITZ, VCZ and TBF were effective against both E. attenuata and E. 
nishimurae. Activities against E. spinifera and P. exophialae were in the same range.  
 
 
 
FLZ showed a low degree of dose-dependent activity, E. attenuata  being the most 
sensitive species. In contrast, AMB and 5-FC were least effective and showed variability 
among isolates. Therefore it will be appropriate to tes t susceptibility in any case isolates 
corresponding to this species prior to application of these drugs. It is apparent that in 
black yeasts susceptibility profiles may differ slightly with the species and may reflect its 
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phylogenetic position [35]. Proper identification at species level is recommended before 
onset of antimycotic therapy, at least in laboratories where access to rapid molecular 
techniques makes this practicable. 
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Summary 
 
Antifungal susceptibility profiles were determined for sixteen strains of the black yeast 
Exophiala spinifera applying different temperature regimens. Fluconazole was the least 
effective in vitro. Lowest minimal inhibitory concentration (MIC) values were found with 
itraconazole. The activities of antifungal agents against environmental and clinical strains 
were similar. Post antifungal effect (PAFE) of four drugs was determined for 11 clinical 
strains. PAFE was observed only for amphotericin B, with extended inhibition times seen 
at high drug concentrations. 
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Introduction 
 
Black yeasts and their filamentous relatives in the order Chaetothyriales are found in the 
environment in a diversity of niches such as soil, fresh water, fungal fruiting bodies, 
moist tiles, surfaces of fruits, and creosote-treated wood. Their abundance is usually very 
limited, however, and they are therefore isolated only when selective techniques are 
applied. In comparison with this low density in nature, the occurrence of these fungi in 
clinical settings is remarkably high. Currently thirty species have been reported to be 
involved in mycoses of humans and other vertebrates [1]. In the past, the slow-growing 
black colonies of Chaetothyriales were frequently discarded as purported saprobic 
contaminants, but it is increasingly realized that these fungi may be the primary cause of 
a wide array of infections. The mycoses reported range from mild cutaneous forms to 
devastating systemic infections that are mostly fatal.  
Exophiala spinifera is known as etiologic agent of disseminated infection [2], 
causing chronic systemic infections with disfiguring secondary cutaneous lesions in 
children and adolescents. Such infections are nearly always fatal [3-5]. However, about 
half of the strains held in collections were recovered from the environment [6]. Direct 
transmission from environmental sources to the symptomatic patient has as yet not been 
proven. Two possibilities exist. Clinical strains may be genotypically different from their 
environmental counterparts, e.g., in virulence, thermotolerance, ability to grow in 
submersion, or susceptibility to antimycotics. Alternatively, environmental strains may 
have genetic make-up and pathogenic potential similar to those of their clinical 
counterparts, and their occurrence in a habitat other than a human host may be 
coincidental. Clinical and environmental strains of the same species then should be 
treated with similar precautions. One of the aims of the present study is to investigate 
whether there are differences in antifungal drug susceptibility between strains from the 
environment and strains from proven cases of human infection.  
 The correlation between minimal inhibitory concentration (MIC) values obtained 
according to criteria of the National Committee of Clinical and Laboratory Standards [7] 
and the clinical response of infected patients remains problematic. MIC values, 
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determined in a system in which the fungus is exposed to a constant drug concentration, 
may be misleading with regard to the in vivo situation, where organisms usually 
experience fluctuating drug levels [8]. Using an animal model for Aspergillus infection, it 
was found that this in vivo fluctuation is especially important in amphotericin B therapy, 
but less important for itraconazole and voriconazole treatment [8]. 
The study of post antifungal effects (PAFE) could be helpful in determining the 
overall effect of antifungal drugs, since such studies simulate the in vivo situation which 
of fluctuating drug levels occur. In the present study, antifungal drug susceptibilities were 
studied comparing environmental and clinical strains. PAFE was also evaluated, being 
the first study of this effect in a member of the “black yeasts” (anamorphic 
Herpotrichiellaceae), exemplified by Exophiala spinifera strains.  
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Materials and methods 
Strains and chemicals 
Eight clinical and eight environmental well documented isolates of Exophiala spinifera 
were used (Table 1). For PAFE 3 more clinical isolates were added. Drugs tested were 
amphotericin B (AMB) (Bristol-Myers Squibb, Woerden, The Netherlands), itraconazole 
(ITZ) (Janssen-Cilag, Beerse, Belgium), voriconazole (VCZ) (Pfizer Central Research, 
Sandwich, United Kindgdom), terbinafine (TBF) (Novartis, Basel, Switzerland), 
fluconazole (FCZ) (Pfizer Central Research, The Netherlands) and 5-fluorocytosine (5-
FC) (ICN Pharma BV, Zoetermeer, The Netherlands). Aliquots of stock solutions were 
stored at –70ºC until used. All drugs with the exception of FCZ were dissolved in 
dimethylsulfoxide (DMSO) at concentrations of 3200 µg/ml or 3.2 mg/ml for AMB, ITZ 
and TBF, 12800 µg/ml for 5-FC, and 1600 µg/ml for VCZ. FCZ was dissolved in water 
at concentration of 25600 µg/ml. Two fold serial dilutions of the drugs were made in 
RPMI-1640 medium (GIFCO BRL, Woerden, The Netherlands) in order to obtain final 
concentrations that ranged from 0.015 to 16 µg/ml for AMB, ITZ and TBF; 0.063 to 64 
µg/ml for 5-FC and 0.125 to 128 µg/ml for FCZ. RPMI 1640 medium (with L-glutamine, 
without bicarbonate) was buffered to pH 7.0 with 0.165 M morpholinopropansulfonic 
acid (MOPS) (Sigma-Aldrich, Steinheim, Germany).  
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Table 1. Source and numbers of the strains tested. For detailed isolation data, see De 
Hoog et al. [6] and Vitale & De Hoog [13]. 
 
CBS Other 
reference 
Source 
425.92  Heated apple juice 
 dH 11324 Maize 
236.93  Apple juice 
669.76  Palm fruit 
 IFM 41692 Bark 
 IFM 41856 Soil 
 IFM 41846 Cactus 
667.76  Fallen palm 
194.61  Disseminated 
899.68 ATCC 18218 Nasal granuloma 
 dH 11328 Skin 
 dH 11326 Skin 
356.83  Skin 
 dH 12309 Chromoblastomycosis
 dH 11327 Head lesion 
269.28  Skin 
 
Abbreviations used: ATCC = American Type Culture Collection, Manassas, U.S.A.; CBS = 
Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands; dH = G.S. de Hoog private 
collection; IFM = Research Institute for Pathogenic Fungi, Chiba, Japan. 
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Susceptibility testing 
Isolates were subcultured serially at intervals of 5-7 days at 28ºC on potato dextrose agar 
(PDA) to obtain adequate sporulation. Conidia were collected with a cotton swab and 
suspended in saline with 0.5% Tween 20. After the heavy particles were allowed to settle, 
concentrations of conidia were determined microscopically by haemacytometer and 
adjusted to obtain a suspension of 106 conidia/ml. Viability was confirmed by plating 
serial dilutions on Sabouraud glucose agar (SGA) incubated at 28ºC and determining 
colony counts. Inocula were prepared from conidial suspensions diluted 1:100 to a final 
concentration of 0.5 x 104  to 4.5 x 104 colony forming units (CFU) per ml.  
A broth microdilution method was applied according to the NCCLS guideline M38-P [7]. 
Tests were performed in 96-well flat-bottom microtitration plates (Corning, Ames, MA, 
U.S.A.) which were kept at -70ºC until the day of testing. Conidial suspensions were 
diluted in RPMI 1640 to obtain two times the desired inoculum concentration. A drug-
free well containing 0.01% DMSO in the medium served as the growth control. Plates 
were incubated at 28, 35 and 37ºC for 48, 72 and 96h. The MICs were determined using a 
spectrophotometric reader (Rosys Anthos ht3, Anthos Labtex, Salzburg, Austria). The 
relative optical densities (ODs) for each well based on measurements at 405 nm were 
calculated (in percent) based on the following equation: [(OD of drug-containing well – 
background OD)/(OD of drug-free well – background OD)] x 100%. The MIC for 
amphotericin B was defined as the lowest concentration of the drug that showed at least 
95% reduction of growth compared with that of the growth control (MIC-0). For the 
remaining drugs, the MIC was defined as the lowest concentration of the drug that 
showed 50%  reduction of growth compared with that of the growth control (MIC-2). All 
assays were done in duplicate. 
 
PAFE assay 
For PAFE 11 clinical isolates of E. spinifera were tested with AMB, ITZ, TBF and 5-FC 
applying the method adapted for use in filamentous fungi [9]. AMB, ITZ, TBF were 
dissolved in DMSO at initial concentrations of 400 µg/ml and 5-FC in water at an initial 
concentration of 3200 µg/ml. Stock solutions were stored at –70ºC until used. Then they 
were diluted in buffered RPMI 1640 medium. Serial dilutions of the drugs were made in 
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buffered RPMI 1640 at final concentrations of 4x and 1x the corresponding MIC for each 
strain for AMB and 5-FC, and 10x the MIC for ITZ and TBF. Control conidial 
suspensions were made in buffered RPMI 1640. Inocula were prepared as described 
above. The concentration of conidia was established microscopically by 
hemotocytometer Bürker-Türk chambers. Final concentration was adjusted to 4 x 105 
CFU/ml. Samples were incubated for 4 h with continuous shaking at 37ºC, washed three 
times with saline and centrifuged at 3,500 x g for 15 min. 98% of the supernatant was 
decanted and the sediment was resuspended in 10 ml buffered RPMI-1640. A procedure 
with two washings and removal of 90% of supernatant has been shown to reduce the 
antimicrobial concentration 100-fold, while with two washings and complete decanting 
the concentrations are reduced 10,000-fold [10]. Following this step, 100 µl of sample 
was diluted 10-fold in sterile water and 30 µl aliquots were plated on SGA for colony 
count determination, and incubated at 37ºC. The concentration of viable CFU/ml for 
exposed conidia was determined in order to verify the viability after drug exposure and to 
compare the CFU/ml  both control with exposed cells. 200 µl of the resuspended 
suspensions were transferred to microtitration plates which were incubated at 37ºC in a 
computerized spectrophotometric reader (Rosys Anthos ht3, Anthos Labtex Instruments 
GmbH, Salzburg, Austria). Growth measured as change in turbidity at 405 nm was 
monitored automatically at 10 min intervals for 96 h. All assays were performed in 
duplicate. 
 
Data analysis 
Effects of drugs at different temperatures and incubation periods were analyzed 
for each isolate group (environmental and clinical) by ANOVA (Friedman test) and 
comparison between these by T-test (Mann Whitney test). P values of <0.05 were 
considered to be statistically significant. 
PAFE was calculated using the point in the growth curve (OD0 ) that corresponds 
with the first significant increase in OD as was described previously [9] by using the 
formula PAFE = T - C, where T was the time of the first significant increase in OD0 of 
the exposed spores after removal of the drug and C was the time of the first significant 
increase in OD0 of the control. Thus, PAFE was defined as the difference in time (∆t) 
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between exposed and controls to reach the defined point in the growth curve and was 
expressed in hours. The time to reach this chosen point OD0 of at least 6 controls for each 
species was calculated and the mean, range, upper 95% confidence interval (CI) and the 
coefficient of variation were calculated in order to determine the reproducibility of the 
control curves at that point and to establish the reproducibility of the experiments. For 
each species the upper 95% CI of the controls was chosen as the cut-off level that 
distinguished between presence or absence of PAFE.   
When re-growth of the exposed isolates occurred within the upper 95% CI time-
frame of the controls, PAFE was considered to be absent. Alternatively, if re-growth was 
delayed following drug exposure and the lower 95% CI of the exposed isolates was 
delayed until beyond the upper 95% CI of the controls, PAFE was considered to be 
present. Growth curves of each exposed isolate were compared only with pooled controls 
from that same isolate. 
 
Results 
 
The geometric means and the range of MICs obtained after 72h are given in Table 2. No 
significant differences were found in MICs after 72 and 96h of incubation (data not 
shown). The most active drug was ITZ against both environmental and clinical strains 
regardless of the temperature of incubation with geometric mean 0.04 and 0.06 µg/ml, 
respectively. VCZ (G means 0.4 and 0.2 µg/ml, respectively) and TBF (G mean 0.2 and 
0.3 µg/ml, respectively) at 35ºC were also inhibitory. AMB susceptibility values varied 
among the isolate classes, environmental and clinical, with G mean at 35ºC of 0.3 for 
environmental isolates and 0.9 for clinical isolates. Differences were also seen in 5-FC 
values which were 1.83 for environmental and 5.66 clinical isolates. FCZ showed little 
effect but some strains showed MIC values of 8-16 and 32 µg/ml at all temperatures.  
Statistical analysis was performed for each drug under different incubation 
regimens. Susceptibilities of environmental strains tested (a) after incubation periods of 
72 and 96h were compared at 28, 35 and 37ºC. The same was done (b) among the clinical 
strains, and finally pooled data of environmental and clinical strains (c) were compared: 
for (a) and (b) no statistically significant differences were observed (P>0.05); for (c) no 
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statistically significant differences were found between incubation periods, but a 
temperature-related difference was observed with AMB (P<0.05) between environmental 
and clinical strains.  
 
 
Eleven clinical isolates were selected for PAFE experiments. The MIC range were 
from 0.5 to 2 µg/ml for AMB, from 0.031 to 0.125 µg/ml for ITZ, from 0.063 to 0.5 
µg/ml for TBF and from 0.5 to 64 µg/ml for 5-FC. When PAFE was present the growth 
curve of the exposed conidia shifted to the right compared with that of the control (Fig. 
1). After 4 h of incubation at 4x MIC all strains displayed significant PAFE with AMB 
with a mean of 16.2 h and a range of 9.7 to 19 h. An example of PAFE observed in strain 
dH 12309 is shown in Fig. 1. For 1x MIC, 7 out of 11 strains tested showed PAFE, with a 
mean of 9.8 h and a range of 1.6 to 16 h (Table 3). For the other drugs PAFE was not 
observed (data no shown). The growth curve after exposure to ITZ for strain dH 12309 is 
given in Fig. 2 where PAFE was not observed at 4 and 10 times the MIC.  
 
 
 
 
 
 
Table 2. MICs of environmental and clinical strains at different temperatures after 72 h. 
 Gm: geometric mean. 
 
Drugs Environmental Clinical 
28ºC 35°C 37ºC 28ºC 35ºC 37°C  
Gm Range Gm Range Gm Range Gm Range Gm Range Gm Range 
AMB 0.77 0.125-4 0.35 0.125-0.5 0.59 0.125-2 1.30 0.25-4 0.92 0.5-2 1.09 0.5-4 
FCZ 26.91 16-64 41.50 16-128 38.05 16-64 32.00 8-64 45.25 16-128 38.05 8->128 
VCZ 0.25 0.125-0.5 0.46 0.125-4 0.25 0.063-0.5 0.28 0.031-1 0.27 0.031-0.5 0.25 0.063-0.5 
TBF 0.12 0.031-0.5 0.25 0.031-2 0.30 0.031-1 0.63 0.5-1 0.30 0.031-1 0.35 0.063-1 
5-FC 3.17 1-8 1.83 0.125-64 1.83 0.25-16 2.69 0.25-16 5.66 0.5-64 5.19 1-16 
ITZ 0.02 0.016-0.031 0.04 0.016-0.125 0.05 0.016-0.125 0.07 0.031-0.125 0.06 0.031-0.125 0.05 0.016-0.125
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Table 3. PAFEs induced by exposure of Exophiala spinifera to amphotericin B at 
concentrations of 4 and 1 times the MIC, after 4 h of exposure using OD0
criteria. 
Strain Control
(U 95% CI)
4x MIC
(L 95% CI)
PAFE (h) 1x MIC
(L 95% CI)
PAFE ( h)
12309 35.6 47.9 18.4* 36.1 7.7*
194.61 40.6 43.4 19.0* 43.9 16.0*
12308 55.7 62.0 10.7* 54.5 6.2
12301 56.7 57.4 9.7* 54.1 8.9
356.83 39.0 47.4 19.0* 42.8 13.5*
12304 46.3 57.9 19.0* 49.6 14.5*
11328 42.3 49.9 18.6* 49.0 13.1*
899.68 57.7 63.9 16.4* 59.3 10.6*
11327 12.2 25.3 16.5* 10.5 10.2
12312 18.1 34.7 13.0* 18.7 6.0*
269.28 24.8 39.3 18.0* 13.3 1.6
U 95% CI: Upper 95% confidence interval
L 95% CI: Lower 95% confidence interval
*: statistically significant PAFE
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Discussion 
 
Our antimycotic susceptibility data for AMB and VCZ are similar to those given by 
McGinnis & Pasarell [11], but we obtained higher susceptibility values for ITZ. Our ITZ, 
TBF, VCZ and AMB MIC values matched those of Meletiadis et al. [12].  
Since Exophiala spinifera is encountered in soil and in association with plant 
material such as maize ears and fruit juices , it is presumably a saprotrophic fungus. 
However, about half of the strains collected to date were obtained as agents of skin and 
soft-tissue infections or of fatal, systemic infections [6]. Traumatic cutaneous or 
subcutaneous infections have mainly been observed in adults, while systemic cases for 
which no portal of entry has been defined, have occurred only in children and 
Fig. 1. PAFE of 18.4 h observed in strain dH 12309 after exposure to amphotericin B for 
 4 h at 4 times the MIC. 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 2. PAFE absent from strain dH 12309 after exposure to itraconazole for 4 h at 4 times the 
MIC. The same graph was obtained after exposure to drug at 10 times the MIC. 
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adolescents. This remarkable ecological and clinical spectrum of E. spinifera raises the 
possibility that some strains may be more tolerant than others of higher temperatures. Our 
results, however, show that susceptibilities to antifungal agents generally were not 
influenced by temperature. The only exception was a small but statistically significant 
difference in activity of AMB at different temperatures (table 2). This deviation was 
based on a single difference of two dilution steps.   
Recently we described a new species, E. attenuata, which is morphologically 
similar to E. spinifera and which as yet has not been reported to cause infection in 
humans [13]. Whether it has an opportunistic potential to humans similar to that of E. 
spinifera is not known. The close phylogenetic kinship of the two fungi suggests this 
potential. The etiologic agent of a case in a cat ascribed to E. spinifera by Chermette et 
al.[14] was later recognized to be E. attenuata by Vitale & De Hoog [13]. The 
significance of phylogeny for predicting the clinical significance of fungal species was 
stressed earlier by De Hoog [15] and McGinnis & Pasarell [11]. De Hoog [16] used 
phylogenetic relationships with known human pathogens as one of the criteria to assign 
fungal species to a particular BioSafety Level. In view of this predicted opportunistic 
potential we included environmental E. spinifera isolates in our study. 
Therapeutic measures used in cases of E. spinifera infection have been highly 
diverse, including surgical excision, systemic use of antifungals, or a combination of 
both. Relapses have frequently been observed, and therefore long-term antimycotic 
therapy seems mandatory. The optimal treatment is still in dispute [17], the efficacy of 
applied antifungal therapy regimens is variable. Rajam et al. [3], Lacaz et al. [18], Dai et 
al.[4] Dieye et al.   [19], Wang et al. [20], Mirza et al. [21], Campos et al.[22], Padhye et 
al.[5] and Lacroix et al. [23] refrained from use of any therapy, while Nielsen & Conant 
[2], and Gold et al.[24] used surgery alone. A chromoblastomycosis-like infection 
reported by Barba et al. [25] was successfully treated with 200 mg ITZ daily for 12 
months. The isolate involved had an in vitro MIC value of 0.031 µg/ml. Padhye et al. 
[26] in treating a similar case caused by strain CDC B-5383 used cryosurgery followed 
by KTZ (up to 400 mg/d), 5-FC and FCZ, all without success. The in vitro data showed 
that the strain had an MIC of 64 µg/ml for FCZ, 2 µg/ml for 5-FC and 0.125 µg/ml for 
ITZ. Clinical improvement was obtained with the combination of ITZ and 5-FC, but the 
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patient later relapsed. A subcutaneous lesion caused by isolate CDC B-3868 was treated 
by Padhye et al. [27] using KTZ monotherapy. The dose was raised from 200 mg/d to 
400 mg/d during treatment. After 6 weeks, growth of the isolate was again obtained from 
the lesion, and hence the therapy was changed to KTZ (600 mg/d) plus 5-FC (2 g/d). The 
lesion resolved after 1 month. Our present data showed a 5-FC MIC value of 4 µg/ml for 
the same strain; hence the healing that occurred should be ascribed to KTZ. Sharkey et al. 
[28] described cases of phaeohyphomycoses by members of various dematiaceous genera 
where treatment with amphotericin B, ketoconazole or miconazole appeared inadequate. 
Among these cases was an infection in a joint due to E spinifera. A total dose of 450 mg 
amphotericin B was given within a 1 month which led to improvement, although 
subsequent cultures remained positive after azole therapy. Ketoconazole was given at 100 
mg/day during 8 months, subsequently 400 mg/day for four more months, but 
progression was observed. Further,  itraconazole with a daily dose of 100 mg was 
administered, but total remission after 8 months was observed. The in vitro MIC for this 
strain was 0.15 µg/ml.  Kotylo et al. [29] administered KTZ 200 mg twice daily to their 
patient, but the lesion did not improve. They then performed surgery followed by ITZ 
therapy of 50 mg/day for 6 weeks, then 100 mg/day for 5 weeks. This treatment was 
successful. Negroni et al. [30] documented a patient with a skin lesion and adenopathy 
who was treated with ITZ 5 g/day and 5-FC 200 mg/day for 8 months. Improvement was 
noted, but two years later relapse occurred. The same was observed with ITZ 200 mg/day 
and 5-FC 6 g/day for 4 months, even after the ITZ dosage was raised to 400 mg/day. 
AMB and liposomal AMB were then started but discontinued due to serious adverse 
effects. Thereafter, 400 mg/day ITZ, 6 g/day 5-FC and 300 mg/day ranitidine were given 
for 8 months, leading to remission. The in vitro MIC values for this strain were 0.031 
µg/ml for ITZ and 4 µg/ml for 5-FC. Treatment of two cases in cats [14, 31] was 
unsuccessful. It should be noted, that the causative agent in the case reported by 
Chermette et al.[14] has been re-identified as E. attenuata Vitale et al [13]; the strain of 
Kettlewell et al. [31] is not known to be preserved. 
In vivo antimycotic data for E. spinifera are scant. Most existing studies are based 
on older, less effective compounds. The overview given above clearly illustrates the 
persistent nature of infections caused by E. spinifera. Relapse is common despite 
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prolonged treatment, and poor resolution is frequently obtained despite relatively 
promising MIC values for the drug used. Correspondence of in vitro data to in vivo 
efficacy seems to be low.  
Post antibiotic effect (PAE), i.e., persisting suppression of growth of a microbe 
after limited exposure to an antibiotic compound, may simulate the situation in vivo better 
than standard MIC testing does, since the organism is exposed only temporarily to an 
inhibitory drug level. The PAE effect was first reported with bacteria [10]. It was found 
to be dependent on several factors such as concentration of the drug, exposure time, 
inoculum, and type of medium. Later, similar phenomena were observed in fungi and 
referred to as Post Antifungal Effect (PAFE) [9, 32]. In our study we found that PAFE 
was dependent on concentration. This is slightly different from data reported in 
Aspergillus [9], with Exophiala longer values of PAFE being obtained. Candida species 
also displayed relatively long PAFEs when exposed to amphotericin B at concentrations 
above the MIC, and relatively short PAFEs after exposure to sub-MIC drug levels [32]. 
The inability of itraconazole to induce PAFE in Exophiala is in accordance with 
observations reported for Aspergillus and Candida where no measurable PAFE was 
observed following exposure to azoles [9, 32, 33]. The absence of PAFE mediated by 
these drugs may be related to the different mechanisms by which the drugs act. AMB acts 
directly by binding to sterols in the fungal cell and altering membrane permeability, 
which leads to cell death, whereas azoles or allylamines interfere with the biosynthesis 
pathway of ergosterol. The exposure times applied in PAFE testing may be too short to 
allow these drugs to exert a significant action. PAFE was not observed when E. spinifera 
was tested with 5-FC. PAFE was induced with 5-FC PAFE in Candida [34]. The 
discrepancy is perhaps explained by the fact that these authors used YNB media rather 
than RPMI-1640. YNB was found as more nutritious media provided highest growth 
compared with RPMI-1640 [35].  The action of the drug is dependent in the fungi 
growth, so might be possible that the media influence in the presence of PAFE.  
PAFE is an alternative in vitro susceptibility assay that may provide additional 
information on the interaction of antifungal agent and fungus. In vivo experiments are 
needed to evaluate the importance of this phenomenon as a method to determine 
antifungal therapeutic regimens.  
Activity of antifungal drugs and PAFE against Exophiala spinifera 
 67
 
References 
 
1. De Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of Clinical Fungi. Centraalbureau 
voor Schimmelcultures / Universitat Rovira i Virgili.. 2nd ed. Utrecht / Reus.; 2000. 
p. 1126. 
2. Nielsen HS, Jr., Conant NF. A new human pathogenic Phialophora. Sabouraudia 
1968; 6:228-231. 
3. Rajam RV, Kandhari KC, Thirumalachar M. Chromoblastomycosis caused by a rare 
yeast-like dematiaceous fungus. Mycopath Mycol Appl 1958; 9:5-19. 
4. Dai WL, Wang DL, Ren ZF, Li RY, Wang JZ. First case of systemic 
phaeohyphomycosis caused by Exophiala spinifera in China. Chin J Derm 1987; 
20:13-15. 
5. Padhye AA, Ajello L, Chandler FW, Banos JE, Hernandez-Perez E, et al. 
Phaeohyphomycosis in El Salvador caused by Exophiala spinifera. Am J Trop Med 
Hyg 1983; 32:799-803. 
6. De Hoog GS, Poonwan N, Gerrits van den Ende AHG. Taxonomy of Exophiala 
spinifera and its relationship to E. jeanselmei. Stud Mycol 1999; 43:133-142. 
7. NCCLS. Reference method for broth dilution antifungal susceptibility testing of 
conidium-forming filamentous fungi; proposed standard. Document M-38P: National 
Committee for Clinical Laboratory Standards, Wayne, PA.; 1998. 
8. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, et al. Correlation 
between in-vitro susceptibility testing to itraconazole and in-vivo outcome of 
Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40:401-414. 
9. Vitale RG, Mouton JW, Afeltra J, Meis JF, Verweij PE. Method for measuring 
postantifungal effect in Aspergillus species. Antimicrob Agents Chemother 2002; 
46:1960-1965. 
10. Craig WA, Gudmunsson S. Postantibiotic effect. In: Victor Lorian ME, editor. 
Antibiotics in Laboratory Medicine. 3 ed. Baltimore: Williams & Wilkins; 1991. p. 
403-431. 
Chapter 2.2 
 68
11. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous 
ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of 
phylogenetic implications. J Clin Microbiol 1998; 36:2353-2355. 
12. Meletiadis J, Meis JF, de Hoog GS, Verweij PE. In vitro susceptibilities of 11 clinical 
isolates of Exophiala species to six antifungal drugs. Mycoses 2000; 43:309-312. 
13. Vitale RG, De Hoog GS. Molecular diversity and new species in the Exophiala 
spinifera clade. Med Mycol 2002;:in press. 
14. Chermette R, Ferreiro L, De Bièvre C, Camadro P, Mialot M, et al. Exophiala 
spinifera nasal infection in a cat and a review of feline phaeohyphomycosis. J Mycol 
Méd 1997; 7:149-158. 
15. De Hoog GS. Significance of fungal evolution for the understanding of their 
pathogenicity, illustrated with agents of phaeohyphomycosis. Mycoses 1997; 40:5-8. 
16. De Hoog GS. Risk assessment of fungi reported from humans and animals. Mycoses 
1996; 39:407-417. 
17. Singh N, Chang FY, Gayowski T, Marino IR. Infections due to dematiaceous fungi in 
organ transplant recipients: case report and review. Clin Infect Dis 1997; 24:369-374. 
18. Da Silva Lacaz C, Porto E, De Andrade JG, Telles Filho F. Feohifomycose 
disseminada por Exophiala spinifera. An Bras Derm 1984; 59:238-243. 
19. Dieye M, Dieng MT, Raphenon G, Develoux M, Guého E. Premier cas de 
chromoblastomycose au Sénégal: isolement de Exophiala spinifera chez un patient 
lépromateux. Abstr Réun Soc Fr Mycol Méd 1998;:5. 
20. Wang D, Li R, Wang X, Dai W. Studies on three strains of Exophiala spinifera. Acta 
Mycol Sin 1987; 6:229-232. 
21. Mirza SH, Hannan A, Ahmad A, Ahmad M. Subcutaneous phaeohyphomycosis. J 
Infect 1993; 27:75-78. 
22. Campos-Takaki GM, Jardim ML. Report of chronic subcutaneous abscesses caused 
by Exophiala spinifera. Mycopathologia 1994; 127:73-76. 
23. Lacroix C, Barrazza V, Levy A, Brette D, Dehen L, et al. Lésions cutanées végétantes 
à Exophiala spinifera chez un patient immunodéprimé. Abstr Réun Soc Fr Mycol Méd 
1998; 25. 
Activity of antifungal drugs and PAFE against Exophiala spinifera 
 69
24. Gold WL, Vellend H, Salit IE, Campbell I, Summerbell R, et al. Successful treatment 
of systemic and local infections due to Exophiala species. Clin Infect Dis 1994; 
19:339-341. 
25. Barba-Gomez JF, Mayorga J, McGinnis MR, Gonzalez-Mendoza A. 
Chromoblastomycosis caused by Exophiala spinifera. J Am Acad Dermatol 1992; 
26:367-370. 
26. Padhye AA, Hampton AA, Hampton MT, Hutton NW, Prevost-Smith E, et al. 
Chromoblastomycosis caused by Exophiala spinifera. Clin Infect Dis 1996; 22:331-
335. 
27. Padhye AA, Kaplan W, Neuman MA, Case P, Radcliffe GN. Subcutaneous 
phaeohyphomycosis caused by Exophiala spinifera. Sabouraudia 1984; 22:493-500. 
28. Sharkey PK, Graybill JR, Rinaldi MG, Stevens DA, Tucker RM, et al. Itraconazole 
treatment of phaeohyphomycosis. J Am Acad Dermatol 1990; 23:577-86. 
29. Kotylo PK, Israel KS, Cohen JS, Bartlett MS. Subcutaneous phaeohyphomycosis of 
the finger caused by Exophiala spinifera. Am J Clin Pathol 1989; 91:624-627. 
30. Negroni R, Robles AM, Arechavala A. Disseminated phaeohyphomycosis caused by 
Exophiala spinifera. Revta Argent Micol 1995; 18:2-10. 
31. Kettlewell P, McGinnis MR, Wilkinson GT. Phaeohyphomycosis caused by 
Exophiala spinifera in two cats. J Med Vet Mycol 1989; 27:257-264. 
32. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and 
polyene antifungal agents against Candida albicans and Cryptococcus neoformans. 
Antimicrob Agents Chemother 2000; 44:1108-1111. 
33. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. The postantibiotic effect of 
antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994; 
34:83-92. 
34. Scalarone GM, Mikami Y, Kurita N, Yazawa K, Miyaji M. The postantifungal effect 
of 5-fluorocytosine on Candida albicans. J Antimicrob Chemother 1992; 29:129-136. 
35. Meletiadis J, Meis JF, Mouton JW, Verweij PE. Analysis of growth characteristics of 
filamentous fungi in different nutrient media. J Clin Microbiol 2001; 39:478-84. 
 
 
Chapter 2.2 
 70
 
  
 
 
 
In vitro activity of amphotericin B and 
itraconazole in combination with flucytosine, 
sulfadiazine and quinolones against Exophiala 
spinifera. 
                                       
 
 
Journal of Antimicrobial Chemotherapy 2003;51:1297-
1300.  
 
 
 
 
 
Chapter 2.3 
 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial combinations against Exophiala spinifera 
 73 
 
In vitro activity of amphotericin B and itraconazole in 
combination with flucytosine, sulfadiazine and 
quinolones against Exophiala spinifera 
 
R. G. Vitale1-3, J. Afeltra1,2, G. S. de Hoog3,4, A. J. Rijs1,2 and P. E. 
Verweij1,2* 
 
1Department of Medical Microbiology, University Medical Center Nijmegen,  Nijmegen; 
2Nijmegen University Center for Infectious Diseases; 3Centraalbureau voor  Schimmelcultures, 
Utrecht; 4Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, 
Amsterdam, The Netherlands. 
      
    Received 17 December 2002; returned 25 January 2003; revised 14 February 2003; accepted 16 February 2003 
 
 
Abstract 
 
 
The combined effects of antifungal and antibiotic drugs against Exophiala spinifera  were 
evaluated in vitro by the chequerboard method, calculated as a fractional inhibitory 
concentration (FIC) index. Amphotericin B was combined with flucytosine and 
ciprofloxacin, whereas itraconazole was combined with ciprofloxacin, levofloxacin, 
lomefloxacin and sulfadiazine. Synergic effects were observed for the combinations of 
itraconazole with ciprofloxacin and levofloxacin, and amphotericin B with ciprofloxacin 
and flucytosine. No antagonism was observed for any combination tested.  
 
Keywords: Exophiala, black yeasts, quinolones, drug combinations 
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Black yeast-like fungi are increasingly being recognized as potential human pathogens. 
Clinical pictures include either subcutaneous or systemic mycetoma, 
chromoblastomycosis and phaeohyphomycosis.1 
As model species we selected Exophiala spinifera. Although this is a very rare agent of 
disease in humans, it is one of the most aggressive species of black yeast, potentially 
causing disseminated infections with fatal outcome in children and adolescents. In adults, 
in contrast, infections are mostly localized or subcutaneous lesions.2 
The optimal therapy for black yeast infections is controversial. Surgical excision, 
antifungal drug monotherapy or drug combinations have been used, but prolonged 
treatment is needed because relapses often occur. Consequently, new approaches to 
treatment are overdue. 
Quinolones are potent inhibitors of DNA gyrase and are extensively used in clinical 
practice for bacterial infections.3 
Sulphonamides act as competitive antagonists of p-aminobenzoic acid (PABA), which is 
an integral component of the structure of folic acid. Decreased folic acid synthesis results 
n a decrease in nucleotides with subsequent growth inhibition.4  Both types of drug have 
favourable pharmacokinetic profiles in cerebrospinal fluid and bone.4 
In one report, a nodule on a finger was treated with surgical excision and three 
antifungals, but after a month another lesion appeared in the left arm with no healing of 
the finger lesion. In this case, treatment with co-trimoxazole was initiated on diagnosis of 
a Nocardia superinfection, and after 11 days both lesions had improved. This suggests 
that sulphonamides might be effective in treating this infection.5 
Quinolones have a broad spectrum of activity as inhibitors of DNA gyrase, type 2 
topoisomerase, which is present in prokaryotes and eukaryotes. The presence of high 
levels of topoisomerases I and II has been reported in pathogenic fungi.6 Although they 
are inapplicable as sole antifungal agents, quinolones augment the activity of 
amphotericin B and azoles.7,8 For example, in a murine model study of candidiasis, 
similar survival rates were demonstrated in mice treated with fluconazole alone 80 
mg/kg/day and in those treated with fluconazole (40 mg/kg/day) and ciprofloxacin.8 
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The aim of the present study was to investigate the in vitro activity of quinolones and 
sulfadiazine, either alone or in combination with amphotericin B or itraconazole, as well 
as the combination of amphotericin B and flucytosine against E. spinifera strains. 
Thus, for this study eight clinical and two environmental well-documented isolates of E. 
spinifera were used (Table 1). 
 
 
Drugs tested were amphotericin B (Bristol-Myers Squibb, Woerden, The Netherlands), 
itraconazole (Janssen-Cilag, Beerse, Belgium), flucytosine (ICN Pharma BV, 
Zoetermeer, The Netherlands), ciprofloxacin (Bayer AG, Leverkusen, Germany), 
lomefloxacin (Searle Nederland, Maarssen, The Netherlands), levofloxacin (Hoechst 
Pharma, Amsterdam, The Netherlands) and sulfadiazine (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany). All drugs were dissolved in dimethylsulphoxide (DMSO), with the 
exception of flucytosine and ciprofloxacin, which were dissolved in water. 
Two-fold serial dilutions of the drugs were made in RPMI-1640 medium (Gibco BRL, 
Woerden, The Netherlands) to obtain final concentrations that ranged from: 0.015 to 8 
mg/L for amphotericin B; 0.02 to 1 mg/L for itraconazole; 0.25 to 128 mg/L for 
flucytosine; 0.125 to 8 mg/L for ciprofloxacin; 0.09 to 6 mg/L for lomefloxacin; 0.15 to 
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10 mg/L for levofloxacin; and 2.5 to 160 mg/L for sulfadiazine. RPMI -1640 medium 
(with L-glutamine, without bicarbonate) was buffered to pH 7.0 with 0.165 M MOPS 
(Sigma-Aldrich, Steinheim, Germany). 
Tests were performed in 96-well flat-bottom microtitration plates (Corning, Ames, MA, 
USA), which were kept at –70°C until the day of testing. The MIC of each drug alone 
was tested by a broth microdilution method, according to NCCLS guidelines (M38-P)9 
that provide for testing of polyenes, flucytosine and azole antifungal agents against 
filamentous fungi. 
Conidial suspensions were diluted in RPMI -1640 to obtain twice the desired inoculum 
concentration. A drug-free well containing 0.01% DMSO in the medium served as the 
growth control for the drugs dissolved in this solvent. Plates were incubated at 35°C for 
72 h. The MICs were determined by spectrophotometry. The relative optical densities 
(ODs) for each well based on measurements at 405 nm were calculated (as a percentage) 
based on the following equation: [(OD of drug-containing well – background OD)/(OD 
of drug-free well – background OD)] × 100%. The MIC of each drug alone was defined 
as the lowest concentration of the drug that showed at least 95% reduction of growth 
compared with that of the growth control (MIC-0) for amphotericin B, quinolones and 
sulfadiazine, and for flucytosine and itraconazole as the lowest concentration of the drug 
that showed 50% reduction of growth compared with that of the growth control (MIC-2). 
A two-dimensional, two-agent broth microdilution chequerboard method was used to 
study the interaction between the drugs. For all the combinations tested, MIC endpoints 
considered were MIC-0 when amphotericin B was combined and MIC-2 when 
itraconazole was combined with the corresponding drug. The FICs of both drugs used in 
combination were calculated and added to obtain the FIC indices. The FIC index was 
calculated as follows: (MIC of drug A + drug B/MIC of drug A) + (MIC of drug A + 
drug B/MIC of drug B). 
Drug interactions were defined as synergic if the FIC index was =0.5, antagonistic if the 
FIC index was >4 and noninteractive between 0.5 and 4. 
The MIC of amphotericin B ranged from 0.25 to 2 mg/L; that of itraconazole from 0.031 
to 0.125 mg/L; that of flucytosine from 2 to 32 mg/L. For sulfadiazine and quinolones no 
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activity was found with the drug alone (Table 1). Amphotericin B combined with 
flucytosine showed a synergic effect for five strains and no interactio n for four. For 
amphotericin B plus ciprofloxacin, a synergic effect was observed against five strains and 
no interaction for two (Table 2). 
Itraconazole combined with levofloxacin, lomefloxacin and ciprofloxacin showed 
synergic activity against seven, four and six strains, respectively. No interaction when 
combined with itraconazole was observed with six strains for lomefloxacin, four strains 
for ciprofloxacin and three strains for levofloxacin. When itraconazole was combined 
with sulfadiazine, synergic activity was observed against five strains and no interaction 
against three strains (Table 2). No antagonistic effect was observed in any combination. 
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Only very few in vitro and animal studies have been carried out with this group of fungi. 
One study, on a central nervous system phaeohyphomycosis in mice infected with three 
different genera of black fungi. Ochroconis constricta  showed good correlation in vitro–
in vivo with amphotericin B, although high doses of amphotericin B were needed. For 
Cladophialophora bantiana, flucytosine was the most effective, but no single drug 
achieved full recovery. This drug was also the most effective against Exophiala 
dermatitidis.11 
Quinolones and sulfadiazine were selected for this study because of their favourable 
distribution in the body and their ability to enhance antifungal activity when used in 
combination. 
Flucytosine was selected as a classic drug that possesses activity against black fungi. Our 
study indicates that for some isolates, quinolones augmented the activity either of 
itraconazole or amphotericin B when combined, since synergic effects were sometimes 
observed and antagonism not demonstrated for any combination tested. The 
concentrations tested can be achieved in vivo. Enhanced activity of antifungal agents 
combined with these classes of antimicrobials has also been found for Candida species, 
although occasionally discrepancies were observed between in vitro and in vivo data.8,10 
In our study, we found synergic interaction when sulfadiazine were combined with 
itraconazole. No effect was observed in E. spinifera when the drug was used alone. The 
blood levels that can be reached in vivo (30–60 mg/L)4 exceed the MIC of the 
combination of sulfadiazine and itraconazole. 
Synergic effects between sulphonamides and azoles were also found in Candida in which 
synergy was observed between ketoconazole and co-trimoxazole.13 
In summary, the results presented here strongly suggest that quinolones or sulphonamides 
enhance the antifungal activity of drugs currently used for some isolates of E. spinifera. 
This provides potential alternative therapeutic options in infections from dematiaceous 
fungi. More investigations are needed to confirm these observations. 
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Abstract 
  
An in vitro method for determination of post-antifungal effect (PAFE) in moulds was 
developed by using three isolates each of Aspergillus fumigatus, A. flavus, A. terreus, A. 
nidulans, and A. ustus. MICs of amphotericin B and itraconazole were determined by 
using National Committee for Clinical Laboratory Standards guidelines (M38-P). The 
inoculum was prepared in RPMI 1640 broth buffered with MOPS 
(morpholinepropanesulfonic acid) at pH 7.0, and conidia were exposed to amphotericin B 
and itraconazole at concentrations of 4, 1, and 0.25 times the MIC, each for 4, 2, and 1 h 
at 37°C. The same procedure was followed for controls with drug-free medium. 
Following exposure, the conidia were washed three times in saline and the numbers of 
CFU per milliliter were determined. Exposed and control conidia were then inoculated 
into microtitration plates and incubated at 37°C for 48 h in a spectrophotometer reader. 
The optical density (OD) was measured automatically at 10-min intervals, resulting in 
growth curves. PAFE was quantified by comparing three arbitrary points in the control 
growth curve, the first increase of OD and the points when 20 and 50% of the maximal 
growth were reached, with the growth curve of drug-exposed conidia. Amphotericin B 
induced PAFE in A. fumigatus at four times the MIC after 2 and 4 h of exposure ranging 
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from 1.83 to 6.00 h and 9.33 to 10.80 h, respectively. Significantly shorter PAFEs or lack 
of PAFE was observed for A. terreus, A. ustus, and A. nidulans. Itraconazole did not 
induce measurable PAFE in the Aspergillus isolates at any concentration or exposure 
time tested. Further studies are warranted to investigate the implications of PAFE in 
relation to clinical efficacy and dosing frequency.  
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Introduction 
 
Aspergillus species are documented as some of the most prevalent airborne molds, and 
the frequency of mycoses due to these fungi is rising worldwide, especially invasive 
infections that occur in immunocompromised patients, such as cancer patients, bone 
marrow transplant recipients, solid-organ transplant recipients (13), and human 
immunodeficiency virus-infected patients (18).  
Aspergillus fumigatus and Aspergillus flavus are encountered most frequently, although 
other species have been documented to cause disease. Aspergillus terreus is an increasing 
cause of invasive infection in neutropenic patients and Aspergillus nidulans in patients 
with chronic granulomatous disease (22). Although amphotericin B is considered the 
drug of choice for treatment of invasive aspergillosis, the clinical response is limited, 
especially in infections caused by the latter two species. Alternatively, itraconazole is a 
triazole antifungal drug with good in vitro activity against Aspergillus and has been used 
successfully as first-line treatment in patients with invasive disease (2, 6).  
Methods for in vitro susceptibility testing of molds have been proposed only recently by 
the National Committee for Clinical Laboratory Standards (NCCLS) (19), but the 
correlation between MIC and clinical response remains unclear, especially for 
amphotericin B. With the exception of A. terreus, MICs for clinical Aspergillus isolates 
of amphotericin B are normally below 1 µg/ml, and the distribution range of MICs is 
narrow. A correlation between treatment failure and MIC could not be demonstrated in an 
animal model of invasive aspergillosis (24). Only for itraconazole (7) and voriconazole 
was a good correlation found between MIC and response in animal models. 
One explanation of discrepancies between MIC and clinical efficacy is post-drug-
exposure effects. For instance, the success of intermittent dosing regimens for some 
antimicrobial agents has been attributed to delay in regrowth of microorganisms after 
drug concentrations in the tissues have fallen below the MIC. This so-called 
postantibiotic effect (PAE) was first described for bacteria (20). Post-drug-exposure 
effects in filamentous fungi have not been studied, mainly because of technical problems 
such as the nonhomogeneous growth of molds in liquid media. The aim of this study was 
to develop a system for studying postantifungal effects (PAFE) in filamentous fungi and 
to evaluate the PAFE of amphotericin B and itraconazole against Aspergillus species.  
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Materials and Methods 
  
Isolates. Fifteen clinical strains from our private collection were evaluated: A. fumigatus 
AZN VO2-31, AZN VO2-32, and AZN VO2-33; A. terreus AZN 5914, AZN 2868, and 
AZN 515; Aspergillus ustus AZN 943, AZN 677, and AZN 678; A. nidulans AZN 8033, 
AZN 8950, and AZN 8958; and A. flavus AZN 2865, AZN 4094, and AZN 284. The 
strains were cultured from respiratory secretions (12), the external ear (2), and 
cerebrospinal fluid (1).  
Antifungal agents. Amphotericin B (Bristol-Myers Squibb, Woerden, The Netherlands) 
and itraconazole (Janssen-Cilag, Beerse, Belgium) were utilized for MIC determinations 
and PAFE studies. The drugs were dissolved in dimethyl sulfoxide (DMSO) and aliquots 
of the stock solution were stored at -70°C until used. Then they were diluted in RPMI 
1640 medium (with L-glutamine and without bicarbonate) (GIBCO BRL, Life 
Technologies, Woerden, The Netherlands) buffered to pH 7.0 with 0.165 M 
morpholinepropanesulfonic acid (MOPS) (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany).  
Antifungal susceptibility testing. The isolates were passaged twice at an interval of 5 to 7 
days at 28°C by subculturing onto Sabouraud glucose agar (SGA) to obtain adequate 
sporulation. Conidia were collected with a cotton swab and suspended in saline with 
0.05% Tween 20. After the heavy particles had been allowed to settle, the turbidity of 
supernatants was measured spectrophotometrically (Spectronic 20D; Milton Roy, 
Rochester, N.Y.) at 530 nm, and transmission was adjusted to 80 to 82%, corresponding 
to 0.5 x 106 to 4.5 x 106 CFU/ml. The viability was confirmed by plating serial dilutions 
onto SGA plates.  
For inoculum preparation the conidial suspensions were diluted 1:100 in order to obtain a 
final inoculum of 0.5 x 104 to 4.5 x 104 CFU/ml. A broth microdilution method was 
performed according to NCCLS guidelines (M38-P) (19) using RPMI 1640 medium 
buffered to pH 7.0 with 0.165 M MOPS. Amphotericin B and itraconazole were 
dissolved in DMSO at concentrations of 3,200 µg/ml. Twofold serial dilutions of the 
drugs were made in RPMI 1640 medium in order to obtain final concentrations that 
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ranged from 0.015 to 16 µg/ml for both drugs. A drug-free well containing 0.01% DMSO 
in the medium served as the growth control. The tests were performed in 96-well flat-
bottom microtitration plates (Corning Incorporated, New York, N.Y.), which were kept at 
-70°C until the day of testing. Conidial suspensions prepared as described above were 
diluted 1:50 in RPMI 1640 to obtain twice the desired inoculum. After the inoculation, 
the microtitration plates were incubated at 35°C for 48 h. The MICs were read by 
spectrophotometric reader (Rosys Anthos ht3; Anthos Labtex Instruments GmbH, 
Salzburg, Austria). Background optical density (OD) was determined by 
spectrophotometric measurement of noninoculated wells processed in the same way as 
the inoculated wells. The relative ODs for each well based on measurements at 405 nm 
were calculated (in percentages) with the following formula: [(OD of drug-containing 
well - background OD)/(OD of drug-free well - background OD)] x 100. The MIC of 
amphotericin B was defined as the lowest concentration of the drug that resulted in at 
least 95% reduction of growth compared with the growth control, and that of itraconazole 
was defined as the lowest concentration of the drug that resulted in 50% of reduction of 
growth compared with the growth control.  
PAFE assay. The method used for determining PAFE in molds was based on methods 
used for bacteria and yeasts, with some modifications (4, 10, 12). Amphotericin B and 
itraconazole were dissolved in DMSO at initial concentrations of 400 µg/ml, and aliquots 
of the stock solution were stored at -70°C until used. Then they were diluted 50 times in 
RPMI 1640 medium (with L-glutamine without bicarbonate) buffered to pH 7.0 with 
0.165 M MOPS. Serial dilutions of the drugs were made in RPMI 1640 in order to obtain 
final concentrations of 4, 1, and 0.25 times the corresponding MIC of each drug for each 
strain. Control conidial suspensions were made in RPMI 1640. The isolates were 
passaged twice at an interval of 5 to 7 days at 28°C by subculturing onto SGA to obtain 
adequate sporulation. Conidia were collected with a cotton swab and suspended in saline 
with 0.5% Tween 20. After the heavy particles were allowed to settle, the supernatant 
was transferred to another tube and vortexed for 10 s, and 10- and 100-fold dilutions were 
made. The concentration of conidia was established microscopically by Burker Turk 
hemocytometer chambers. Then the concentration was adjusted to obtain 4 x 105 
conidia/ml. One milliliter of this suspension was added to tubes containing 9 ml of RPMI 
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1640 alone (control) or with amphotericin B or itraconazole at the concentrations 
mentioned above, resulting in a final volume of 10 ml. The hydrophobic nature of 
Aspergillus species made it necessary to add 0.5% Tween 20 to the media in order to 
keep the conidia in the solution during washing. The final inoculum therefore was 4 x 
104 CFU/ml. Following this procedure, each strain was incubated for either 4, 2, or 1 h 
with continuous shaking at 37°C.  
After incubation, the conidia were washed with saline 0.5% Tween 20, and centrifuged at 
3,500 x g during 15 min. After three wash cycles, 98% of the supernatant was completely 
decanted and the pellets were resuspended in a final volume of 10 ml RPMI 1640 with 
0.05% Tween 20. The procedure with two washings and removal of 90% of supernatant 
has been shown to reduce the antimicrobial concentration by 100-fold and with complete 
decanting, two washings can reduce concentrations as much as 10,000-fold (4). 
Following this step, 100 µl of sample was diluted 10-fold in sterile water, and 30-µl 
aliquots were plated onto SGA plates for colony count determination and incubated at 
37°C for 24 and 48 h. The concentration of viable CFU per milliliter for drug-exposed 
conidia was determined in order to verify the concentration of viable conidia after drug 
exposure and to allow adjustment of the inoculum, if necessary, to match that of controls. 
From the resuspended suspension, 200 µl was placed in microtitration plates which were 
incubated at 37°C in a computerized spectrophotometric reader (Rosys Anthos ht3; 
Anthos Labtex Instruments GmbH). Growth was automatically monitored in terms of 
change in turbidity at 405 nm at 10-min intervals for 48 h. All assays were performed in 
duplicate.  
In order to correlate OD changes with the morphology of the Aspergillus species, the 
microscopic morphology was examined in microtitration plates by a reverse microscope 
at different time points for each species for the control and the drug-exposed strains. 
Conidia were counted, and the percent germination was estimated in duplicate at 0, 4, 8, 
12, 16, 24, and 36 h.  
Data analysis. Three points in the growth curve were considered to quantify the PAFE: 
(i) the first significant increase in the OD (repeatable increase in OD for three 
consecutive measurements; OD0) (16); (ii) the point where the OD reached 20% of the 
maximum of the growth curve at 48 h (OD20); and (iii) the point where the OD reached 
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50% of the maximum of the growth curve at 48 h (OD50). The PAFE was quantified by 
using the formula T - C, where T was the time of the first significant increase in OD0 of 
the drug-exposed conidia after removal of the drug and C was the time of the first 
significant increase in OD0 of the control. For OD20 and OD50, T was defined as the time 
required for the relative OD of the drug-exposed conidial suspension to reach the 
absorbance level calculated by the formula FC x (ODmax - ODmin) + ODmin after removal 
of the drug and C was the time required for the relative OD of the drug-free control 
conidial suspension to reach the same absorbance level calculated by the same formula, 
where ODmax is the maximum OD reached, ODmin is the baseline OD level reached, and 
FC is a variable of 0.2 and 0.5 that gives a point at 20% and 50% of the maximum of the 
curve, respectively. Thus, PAFE was defined as the difference in the time required to 
reach the defined point in the growth curves of drug-exposed conidia and controls and 
was expressed in hours.  
The time to reach these chosen arbitrary points (OD0, OD20, and OD50) of at least eight 
controls for each species was determined, and the mean, range, upper 95% confidence 
interval (CI), and coefficient of variation (CV) were calculated in order to determine the 
reproducibility of the control curves at each point and to establish the reproducibility of 
the experiments.  
For each chosen point (OD0, OD20, and OD50) and for each species the upper 95% CI of 
the controls and the lower 95% CI of the drug-exposed isolates were chosen as the cutoff 
that distinguished between presence and absence of PAFE. When regrowth of the drug-
exposed isolates occurred within the upper 95% CI time frame of the controls, PAFE was 
considered absent. Alternatively, if regrowth was delayed following drug exposure and 
the lower 95% CI of the drug-exposed isolates was delayed until beyond the upper 95% 
CI of the controls, PAFE was considered present (Fig. 1). Growth curves of each drug-
exposed isolate were compared only with pooled controls from that same isolate.  
The inter- and intraspecies variation of PAFE were analyzed with all the raw data by 
analysis of variance using Tukey-Kramer multiple-comparison tests. P values of <0.05 
were considered statistically significant.  
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Results 
 
For all Aspergillus isolates tested the amphotericin B MIC was 1 µg/ml and that of 
itraconazole ranged between 0.125 and 2 µg/ml (A. fumigatus, 0.125 to 0.5 µg/ml; A. 
flavus, 0.125 to 0.25 µg/ml; A. terreus, 0.125 µg/ml; A. nidulans, 0.125 to 0.25 µg/ml; 
and A. ustus, 2 µg/ml).  
Inoculum. Based on the inoculum preparation procedure of the NCCLS M38-P 
guideline, the range of numbers of viable CFU per milliliter recovered in the colony 
counts was too great to achieve reproducible growth curves. Therefore, a more stringent 
range was used based on inoculum preparation by hemocytometer. By this method, a 
limited range of 2 x 104 to 4 x 104 viable CFU/ml was achieved. Exposure of conidia to 
amphotericin B and itraconazole for 1 to 4 h had no effect on the viability of the 
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Aspergillus species based on subculture of serial twofold dilutions (data not shown). 
Therefore adjustment of the inoculum following drug exposure to match that of the 
controls was not necessary.  
Microscopic morphology. Microscopic examination of the conidia before and after drug 
exposure showed that germination did not occur within the maximal exposure period of 4 
h for any species except A. flavus, where germ tubes were visible within 4 h of 
incubation. At 8 h, germination had not occurred for any species except A. flavus. For A. 
fumigatus and A. ustus, germination of conidia occurred after 12 h for 95% of the controls 
and drug-exposed conidia in strains where PAFE was not present. When PAFE was 
present, germination of conidia was further delayed. A. terreus and A. nidulans 
germinated after 16 and 20 h, respectively. After 36 h, mycelia were observed for all the 
species for both controls and drug-exposed conidia.  
There were no microscopic differences between drug-exposed conidia and controls. 
During incubation, the morphology of the hyphae and the frequency of branching 
appeared to be similar for both drug-exposed and non-drug-exposed strains. The only 
difference between drug-exposed and non-drug-exposed strains was the time at which 
germination commenced.  
PAFE assay. The shapes of the growth curves were different depending on the species 
tested; however, they were reproducible among the replicates. For the same species, the 
shapes of the control and the drug-exposed strains were identical. When PAFE was 
present, the growth curve of the drug-exposed conidia was shifted to the right compared 
with that of the control. Examples of growth curves for A. fumigatus and A. ustus are 
shown in Fig. 2. A sharp increase in OD was observed for A. ustus after 30 h of 
incubation which was found to be related to the formation of crystals in the well (Fig. 2C 
and D).  
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The variability in OD for each of the chosen points for all tested species was calculated 
by analyzing 180 growth curves in total. In general the variability, expressed as the CV, 
was not significantly different for the three criteria analyzed, although the CV was the 
lowest for OD0 (Table 1). When four replicates were used for both control and drug-
exposed isolates, the CV was lower than 13% for OD0 and lower than 25% for OD20 and 
OD50.  
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Amphotericin B. In general, PAFE was not observed after 1 h of exposure to 
amphotericin B at any concentration for all the species and for any of the three criteria 
used (data not shown). The magnitude of the PAFEs induced by amphotericin B at the 
chosen points in the growth curve (OD0, OD20, and OD50) after 2 and 4 h of exposure and 
at four times the corresponding MIC and at the MIC in RPMI 1640 broth are shown in 
Table 2.  
A. fumigatus. By the OD0 criterion, the PAFE induced by amphotericin B was longer for 
A. fumigatus than for the other Aspergillus species, with mean PAFEs of 9.9 and 4.0 h 
after 4 h of exposure at four times the MIC and at the MIC, respectively, and 4.0 h after 2 
h of exposure to four times the MIC. Also, at concentrations of amphotericin B of four 
times the MIC and equal to the MIC, after 4 h PAFE was observed for A. fumigatus, with 
means of 8.9 and 3.6 h, respectively, using the OD20 criterion. At OD50 the A. fumigatus 
isolates also displayed PAFE, with means of 5.3 h after 4 h of exposure and four times 
the MIC and 2.7 h at the MIC. Amphotericin B induced PAFE against A. fumigatus after 
2 h of incubation at four times the MIC, with a mean of 4.0 h using the OD0 criterion.  
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Other Aspergillus species. For A. terreus and A. nidulans, after 4 h of exposure to 
concentrations of amphotericin B of four times the MIC, the mean PAFEs were 2.5 and 
0.7 h at OD0. Amphotericin B induced PAFE against A. ustus at concentrations of four 
times the MIC and equal to the MIC after 4 and 2 h of exposure, with mean PAFEs of 
3.9, 1.8, 1.0, and 0.4 h, respectively, using the OD0 criterion. The results for A. flavus 
were inconsistent and did not allow conclusions to be drawn.  
At OD0, PAFE was induced by amphotericin B after 4 h of exposure for all three A. 
fumigatus isolates and for two of three strains of A. ustus, A. terreus, and A. nidulans. 
After 2 h of exposure, PAFE was observed only for A. fumigatus for all the chosen 
criteria (Table 2). A statistically significantly longer PAFE was induced by amphotericin 
B after 4 h of exposure at four times the MIC for A. fumigatus than for the other 
Aspergillus species (P < 0.05). For A. fumigatus, significantly longer PAFEs were found 
after 4 h of exposure to amphotericin B at the MIC compared with A. terreus, after 2 h of 
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exposure at four times the MIC compared with A. nidulans, and after 2 h of exposure at 
the MIC compared with A. terreus and A. ustus (P < 0.05). No statistically significant 
intraspecies variation was observed.  
Itraconazole. Itraconazole failed to induce a PAFE at any concentration tested and for 
any exposure time. Even exposure to itraconazole concentrations as high as 10, 20, and 
50 times the MIC failed to induce a PAFE (data not shown).  
 
Discussion 
  
PAFE assay. In this study a method that allows the quantification and study of post-
antifungal-drug-exposure effects in molds was developed. Since the use of viability 
counts to monitor microbial growth kinetics following drug removal is not feasible with 
molds due to their nonhomogeneous growth, OD measurements were used. Although the 
growth curves thus obtained allow quantification of PAFE, microscopic examination of 
the fungal growth in the wells of the microtitration plates is of great importance. Post-
drug-exposure effects other than growth suppression could have an impact on the OD 
measured. For instance, alteration of the frequency of hyphal branching could result in 
changes in the OD. However, careful microscopic examination of the molds at different 
times postexposure revealed no differences in morphology compared with unexposed 
controls. The reliability of measurement of fungal growth using this spectrophotometric 
system has been described before, and even small changes in morphology can be detected 
(16).  
It has been demonstrated that Aspergillus conidia germinate when incubated at 37°C in 
RPMI 1640 after 6 h or more (15, 16), with exception only of A. flavus, which germinates 
within 4 h. Therefore, a maximum exposure period of 4 h was chosen. The exposure of 
Aspergillus conidia to amphotericin B did not affect the viability of the conidia at any of 
the concentrations or incubation times used. Consequently, adjustment of the inoculum to 
match that of the controls was not necessary.  
The criterion used to define PAFE is arbitrary, although most workers have used the 
difference between time required for the control and the drug-exposed bacteria or yeasts 
to increase 1 log10 compared with the initial CFU count (4, 10) or, if a spectrophotometric 
procedure was used, time to reach a 0.05 absorbance level (9). In the present study, PAFE 
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was not evaluated with CFU counts because of the nonhomogeneous growth of molds. 
Therefore, we used a spectrophotometric procedure that was originally developed to 
study growth characteristics of molds (16). Since viability counts were not performed, 
several arbitrary chosen criteria were analyzed to calculate the PAFE, namely, OD0, 
OD20, and OD50. The variability between replicates of control isolates with these three 
criteria was not significantly different. Furthermore, for each criterion, only small 
differences in PAFE were observed, especially for A. fumigatus and A. terreus. However, 
using OD0 to quantify PAFE has several advantages. First, the variability among the 
controls was lower when OD0 was used than with the other two criteria. When four 
replicates were used, the CV was below 13% for both drug-exposed and control strains 
with OD0. Second, OD0 is reached earlier than the other criteria, leaving less impact of 
variables such as production of metabolites, crystals, or cellular debris that might 
interfere with the OD reading (12). Third, in order to calculate OD20 and OD50, the OD 
that corresponds to maximal growth is required, thereby prolonging the time before 
results become available, especially in slow-growing fungi. RPMI 1640 medium was 
chosen since it is recommended by the NCCLS for MIC determination of conidium-
forming fungi. However, it has been shown that RPMI 1640 poorly supports the growth 
of Aspergillus species (16). The optimal growth curve, which contains a lag phase, a log 
phase, and a plateau, is not obtained when Aspergillus species are cultured in RPMI 1640, 
but a linear curve was found with the same spectrophotometric system (16). Maximal 
growth of Aspergillus is not reached within 99 h, and therefore we defined maximal 
growth as the OD that was reached after 48 h of incubation. Alternative media that 
support the growth of Aspergillus more adequately could be useful in this respect, 
although further studies are needed.  
PAFE. PAEs have been found to be dependent on several factors, such as the 
concentration of the antibiotic agent, the time during which the bacteria were exposed to 
the drug, and the characteristics of the drug used to induce the effect (20). PAFE also 
appears to depend on drug, concentration, and duration of exposure, as was described for 
Candida species (10). In the present study, the PAFE displayed by amphotericin B 
showed dependence on the concentration and the exposure period. This is partly 
consistent with a previous published study with Candida, where longer PAFEs were 
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found following exposure to amphotericin B at concentrations above the MIC compared 
with shorter PAFEs following exposure to sub-MIC drug concentrations (10). The 
echinocandin caspofungin (MK-0991) also induced a PAFE against Candida, and the 
magnitude of the effect depended on the concentration of the drug. Both amphotericin B 
and caspofungin exhibit fungicidal activity in vitro against Candida (10, 21, 23).  
Amphotericin B. Overall, the magnitude of the PAFE induced by amphotericin B in 
vitro was the greatest against A. fumigatus. The range found in our study was similar to 
that found in a previous study with Candida species, where the PAFE ranged between 0.5 
and 10 h (9, 11). However, significantly shorter PAFEs were observed for A. terreus and 
A. nidulans, where only exposure to high concentrations of amphotericin B could induce 
a PAFE. Invasive aspergillosis caused by A. terreus and A. nidulans is often clinically 
unresponsive to treatment with amphotericin B (5, 22). The short PAFE or lack of PAFE 
we found in A. terreus and A. nidulans isolates could contribute to the poor clinical 
response.  
Itraconazole. In our study, exposure to the triazole drug itraconazole did not induce 
PAFE in any of the Aspergillus species tested. Even exposure of Aspergillus isolates to a 
concentration of 50 times the MIC for 4 h was not sufficient to induce PAFE. The 
inability of itraconazole to induce PAFE in Aspergillus is in accordance with 
observations reported for Candida, where no measurable PAFE was observed following 
exposure to fluconazole (10, 17, 23). The lack of PAFE induced by azoles could be due to 
the exposure period being too short to cause sufficient damage to the mold. However, 
longer exposure periods could not be investigated with our system, since germination of 
the control strains occurred after 6 h of incubation.  
Implications. Two characteristics determine the time course of antimicrobial activity: the 
effect of increasing drug concentrations on the extent of killing of the microorganism and 
the presence or absence of postexposure effects. Our results indicate that post-antifungal-
drug-exposure effects occur in Aspergillus. The consequences of PAFE of amphotericin 
B in several Aspergillus species for the dosing regimen of the drug remain unclear. Due 
to the pharmacokinetics of amphotericin B, the concentrations in plasma do not normally 
exceed 2 µg/ml (14), and after leaving the circulation, the drug slowly accumulates in 
some tissue compartments (3). Consequently, the concentrations of amphotericin B in the 
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blood do not accurately reflect the concentrations in tissues (14). The concentration in 
mouse kidneys can be up to four times greater than the level in serum, and it may appear 
that antifungal activity persists despite little to no measurable drug in serum (8). The 
MICs for strains tested in this study were 1 µg/ml, indicating that four times the MIC is a 
concentration that is achievable in vivo.  
Given the fact that amphotericin B is administered once daily, our results suggest that 
growth suppression is achieved for a significant period for A. fumigatus depending on the 
concentration at the site of infection. However, a larger collection of isolates should be 
tested and in vivo models are required to confirm our findings. In a murine model of 
invasive candidiasis, the pharmacodynamics of amphotericin B were best predicted by 
the peak serum level/MIC ratio (1). Furthermore, high infrequent doses of amphotericin 
B were as effective as lower, more frequently administered doses in treating invasive 
candidiasis (1). Since PAFEs of amphotericin B for A. fumigatus were similar to those 
observed with Candida albicans, infrequent dosing might be a useful strategy in the 
treatment of invasive aspergillosis due to A. fumigatus.  
In conclusion, we have developed an assay that allows the study of PAFE of different 
antifungal agents in Aspergillus species and other molds. Amphotericin B induced PAFE 
in A. fumigatus, but in A. terreus and A. nidulans short PAFEs or a lack of PAFE was 
observed. However, further studies are warranted, including in vivo experiments, to study 
the impact of PAFE in Aspergillus on dosing regimens of amphotericin B.  
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Abstract 
 
The evaluation of post antifungal effect (PAFE) of amphotericin B and nystatin against 
30 clinical Zygomycetes were performed using two different media. PAFE is a 
suppression of fungal growth after limited drug exposure. The MIC of both drugs was 
determined using NCCLS M38-P guidelines. A spectrophotometric method was used to 
determine PAFE in vitro. Spores were exposed to amphotericin B and nystatin in RPMI -
1640 or AM3 at concentrations of 4x and 1x the MIC for 4h for Absidia sp. and at 1x and 
0.5x the MIC for 1h for the other strains. Drugs were eliminated by washing. Exposed 
and control spores were cultured in microtiter wells and incubated for 48h. PAFE was 
calculated as T-C (Dt) between the control and the exposure fungi. The first increase in 
optical density (OD0) was used to calculate PAFE and was considered significant when 
the value of the lower 95%CI of the exposed strain was > upper 95%CI of the control.  
MIC range in RPMI-1640: 0.06-4 mg/L for amphotericin B and 0.5-8 mg/L for nystatin; 
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in AM3: 0.06-2 mg/L for amphotericin B and 0.5-4 mg/L for nystatin. Killing was not 
observed at the concentration and exposure time used. In RPMI-1640, for amphotericin B 
the rank order for PAFE was A. corymbifera (5.6h) > R. oryzae (5.2h) > Mucor sp (3.5h) 
> R. microsporus (3h) and for nystatin the rank order was Mucor sp (5.8h) > R. oryzae 
(3.3h) > A. corymbifera (2.9h) > R. microsporus (1.7h). PAFE was not induced in 
Rhizomucor sp. PAFE was dependent on drug concentration. 
 
 
Keywords: PAFE, Zygomycetes, amphotericin B, nystatin 
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Introduction 
 
Organisms of the class Zygomycetes were first noted to cause disease in humans in 
publications from the nineteenth century. The first description of a case of disseminated 
disease was in a cancer patient and caused by Absidia corymbifera 1. The main clinical 
syndromes in human disease are sinusitis, rhinocerebral, pulmonary, cutaneous, 
subcutaneous, gastrointestinal and disseminated zygomycosis. Other disease states occur 
with a much lower frequency. Risk factors for developing invasive zygomycosis include 
diabetes with ketoacidosis, neutropenia, transplant or patients with leukemia who receive 
treatment with corticosteroids. The most common causative organisms are Rhizopus, 
Absidia followed by Mucor and Rhizomucor2 ,3.  
Treatment of zygomycosis requires surgical intervention, antifungal therapy and 
resolution of the underlying inmunocompromised condition. Amphotericin B remains the 
first-line choice for treatment of infections due to Zygomycetes. However clinical 
response is poor, especially in patients with disseminated disease 2. Triazoles and 
allylamines exhibit partly in vitro activity against this class of fungi 4 but these agents are 
not used clinically. Nystatin exhibits also good in vitro activity but no clinical data are 
available to confirm their in vivo activity.  
Post drug exposure effects are important to understand and optimalize drug efficacy in 
vivo. We have developed an in vitro model that enables the study of post antifungal 
effects (PAFE) in filamentous fungi 5. The aim of the present study was to evaluate the 
PAFE induced by the polyenes amphotericin B and nystatin against  Zygomycetes and to 
compare the PAFE in two different media. 
 
Materials and methods 
 
Isolates. 30 strains from our private collection were evaluated: Absidia corymbifera 
(AZN 24, AZN 319, AZN 911, AZN 1184, AZN 2134, AZN 2543, AZN 3113, AZN 
3114, AZN 4095, AZN 6429); Rhizopus oryzae (AZN 593, AZN 1523, AZN 3440, 
AZN5618, AZN 6142, AZN 6373, AZN 1925); Rhizopus microsporus (AZN 23, AZN 
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190, AZN 410, AZN 1185, AZN 5005, AZN 5816); Rhizomucor miehei AZN 4839; 
Rhizomucor pusillus AZN 22; Mucor hiemalis (AZN 21, AZN 175, AZN 1379) and 
Mucor rouxii AZN 1183.  
Antifungal agents. Amphotericin B (Bristol-Myers Squibb, Woerden, The Netherlands) 
and Nystatin (Gist-Brocades, Delft, The Netherlands) were utilized for MIC 
determinations and PAFE studies. The drugs were dissolved in dimethyl sulfoxide 
(DMSO) and aliquots of the stock solution were stored at –70ºC until use. Then, they 
were diluted in RPMI-1640 medium (with L-glutamine, without bicarbonate) (GIFCO 
BRL, Life Technologies, Woerden, The Netherlands) and Antibiotic Medium 3 (AM3) 
(BBL/Becton Dickinson, Cockeysville, Md.), both buffered to pH 7.0 with 0.165 M 
morpholinopropansulfonic acid (MOPS) (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany).  
Antifungal susceptibility testing . The isolates were passaged twice at an interval of 5-7 
days at 28ºC by subculturing onto Sabouraud glucose agar (SGA) to obtain adequate 
sporulation. Spores were collected with a cotton swab and suspended in saline with 
0.01% Tween 80%. The resulting spore suspensions were counted with a 
haemocytometer and diluted in RPMI-1640 or AM3 1:100 in order to obtain a final 
inoculum of  1-5 x 104 spores per ml. The viability was confirmed by plating serial 
dilutions onto SGA plates.  
 Amphotericin B and nystatin were dissolved in DMSO at concentrations of 3200 mg/L. 
Two fold serial dilutions of the drugs were made in RPMI-1640 and AM3 medium in 
order to obtain final concentrations that ranged from 0.015 to 16 mg/L of both drugs. A 
drug-free well containing 0.01% DMSO in the medium served as the growth control. The 
tests were performed in 96-well flat bottom microtitration plates (Corning Incorporated, 
N.Y., USA) which were kept at -70ºC until the day of testing. After the inoculation, the 
microtitration plates were incubated at 35ºC for 48 h. The MICs were read by 
spectrophotometric reader (Rosys Anthos ht3, Anthos Labtex Instruments GmbH, 
Salzburg, Austria). Background optical density (OD) was measured 
spectrophotometrically in non inoculated wells processed in the same way as the 
inoculated wells. The relative ODs for each well based on measurements at 405 nm were 
calculated (in percentage) based on the following equation: [(OD of drug containing well 
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– background OD)/(OD of drug-free well – background OD)] x 100%. The MIC for both 
drugs was defined as the lowest concentration of the drug that showed at least 95 % 
reduction of growth compared with that of the growth control (MIC-0).  
PAFE assay. The method used for determining PAFE was recently described for 
Aspergillus spp 5. Amphotericin B and nystatin were dissolved in DMSO at initial 
concentrations of 400 mg/L and aliquots of the stock solution were stored at –70ºC until 
used. Then they were diluted 50 times in RPMI-1640 (with L-glutamine without 
bicarbonate) or AM3 medium buffered to pH 7.0 with 0.165 M MOPS. Serial dilutions of 
the drugs were made in both media in order to obtain final concentrations of 4, 1 and 0.5  
times the corresponding MIC. Control spore suspensions were made in RPMI-1640 and 
AM3 without drug. The isolates were passaged twice at an interval of 5-7 days at 28ºC by 
subculturing onto SGA to obtain adequate sporulation. Spores were collected with a 
cotton swab and suspended in saline with 0.01% Tween 80. After the heavy particles 
were allowed to settle, the supernatant was transferred to another tube, vortexed for 10 
sec, and 10 and 100 times dilutions were made. The concentration of spores was 
established microscopically by haemocytometer Burker Turk chambers. Then, the 
concentration was adjusted to obtain 4 x 105 spores/ml. One milliliter of this suspension 
was added to tubes containing 9 ml of RPMI-1640 or AM3 alone (control) or with 
amphotericin B or nystatin in concentrations mentioned above resulting in a final volume 
of 10 ml. The final inoculum therefore was 4 x 104 CFU/ml. Following this procedure, 
each strain was incubated for 4 or 1 h  with continuous shaking at 37ºC. 
After incubation the spores were washed with saline plus 0.01% Tween 80  and 
centrifuged at 3,500 x g during 15 min. After three wash cycles, 98% of the supernatant 
was completely decanted and the pellets were resuspended in a final volume of 10 ml 
RPMI-1640 or AM3 with 0.01% Tween 80. Following this step, 100 ml of sample was 
diluted 10-fold in sterile water and 30 ml aliquots were plated onto SGA plates for colony 
count determination, and incubated at 37ºC for 24 h. The concentration of viable CFU/ml 
for exposed spores was determined in order to verify the concentration of viable spores 
post drug exposure and to allow adjustment of the inoculum, if necessary, to match that 
of controls. From the resuspended suspension, 200 ml was placed in microtitration plates 
and incubated at 37ºC in a computerized spectrophotometric reader (Rosys Anthos ht3). 
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Any growth was automatically monitored in terms of change in turbidity at 405 nm, at 10 
min intervals for 48 h. All assays were performed in duplicate. 
Data analysis. The repetitive OD measurements for each well resulted in the growth 
curve. PAFE was determined by comparing the growth curve of the exposed spores with 
that of the controls. OD0  was used to calculate PAFE as was previously described5, by 
using the formula PAFE = T - C, where T was the time of the first significant increase in 
OD0 of the exposed spores after removal of the drug and C was the time of the first 
significant increase in OD0 of the control. Thus, PAFE was defined as the difference in 
time (Dt) between exposed and controls to reach the defined point in the growth curve 
and was expressed in hours. The time to reach this chosen point, OD0 , of at least 8 
controls for each species was calculated and the mean, range, upper 95% confidence 
interval (CI) and the coefficient of variance were calculated in order to determine the 
reproducibility of the control curves at that point and to establish the reproducibility of 
the experiments. For each species the upper 95% CI of the controls was chosen as the cut -
off level that distinguished between presence or absence of PAFE.  When re-growth of 
the exposed isolates occurred within the upper 95% CI time-frame of the controls, PAFE 
was considered to be absent. Alternatively, if re-growth was delayed following drug 
exposure and the lower 95% CI of the exposed isolates was delayed until beyond the 
upper 95% CI of the controls, PAFE was considered to be present. Growth curves of each 
exposed isolate were compared only with pooled controls from that same isolate. 
Comparison of PAFE between both media and both drugs were analyzed by analysis of 
variance for repeated observations followed by Bonferroni’s Multiple Comparison Tests. 
P values of < 0.05 were considered statistically significant.  
 
Results 
 
The MIC ranges determined in RPMI-1640 were: 0.063-4 mg/L for amphotericin B (A. 
corymbifera 0.125-0.25 mg/L; R. oryzae 0.5-4 mg/ml; R. microsporus 0.5-2 mg/L; R. 
miehei 0.063 mg/L; R. pusillus 0.125 mg/L; M. hiemalis 0.063-0.25 mg/L and M. rouxii 
0.063 mg/L) and 0.5-8 mg/L for nystatin (A. corymbifera 0.5-1 mg/L; R. oryzae 2-8 
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mg/L; R. microsporus 2-8 mg/L; R. miehei 0.5 mg/L; R. pusillus  1 mg/L; M. hiemalis 0.5 
mg/L and M. rouxii 0.5 mg/L). 
For AM3 the MICs of amphotericin B ranged from 0.063 to 2 mg/L (A. corymbifera 
0.125-1 mg/L; R. oryzae 0.5-2 mg/L; R. microsporus 0.25-2 mg/L; R. miehei 0.063 mg/L; 
R. pusillus 0.125 mg/L; M. hiemalis 0.25-0.5 mg/L and M. rouxii 0.063 mg/L) and for 
nystatin from 0.5 to 4 mg/L (A. corymbifera 0.5-2 mg/L; R. oryzae 1-4 mg/L; R. 
microsporus 1-2 mg/L; R. miehei 0.5 mg/L ; R. pusillus 1 mg/L; M. hiemalis 0.5-1 mg/L 
and M. rouxii 0.5 mg/L). 
Viability of the spores. Exposure of spores to the used concentrations of amphotericin B 
and nystatin for 1 to 4 h had no effect on the viability of the A. corymbifera isolates, but 
for the other genera tested both drugs induced fungicidal activity after 4 or 1h of 
incubation at a concentration of 4 times the MIC (Figure 1). Therefore, PAFE was 
determined for 1 h exposure at 1 and 0.5 times the corresponding MIC for these genera. 
In these conditions killing was not observed for the concentration and exposure time 
chosen  based on subculture of serial two-fold dilutions (data not shown).  
Inoculum. By using a haemocytometer chamber a limited range of 2 to 4 x 104 viable 
CFU/ml was achieved.  
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PAFE assay. All growth curves were reproducible among the replicates. For the same 
species the shape of the growth curve of the control was identical to that of the exposed 
strains. When PAFE was present the growth curve of the exposed spores was shifted to 
the right compared with that of the control. Examples of growth curves for A. 
corymbifera and R. oryzae are shown in Fig. 2.  
 
 
 
Morphology. Microscopic examination of the spores before and after drug exposure 
showed that germination did not occur within the maximal exposure period of 4 h for 
Absidia and 1 h for the other species in both media. In RPMI-1640 even after 5 h of 
incubation germination had not occured for control or exposed spores for any of the 
genera. However in AM3 spores of Rhizopus started to germinate after 3 h, and after 5 h 
100% of spores were germinated. For Absidia 80% of spores had germinated after 5 h of 
incubation. Germination of controls and drug exposed spores occurred at the same time 
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and to the same extent in those strains where PAFE was not present. When PAFE was 
present, germination of spores was further delayed. 
Microscopic examination of the moulds at different time intervals post-drug exposure 
revealed that increase of OD correlated with the development of hyphae as described 
previously 6. No differences in morphology were noted between exposed and non-
exposed fungi. 
The variability in OD, expressed as coefficient of variation (CV) among the control and 
exposed isolates was lower than 13%.  
PAFE was induced by both drugs in both media for all strains tested with the exception of 
Rhizomucor spp. (table 1).  PAFE was induced by amphotericin B after 4 or 1h  of 
exposure for the 10 A. corymbifera and for the 7 R. oryzae strains for all the conditions 
tested. (Table 1).   
Overall, higher concentrations of drug induced longer PAFEs. However, the extent of 
PAFE differed between amphotericin B and nystatin for the various species. 
In general, amphotericin B induced longer PAFE compared with nystatin: 4.6 h for 
amphotericin B versus 2.9 h for nystatin in RPMI-1640 (p <0.05), and 4.3 h versus 3 h 
for amphotericin B and nystatin, respectively, in AM3 (p <0.05). No statistical significant 
difference was observed for amphotericin B and nystatin between both media (p>0.05), 
with the exception of low concentration of nystatin. (Table 2). 
Comparision between different genera: all A. corymbifera strains displayed PAFE for 
both drugs at 4 and 1x times the MIC after 4 h exposure in the same medium. However 
for nystatin longer PAFEs in AM3 for both concentrations was seen compared with 
RPMI-1640 (Table  1). PAFE was not induced by amphotericin B or nystatin after 1 h 
exposure (data not shown). For Rhizopus spp. no differences in PAFE values were seen 
when both drugs were compared. Both drugs tended to induce longer PAFE in R. oryzae 
compared with R. microsporum. (Table 1). For Mucor spp. nystatin tended to induce 
longer PAFE values than with amphotericin B in the same medium. This observation was 
only found for this genus. Both, amphotericin B and nystatin failed to induce PAFE in 
Rhizomucor strains.    
Sub MIC exposure: A. corymbifera did not display any PAFE in contrast to the other 
genera where most showed significant PAFE values. For amphotericin B, Rhizopus spp 
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and Mucor spp displayed PAFE in RPMI-1640, but in AM3 only Mucor spp did not show 
the effect. 
For nystatin Rhizopus spp and Mucor spp displayed PAFE in RPMI -1640 and in AM3 
only R. microsporus did not show the effect. 
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Discussion 
 
The method to quantify post antifungal drug exposure in Zygomycetes was based on the 
method recently described for Aspergillus species using a spectrophotometric procedure 
and OD0 (first increase in OD) as criterion to calculate PAFE 5. The reliability of 
measurement of fungal growth using this spectrophotometric system has been described 
previously and even small changes in morphology can be detected. Furthermore the 
system was validated previously for Rhizopus  6.   
The exposure of Absidia spores to amphotericin B or nystatin did not affect the viability 
of the spores at any of the concentrations or incubation periods tested. This finding was 
similar to that observed for Aspergillus species, where viability was not affected by 
exposure of the conidia to amphotericin B 5. However, exposure of the other genera of 
zygomycetes at concentrations above the MIC, resulted in significant decrease in viability 
indicating rapid fungicidal activity.  Rapid fungicidal activity was observed previously 
for Candida at concentrations of amphotericin B above the MIC 7. 
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Post antibiotic effects have been found to be dependent of several factors such as the 
concentration of the antibiotic, exposure time, media used and pH8. In Zygomycetes, 
PAFE appears also to depend on the class of drugs, concentration and duration of 
exposure, as was previously described for Candida and Aspergillus species 5,9.  
The nutrient medium is a major factor that influences the results of in vitro susceptibility 
tests 10. RPMI-1640 has been evaluated extensively for in vitro susceptibility testing of 
yeasts and moulds and has been shown to give reproducible results 11-13. AM3 has been 
shown to discriminate better between Candida strains susceptible and resistant to 
ampothericin B 14, although there are no data that show that this is also the case for 
zygomycetes. Since batch-to-batch variation was described for the in vitro testing of 
antifungal agents with AM3, a single batch was used in the present study. In our  
evaluation  PAFE was observed for both  media, indicating that the effect was not 
dependent on the media used.  
In general, PAFE was similar in RPMI -1640 and AM3 for both drugs with the exception 
of A. corymbifera for which nystatin tended to induce longer PAFE in AM3 than in 
RPMI-1640.  
Amphotericin B and nystatin belong to the polyenes which have a broad  fungicidal 
spectrum in vitro. Due to problems of solubilization and toxicity, parenteral 
administration of nystatin is not use for systemic treatment 15. However the incorporation 
of this drug in liposomes reduced toxicity and preserved antifungal activity 16. 
Intravenous liposomal nystatin studied in rabbits displayed  nonlinear pharmacokinetics, 
potentially therapeutic peak plasma concentrations and substantial penetration in tissues. 
After multiple dosing over 15 days the maximum concentrations in mg/g (mean) were: in 
lung (72.84); liver (41.26); spleen (46.57); kidney (22.85) with a plasma concentration of 
34.74 mg/L 17. 
When studying the relationship between drug concentration and antimicrobial effect, the 
time course of antifungal activity of polyenes is characterised by concentration-dependent 
killing, i.e. enhanced microbial killing by increasing drug levels, and long PAFE 18. 
Although this relationship was studied with conventional amphotericin B, it has been 
demonstrated with antibacterial drugs that specific pharmacodynamic parameters 
predictive of activity varies for different drug classes but not for drugs within a class 18. 
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This was confirmed in the present study where amphotericin B and nystatine, both 
polyenes, showed comparable PAFE characteristics against zygomycetes. It can be 
assumed that the same is true for lipid-formulations of amphotericin B since the active 
compound is amphotericin B.  
The interpretation of our results can only be meaningful if drug levels that induce PAFE 
in vitro are within the range achievable in humans. Although serum concentrations of 
conventional amphotericin B are generally below 2 mg/l, higher levels have been found 
at the site of infection 19,20. The association between dosing of conventional amphotericin 
B and treatment effect is best described by the pharmacodynamic parameter peak level / 
MIC, indicating that the peak concentration achieved in the tissues is a major factor in 
relation to efficacy 18,21 . The drug levels of the lipid formulations of amphotericin B are 
higher than those of conventional amphotericin B, although the pharmacodynamic 
properties of the individual lipid-formulations differ significantly 22. Also for some 
isolates even sub-MIC concentrations induced PAFE.  
The strains tested in this study had a maximum MIC value of 8 mg/ml for nystatin and 
4mg/ml for amphotericin B, indicating that testing the PAFE by using 4 times the MIC, 
the maximum concentration is 32 or 16 mg/L respectively, values that are achievable in 
tissues.  
For both drugs PAFE was observed, however amphotericin B displayed longer values 
compared with nystatin.  
PAFE displayed by amphotericin B and nystatin were concentration dependent. This is 
consistent with previous studies with Aspergillus and Candida where longer PAFEs were 
found following exposure to amphotericin B or nystatin at higher concentrations 5,7,9.  
The mean PAFE values found in our study for all zygomycetes were similar to those 
described for Aspergillus species previously tested  although amphotericin B induced 
longer PAFE against A. fumigatus (mean PAFE= 9.94 h) 5. For nystatin similar PAFEs 
were found for  Candida albicans (mean= 6.85 h) whereas C. non-albicans species 
presented longer PAFE 23.  
In conclusion, amphotericin B and nystatin induced PAFE in Zygomycetes but lower 
PAFE values were observed with nystatin. In general the used media did not significantly 
influence the effect. Determination of PAFE could be useful as an in vitro tool together 
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with the in vitro susceptibility testing  to give a better understanding of the activity of 
antifungal agents. There are not available data of in vivo studies of PAFE for 
Zygomycetes that could support any theory about the importance of this effect as 
predictor of  therapy failure . For this reason , further studies are warranted, including in 
vivo experiments, to study the impact of PAFE in Zygomycetes on dosing regimens of 
amphotericin B or nystatin and the usefulness of this assay to assist in predicting clinical 
outcome.   
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Abstract 
 
The in vitro activity of two phenothiazine compounds, chlorpromazine and 
trifluopherazine were evaluated against Aspergillus species, Zygomycetes and 
Scedosporium species. Both drugs inhibited the growth of all species tested at 
concentrations of 16 to 64 µg/ml. Growth inhibition was also observed after exposure and 
removal of the drug (post-antifungal effect, PAFE). For Aspergillus species the mean 
PAFE was 3.7 h and 4.7 h; for zygomycetes, 3.1 h and 3.4 h; for Scedosporium, 4.3 h and 
5.3 h for chlorpromazine and trifluoroperazine, respectively. This study shows that these 
phenothiazine compunds are moderately active against a broad range of filamentous 
fungal pathogens. 
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Introduction 
 
Opportunistic fungi have emerged during the past decade as important causes of 
morbidity and mortality in immunocompromised patients. The spectrum of moulds that 
cause invasive fungal infections is evolving from predominantly Aspergillus to a variety 
of molds including zygomycetes and Scedosporium (26). Aspergillus species remain the 
most common infectious cause of pneumonia in hematopoietic stem cell transplant 
recipients. Zygomycetes cause aggressive infections especially in patients with diabetic 
ketoacidosis, neutropenia or in those receiving corticosteroids. An increasing number of  
members of the class of zygomycetes are reported to cause lethal infections, despite 
aggressive medical and surgical interventions (15, 26). Scedosporium species have 
evolved into important agents causing disseminated infections, mainly in neutropenic 
patients and often treatment with antifungals agents has been unsuccesfull (7). Both 
Scedosporium apiospermum and S. prolificans are intrinsically resistant to many 
antifungal agents (7, 20). 
Although voriconazole was shown to be superior to amphotericin B and other licenced 
antifungal therapy for the primary treatment of invasive aspergillosis, the response rates 
remain low. The outcome of treatment of invasive zygomycosis and scedosporiosis 
remains poor even with the use of lipid-formulations of amphotericin B (4, 6, 23). The 
poor outcome of treatment of invasive mould infections is primarily due to host factors 
such as the underlying condition. Furthermore, delay in obtaining a diagnosis and correct 
identification of the infecting mould is believed to contribute to the poor outcome. 
Finally, the susceptibility of the infecting strain is important with respect to the response. 
However, the efficacy of treatment is as low as 50% even when the infecting strain is 
susceptible to the drug administered. Given this situation the potential of other 
compounds should be investigated for their antifungal activity, especially when they 
interact with a target that differs from known targets of conventional antifungal drugs.  
Phenothiazine compounds as chlorpromazine and trifluopherazine are antipsychotic 
agents that inhibit calmodulin leading to multiple cellular effects including modification 
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of membranes, alteration of cyclic nucleotide metabolism and intercalation into DNA (17, 
19).  
Calmodulin, a Ca2+ binding protein, was suggested in genetic studies as essential for 
growth of fungi (16). Calmodulin has been reported to be essential for cell proliferation in 
fungi including Saccharomyces cerevisiae, Schizosaccharomyces pombe , Cryptococcus 
neoformans, Candida albicans and Aspergillus nidulans (14, 16, 21). Phenothiazine 
compounds  have been reported to exhibit antibacterial and antifungal activity in vitro 
and in vivo (2, 3, 5, 8, 24, 27, 28). The  aim of this study was to determine whether 
phenothiazines possess in vitro activity  against difficult-to-treat filamentous fungi. 
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Materials and methods 
 
Isolates. 84 strains from our private collection were evaluated: A. fumigatus (AZN 58, 
AZN 59, AZN 60, AZN 62, AZN 63, AZN 64, AZN 65, AZN 5161, AZN 7820, AZN 
8248, AZN 9339, AZN 9370, AZN 5241, AZN 5242, AZN 7720, AZN 7722, AZN 9360, 
AZN 9362, AZN 9372, AZN 267); A. ustus (AZN 677, AZN 678, AZN 741, AZN 924, 
AZN 2725, AZN 6989, AZN 943, AZN 7463, AZN 9420); A. terreus (AZN 142, AZN 
286, AZN 299, AZN 515, AZN 2868, AZN 5914, AZN 8764, AZN 9152, AZN 4061, 
AZN 7320); A. corymbifera (AZN 24, AZN 319, AZN 911, AZN 1184, AZN 2134, AZN 
2543, AZN 3113, AZN 3114, AZN 4095, AZN 6429); R. oryzae (AZN 593, AZN 1523, 
AZN 3440, AZN5618, AZN 6142, AZN 6373, AZN 1925); R. microsporus (AZN 23, 
AZN 190, AZN 410, AZN 1185, AZN 5005, AZN 5816); S. apiospermum (AZN 409, 
AZN 631, AZN 1711, AZN 2036, AZN 2420, AZN 6476, AZN 7110, AZN 9604, AZN 
4-59, AZN 7-20) and S. prolificans (AZN 7307, AZN 7889, AZN 7891, AZN 7892, AZN 
7893, AZN 7894, AZN 7895, AZN 7897, AZN 7898, AZN 7900). 
Antifungal agents . Chlorpromazine and trifluopherazine (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) were utilized for MIC determinations and post antifungal effect 
(PAFE) studies. The drugs were dissolved in water and aliquots of the stock solution 
were stored at –70 ºC until use. Then, they were diluted in RPMI 1640 medium (with L-
glutamine, without bicarbonate) (GIFCO BRL, Life Technologies, Woerden, The 
Netherlands)  buffered to pH 7.0 with 0.165 M morpholinopropansulfonic acid (MOPS) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany).  
Antifungal susceptibility testing. Antifungal susceptibility testing. The test was 
performed following the NCCLS guidelines (22). The isolates were passaged twice at an 
interval of 5-7 days at 35ºC by subculturing onto Sabouraud glucose agar (SGA) to 
obtain adequate sporulation. Spores were collected with a cotton swab and suspended in 
saline with 0.01% Tween 20 or Tween 80. The resulting conidia or spore suspensions 
were counted with a haemocytometer and diluted in RPMI-1640 1:100 in order to obtain 
a final inoculum of  1-5 x 104 conidia or spores per ml. The viability was confirmed by 
plating serial dilutions onto SGA plates.  
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Chlorpromazine and trifluopherazine were dissolved in water at concentrations of 10,200 
mg/L. Two fold serial dilutions of the drugs were made in RPMI-1640 in order to obtain 
final concentrations that ranged from 0.5 to 256 mg/L of both drugs. A drug-free well 
containing 0.01% water in the medium served as the growth control. The tests were 
performed in 96-well flat bottom microtitration plates (Corning Incorporated, N.Y., USA) 
which were kept at -70ºC until the day of testing. After the inoculation, the microtitration 
plates were incubated at 35ºC for 24 to 72 h. The MICs were read by spectrophotometric 
reading (Rosys Anthos ht3, Anthos Labtex Instruments GmbH, Salzburg, Austria). 
Background optical density (OD) was measured spectrophotometrically in non-inoculated 
wells processed in the same way as the inoculated wells. The rela tive ODs for each well 
based on measurements at 405 nm were calculated (in percentage) based on the following 
equation: [(OD of drug containing well – background OD)/(OD of drug-free well – 
background OD)] x 100%. The MIC for both drugs was defined as the lowest 
concentration of the drug that showed at least 95 % reduction of growth compared with 
that of the growth control (MIC-0). The susceptibility was performed in duplicate. 
PAFE assay.  The method used for determining PAFE was described for Aspergillus spp. 
(25). Chlorpromazine and trifluopherazine were dissolved in water to obtain an initial 
concentration of 16,000 mg/L and aliquots of the stock solution were stored at –70ºC 
until used. The day that the assay was done, the drugs were diluted in water to obtain a  
dilution of 5,100 mg/L. Serial dilutions of the drugs were made in RPMI-1640 with 
MOPS in order to obtain final concentrations of 2 and 1 times the corresponding MIC. 
Control conidia or spore suspensions were made in RPMI-1640 without drug. The 
isolates were passaged twice at an interval of 5-7 days at 35ºC by subculturing onto SGA 
to obtain adequate sporulation. Conidia or spores were collected with a cotton swab and 
suspended in saline with 0.01% Tween 20 or 80. Tween 20 was used for Aspergillus and 
Scedosporium species and Tween 80 for Zygomycetes. After the heavy particles were 
allowed to settle, the supernatant was transferred to another tube, vortexed for 10 sec, and 
10 and 100 times dilutions were made. The concentration of conidia or spores was 
established microscopically by hematocymeter Burker Turk chambers. Then, the 
concentration was adjusted to obtain 4 x 105 conidia or spores/ml. One milliliter of this 
suspension was added to tubes containing 9 ml of RPMI-1640 alone (control) or 
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chlorpromazine or trifluopherazine in concentrations mentioned above resulting in a final 
volume of 10 ml. The final inoculum therefore was 4 x 104 CFU/ml. Following this 
procedure, the incubation was for 1 up to 6 h with continuous shaking at 37ºC according 
to the corresponding strain. 
After incubation, the conidia or spores were washed with saline plus 0.5 % Tween 20 or 
80 and centrifuged at 3,500 x g during 15 min. After three wash cycles, 98% of the 
supernatant was completely decanted and the pellets were resuspended in a final volume 
of 10 ml RPMI-1640 with 0.01% Tween 20 or 80. Following this step, 100 ml of sample 
was diluted 10-fold in sterile water and 30 ml aliquots were plated onto SGA plates for 
colony count determination, and incuba ted at 37ºC for 24 up 72 h. The concentration of 
viable CFU/ml for exposed conidia or spores was determined in order to verify the 
concentration of viable conidia or spores post drug exposure compared with the controls. 
From the resuspended suspension, 200 ml was placed in microtitration plates and 
incubated at 37ºC in a computerized spectrophotometric reader (Rosys Anthos ht3). Any 
growth was automatically monitored in terms of change in turbidity at 405 nm, at 10 min 
intervals for 48 h to 72 h. All assays were performed in duplicate. 
Data analysis. The repetitive OD measurements for each well resulted in the growth 
curve. PAFE was determined by comparing the growth curve of the exposed spores with 
that of the controls. OD0  was used to calculate PAFE as was previously described 21, by 
using the formula PAFE = T - C, where T was the time of the first significant increase in 
OD0 of the exposed conidia or spores after removal of the drug and C was the time of the 
first significant increase in OD0 of the control. Thus, PAFE was defined as the difference 
in time (Dt) between exposed and controls to reach the defined point in the growth curve 
and was expressed in hours. The time to reach this chosen point, OD0 , of at least 8 
controls for each species was calculated and the mean, range, upper 95% confidence 
interval (CI) and the coefficient of variance were calculated in order to determine the 
reproducibility of the control curves at that point and to establish the reproducibility of 
the experiments. For each species the upper 95% CI of the controls was chosen as the cut -
off level that distinguished between presence or absence of PAFE.  When re-growth of 
the exposed isolates occurred within the upper 95% CI time-frame of the controls, PAFE 
was considered to be absent. Alternatively, if re-growth was delayed following drug 
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exposure and the lower 95% CI of the exposed isolates was delayed until beyond the 
upper 95% CI of the controls, PAFE was considered to be present. Growth curves of each 
exposed isolate were compared only with pooled controls from that same isolate. 
Comparison of PAFE between both drugs en each group for both concentrations were 
analyzed by analysis of variance for repeated observations followed by Bonferroni’s 
Multiple Comparison Tests. P values of < 0.05 were considered statistically significant. 
 
Results 
 
Chlorpromazine  and trifluopherazine were active in vitro against all moulds tested. 
(Table 1). The geometric mean (GM) in mg/L of chlorpromazine were: A fumigatus : 
42.2; A. ustus: 64; A. terreus: 64;  A. corymbifera: 59.7; R. oryzae: 32; R. microsporum: 
32; S. apiospermum: 48.5 and S. prolificans: 34.3. 
The GM, in mg/L, of trifluopherazine were: A fumigatus: 34.3; A. ustus: 32; A. terreus : 
34.3; A. corymbifera: 34.3; R. oryzae: 16; R. microsporum: 16; S. apiospermum: 39.4; 
and S. prolificans: 32. 
Viability of the conidia or spores. Exposure of conidia to the used concentrations of 
chlorpromazine and trifluopherazine for 6 h had no effect on the viability of the 
Aspergillus and Scedosporium species. For Zygomycetes exposure of spores to the used 
concentrations of chlorpromazine and trifluoperazina for 4 h had no effect on the viability 
of A. corymbifera but for the Rhizopus species tested both drugs reduced the 
concentration of viable spores by more than 80 % compared with the control. Therefore, 
PAFE was determined for 1 h exposure at 2 and 1 times the corresponding MIC for 
Rhizopus species. In these conditions viability was not affected based on subculture of 
serial two-fold dilutions (data not shown).  
Inoculum. By using a haemocytometer chamber a limited range of 2 to 4 x 104 viable 
CFU/ml was achieved.  
PAFE assay. All growth curves were reproducible among the replicates although they 
were different depending on the strain evaluated. The shape of the curves was identical 
for both drugs. 
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For the same species the shape of the growth curve of the control was identical to that of 
the exposed strains. When PAFE was present the growth curve of the exposed spores was 
shifted to the right compared to that of the control. Examples of growth curves are shown 
in Fig. 1.  
Microscopic morphology. Microscopic examination of the conidia or spores before and 
after drug exposure showed that germination did not occur within the maximal exposure 
period in each case. Germination of controls and drug exposed conidia or spores occurred 
Table 1. The in vitro activity of chlorpromazine and trifluopherazine against 84
filamentous fungi.
MIC90 mg/L (range)Fungus (n= number of isolates)
Chlorprom azine Trifluopherazine
Aspergillus fumigatus
(n=20)
64 (32-64) 32 (32-64)
Aspergillus terreus (n=10) 64 (64) 32 (32-64)
Aspergillus ustus (n=10) 64 (64) 32 (32)
Absidia corymbifera (n=10) 64 (32-64) 32 (32-64)
Rhizopus oryzae (n=7) 32 (32) 16 (16)
Rhizopus microsporum
(n=7)
32 (32) 16 (16)
S. apiospermum (n=10) 64 (32-64) 64 (32-64)
S. prolificans (n=10) 64 (32-64) 32 (32)
MIC 90: minimal inhibitory concentration that inhibited 90% of the isolates tested.
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at the same time and to the same extent in those strains where PAFE was not present. 
When PAFE was present, germination of the exposed conidia or spores was further 
delayed. 
 
 
 
 
 
Table 2. PAFEs induced by chlorpromazine against 84 filamentous fungi. 
 
PAFE (h)  Fungus (n= number of 
isolates) Cc* Mean Range N/TN 
2x 3 0.9-5.8 15/20 A.fumigatus ( n=20) 
1x 0.2 -0.5-0.8 0/20 
2x 3.2 1.1-5.3 6/10 A. terreus (n=10) 
1x 0.2 -1.2 2/10 
2x 5.5 4-7.3 10/10 A. ustus (n=10) 
1x 1.3 -1.2-4.2 2/10 
2x 3.7
 
0.9-7.3 31/40 Overall: Aspergillus species 
(n=40) 1x 0.4 -2.1-4.2 4/40 
2x 4.2 3.1-5 10/10 A.corymbifera (n=10) 
1x 1.8 0.5-2.5 8/10 
2x 2.5 1.3-3.8 7/7 R.oryzae (n=7) 
1x 0.3 0.1-0.6 0/7 
2x 2 1.1-3 7/7 R. microsporus (n=7) 
1x 0.3 -0.03-0.9 0/7  
2x 3.1 1.1-5 24/24 Overall:  Zygomycetes 
(n=24) 1x 0.9 -0.03-2.5 8/24 
2x 4.5 0.5-10.7 8/10 S. apiospermun (n=10) 
1x 1.3 0.4-2.1 1/10 
2x 4.1 2.5-7.4 10/10 S. prolificans (n=10) 
1x 0.9 0.4-2.1 0/10 
2x 4.3 0.5-10.7 18/20 Overall:  Scedosporium 
species 
 (n= 20) 
1x 1.1 -1.8-3.5 1/20 
*
: concentration of the drug tested. 2 times (2x) and 1 time (1x) the corresponding MIC. 
 N/TN: number of strains for which trifluopherazine displayed significant PAFE/ total number of st rains tested considering the 95% 
CI.  
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Comparison amongst all the strains. In general, PAFE was induced by both drugs and  
was influenced by concentration. The highest concentration resulted in the longest PAFE 
in all the strains tested. (Table 2-3).  
Overall, the mean and the range of the PAFE induced by chlorpromazine at 1 and 2 times 
the MIC were  0.7 h (-2.1-4.2) and 3.6 h (0.5-10.7), respectively, compared with  0.5 h ( -
2.3-3.9) and 4.5 h (-3.2-10) for trifluopherazine. At 2 times the MIC, 87 % (73/84) of all 
strains showed PAFE for chlorpromazine and  93 % (78/84) for trifluopherazine.  
Comparison between Aspergillus species. PAFE was not observed for A. fumigatus at 1 
time the MIC for both drugs. However, for these species at 2 times the MIC, 
chlorpromazine induced PAFE against 75% of the strains (mean PAFE 3h) and 
trifluopherazine against 85% of the strains (mean PAFE 4h). (Table 2-3).Chlorpromazine 
induced PAFE against 60% of A. terreus and A. ustus strains and trifluopherazine against 
100% of the strains at 2 times the MIC. For these species chlorpromazine induced PAFE 
at 1 time the MIC for only 2 of the 10 strains tested. (Table 2-3). 
Overall, for Aspergillus species, chlorpromazine induced PAFE at 2 times the MIC for 
76% of the strains and trifluopherazine for 92%. (Table 2-3). 
Both drugs induced the longest PAFE at 2 times the MIC for A. ustus with statistical 
significant difference compared with A. fumigatus and A. terreus (p<0.05). (Table 2-3). 
The PAFE induced by  trifluopherazine at 2 times the MIC  was significantly longer than 
by chlorpromazine  (p<0.05).  (Table 2-3). 
Comparison between different genera of Zygomycetes. PAFE was observed for all the  A. 
corymbifera strains at 2 times the MIC with a mean of 4.2 h for chlorpromazine and 4.5 h 
for trifluopherazine. For Rhizopus spp. no differences in PAFE values were seen between 
both drugs. 
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Chlorpromazine induced PAFE for R. oryzae and R. microsporus at 2 times the MIC, 
(mean PAFE 2.5 h and 2 h respectively), whereas for trifluopherazine the mean PAFE 
values were 2.5 h and 2.8 h, respectively. No PAFE was observed after exposure of both 
species to either drug at a concentration equivalent to the MIC. (Table 2-3). 
Overall, for Zygomycetes, chlorpromazine and trifluopherazine induced PAFE at 2 times 
the MIC for 100% of the strains. (Table 2-3). 
O
D
Time (h)
15                30 15                30
0.57
0.47
0.37
0.27
0.17
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Control
1x MIC
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Figure 1. Growth curves of 4 filamentous fungi exposed to trifluopherazine 
at 1 and 2 times the MIC values
a: A. fumigatus b: A. corymbifera
c: R. oryzae d: S. prolificans
a
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Both drugs  induced the longest PAFE  at 2 times the MIC , with a mean PAFE value of 
3.6 h and 4.5 h for chlorpromazine and trifluopherazine, respectively. Thus statistical 
significant difference between both drugs was observed (p<0.05). (Table 2-3).  
Comparison between S. apiospermum and S. prolificans. The mean PAFE value for 
chlorpromazine at 2 times the MIC was 4.5 h for S. apiospermum and 4.1 h for S. 
prolificans and for trifluopherazine was 4.7 h and 5.9 h, respectively. (Table 2-3).  For 
only one strain of S. apiospermum of the 20 tested  both drugs induced PAFE at 1 time 
the MIC, whereas at 2 times the MIC, for 90% of the strains  the effect was observed with 
Table 3. PAFEs induced by trifluopherazine against 84 filamentous fungi. 
PAFE (h) Fungus (n= number of 
isolates) Cc* Mean Range N/TN 
2x 4 0.3-6.6 17/20 A.fumigatus ( n=20) 
1x -0.1 -1.2-0.9 0/20 
2x 4.5 1-8.6 10/10 A. terreus (n=10) 
1x 0.7 -1.4-3.1 2/10 
2x 6.5 2.9-10 10/10 A. ustus (n=10) 
1x -0.07  -2.3-2.3 0/10 
2x 4.7
 
0.3-10 37/40 Overall: Aspergillus species 
(n=40) 1x 0.1 -2.3-3.1 2/40 
2x 4.5 3.5-6 10/10 A.corymbifera (n=10) 
1x 1.4 0.1-2.3 6/10 
2x 2.5 1.2-3.6 7/7 R.oryzae (n=7) 
1x 0.6 0-1.3 0/7 
2x 2.8 2-3.4 7/7 R. microsporus (n=7) 
1x 0.8 0.1-1 0/7 
2x 3.4 1.2-6 24/24 Overall:  Zygomycetes 
(n=24) 1x 1 -0.03-2.3 7/24 
2x 4.7 -3.2-9.8 7/10 S. apiospermun  (n=10) 
1x 1.1 -1.6-3.9 1/10 
2x 5.9 3-9.7 10/10 S. prolificans (n=10) 
1x 0.4 -2.3-2.2 0/10 
2x 5.3 -3.2-9.8 17/20 Overall:  Scedosporium 
species 
 (n= 20) 
1x 0.7 -2.3-3.9 1/20 
*
: concentration of the drug tested. 2 times (2x) and 1 time (1x) the corresponding MIC.  
  N/TN: number of strains for which trifluopherazine displayed significant PAFE/ total number of strains tested considering the 95% 
CI.  
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mean PAFE values of 4.3 h and 5.3 h for chlorpromazine and trifluopherazine, 
respectively. No statistical significant difference was found between both drugs (p>0.05). 
(Table 2-3). Overall, for these species, chlorpromazine induced PAFE at 2 times the MIC 
for 90% of the strains and trifluopherazine for 85%. (Table 2-3). 
 
Discussion 
 
In this study, chlorpromazine and trifluopherazine were shown to be moderately active 
against Aspergillus, zygomycetes and Scedosporium at concentrations ranging from 16 to 
64 µg/ml. These concentrations are beyond the achievable plasma concentrations in 
humans, that vary between 0.5 and 1 µg/ml. Although the plasma concentrations of these 
drugs is low, they may be concentrated to as much as 70 to 100 fold the plasma level in 
tissues and macrophages (2, 12). In autopsy studies concentrations of phenothiazines of 
up to 190 mg/g were found in the liver (13). The in vitro activity observed is comparable 
with that shown for Candida species (10 to 40 µg/ml) (8, 28) and C. neoformans (40 
µg/ml) (27). Activity at similar concentrations was also reported against Staphylococcus 
aureus (35 µg/ml), Acinetobacter species (40 µg/ml), Streptococcus faecalis (60 µg/ml) 
and Escherichia coli (80 µg/ml) (1). In a murine model of invasive candidosis the 
survival of infected control mice with C. albicans was 14% while for mice receiving 
daily injections of 4.2 mg/kg of body weight of trifluopherazine, 85.7% survived. Similar 
results were obtained in a C. neoformans in vivo model in which the survival increased 
from 10% to 70% for mice receiving daily injections of 7 mg/kg of body weight of 
trifluopherazine  (8). 
The mechanism of action of these drugs against fungi is unknown, although they induce 
multiple effects in eukaryotic cells including modification of membranes, alteration of 
cyclic nucleotid metabolism and action on calmodulin (8, 17, 19). Since the presence of 
calmodulin in Candida was reported, this could act as target for these drug s(14). A. 
nidulans contains genes encoding for Ca2+ binding proteins that are essential for growth 
(16). Alternatively, phenothiazines were found to be modulators of membrane drug 
transporters (multidrug efflux pumps), which might be an alternative mechanism of 
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action. However, the exact mode of action in the fungal pathogens tested in our study 
remains to be established.  
Besides inhibition of growth, exposure of Aspergillus , zygomycetes and Scedosporium to 
the phenotiazines resulted in a concentration-dependent post antifungal effect. In previous 
studies with Aspergillus  and Candida using this and other in vitro models, PAFE was 
observed only for polyenes and not for other antifungal agents including azoles and 
allylamines (9-11, 25).  Amphotericin B induced longer PAFE than the antipsychotic 
drugs against  A. fumigatus; 9.9 h for amphotericin B compared with 3.7 h for 
chlorpromazine  and 4.7 h for trifluopherazine. However , for A. terreus and A. ustus 
similar PAFE values were observed for  amphotericin B and chlorpromazine and 
trifluopherazine (25). The phenothiazines are the first drugs to induce PAFE against 
Scedosporium.   
The role of phenothiazines for the treatment of patients with fungal infection is unknown, 
given the high number of side-effects which suggests non-specific toxicity against 
eukaryotic cells. This is supported by the fact that a large variety of micoorganisms, both 
prokaryotic and eukaryotic, are inhibited by similar concentrations of drug. However, the 
profile of effects induced by the drugs is greatly influenced by geometric 
stereoisomerisim of the compounds. The cis form of the compounds possess both 
neuroleptic and antifungal activity, while the trans form shows antifungal activity but no 
neuroleptic effects (18).  
Given the geometric stereoisomerism, the pharmacokinetic properties of the drugs with 
high drug levels in brain tissue, and the potent post antifungal effect in difficult-to-treat 
moulds,  phenothiazines might be an interesting drug to further explore for its potential 
for treatment of invasive fungal infection either alone or in combination with antifungal 
agents. For this, the mechanism of action in fungi needs to be identified.  
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Abstract 
 
We evaluated the minimal inhibitory concentration (MIC), minimal fungicidal 
concentration (MFC) and post antifungal effect (PAFE) of amphotericin B (AMB), 
itraconazole (ITZ) and fluconazole (FCZ), in nine clinical strains of Aspergillus 
fumigatus of which three were ITZ susceptible (ISS), three ITZ resistant (IRS) and three 
ITZ mutants (IRM). The evaluation was carried out by pre-incubating all strains at sub-
inhibitory concentrations of ITZ, AMB and FCZ, and by comparing the results with those 
from the wild-type strains. 
The MICs and MFCs of AMB were similar for the pre and wild-type strains. The MICs 
for ITZ were similar after 1 week of pre-incubation although the MFCs for the ISS 
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increased.  However, after 8 weeks of pre-incubation the MICs of the ISS also increased. 
When the strains were pre-incubated with FCZ, the MICs of ITZ for the non and pre-
incubated strains were similar whereas the MFCs were higher for the pre-incubated 
strains. Preincubation with AMB did not alter the MICs and MFCs  of ITZ.  
For the wild-type strains, PAFE was induced by AMB at 4, 1 and 0.5 times the 
corresponding MIC but not by ITZ or FCZ. After pre-incubation longer PAFEs were 
observed with the exception of those pre-incubated with ITZ during 1 week at 1 and 0.5 
times the MIC. In all cases, PAFE was concentration dependent.  
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Introduction 
Invasive fungal infections are a common cause of morbidity and mortality in 
immunocompromised patients such as neutropenic patients or hematopoietic stem cell 
transplant recipients (2). AMB remains a first line drug for treatment of fungal infections 
but in certain high risk patient groups establishing prophylactic strategies is vital to 
prevent invasive infections. The use of AMB as prophylactic agent is limited due to a 
lack of gastrointestinal absorption and its side effects (3). FCZ is well absorbed and has a 
favorable toxicity profile but has a narrow spectrum of activity excluding several non-
albicans Candida species and moulds (8). ITZ has a broad spectrum of activity and is 
frequently used for prophylaxis of invasive fungal infections (3, 7, 20, 21). However, 
attenuation of the effectiveness of AMB after ITZ prophylaxis has been reported (3, 7, 
24). It has been postulated that azoles inhibit the biosynthesis of ergosterol resulting in its 
depletion thereby reducing the target for AMB. Thus, subsequent exposure of fungi to 
azoles and AMB would result in an antagonistic interaction. This effect was described for 
Candida species and Aspergillus species in vitro and in vivo (9, 10, 18, 22). In contrast, 
administration of AMB followed by azoles was reported to be effective (1, 12, 19) and 
administration of AMB and azoles simultaneously appears not to result in significant 
antagonism between the drugs.  
Since patients at high risk for fungal infections commonly receive either FCZ or ITZ 
prophylaxis and switch to an AMB formulation when suspected for invasive fungal 
infection, we sought to simulate this situation in vitro. Aspergillus fumigatus strains with 
variable susceptibility to ITZ were selected including susceptible strains, laboratory 
resistant mutants and clinical resistant strains. The strains were pre-incubated with the 
azoles ITZ and FCZ, and with the polyene AMB during a period of up to eight weeks. 
The activity of AMB, ITZ and FCZ against the wild-type and pre-incubated strains was 
determined using several methods including minimal inhibitory concentration (MIC), 
minimal fungicidal lethal concentration (MFC) and post antifungal effect (PAFE).  
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Materials and methods 
Isolates. Nine A. fumigatus strains from our private collection were evaluated. ITZ 
susceptible (ISS) were AZN 9339, AZN 5161, AZN 7820. These isolates were used to 
create laboratory resistant mutants to ITZ (IRM): AZN 5161, AZN 9339, AZN 7820 and 
ITZ resistant strains (IRS) that were clinical strains obtained from different patients with 
high MIC values of ITZ (AZN 7722, AZN 58, AZG 7). 
Antifungal agents. AMB (Bristol-Myers Squibb, Woerden, The Netherlands), ITZ 
(Janssen-Cilag, Beerse, Belgium) and FCZ (Pfizer, Capelle aan den IJssel, The 
Netherlands) were utilized for all in vitro studies. AMB and ITZ were dissolved in 
dimethyl sulfoxide (DMSO) and FCZ in water. Aliquots of the stock solution were stored 
at –70 ºC until use. The stock solutions were diluted in RPMI-1640 medium (with L-
glutamine without bicarbonate) (GIBCO BRL, Life Technologies, Woerden, The 
Netherlands) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany). 
ITZ resistant mutants. In order to obtain resistant mutants, the wild-type strains were 
maintained on potato dextrose agar for 6 days at 35ºC and the conidia were collected to 
prepare a suspension. The concentration of conidia was established microscopically by 
hematocymeter Burker Turk chambers. Approximately 5 x 106 conidia per plate were 
spread on potato dextrose agar plates containing 8 mg/ml of ITZ. The plates were 
incubated for 6 days at 35ºC and then were subcultured following the same procedure 
once a week during 6 months. The in vitro activity of ITZ was determined over time 
using the NCCLS M-38A guideline (16). 
Pre-incubation of the strains. All A. fumigatus strains were preincubated at 
subinhibitory concentrations of the drugs in plates containing solid media. The plates 
were prepared as follows: RPMI-1640 was prepared at double concentration (2x) and 
sterilized by filtration. Agar-agar was prepared at double concentration (2x) and 
autoclaved. Then, both media were mixed and when the temperature was appropriate, the 
drugs were added.  
The final drug concentrations in the media were: ITZ 0.06 mg/ml for ISS and 1mg/ml for 
IRS; 0.12 mg/ml for AMB and 8 mg/ml for FCZ for all strains. Each strain was then 
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subcultured once a week in these plates containing antifungals during a total period of 8 
weeks. 
Antifungal susceptibility testing. The MICs of AMB, ITZ and FCZ were determined 
according to the NCCLS guideline (16). The wild-type isolates were passaged twice at an 
interval of 5-7 days at 28ºC by subculturing onto Sabouraud glucose agar (SGA) to 
obtain adequate sporulation. The susceptibility of the pre-incubated strains was 
determined after one and eight weeks of pre-incubation of the wild-type strains with each 
drug. Conidia were collected with a cotton swab and suspended in saline with 0.05% 
Tween 20%. After the heavy particles were allowed to settle, the turbidity of supernatants 
was measured spectrophotometrically (Spectronic 20D; Milton, Roy, Rochester, N.Y., 
USA) at 530 nm and transmission was adjusted to 80-82% corresponding to 0.5 to 4.5 x 
106 CFU/ml. The viability was confirmed by plating serial dilutions onto SGA plates.  
For inoculum preparation the conidia suspensions were diluted 1:100 in order to obtain a 
final inoculum of 0.5 to 4.5 x 104 CFU/ml. A broth microdilution method was performed 
according to the NCCLS guideline (16) using RPMI-1640 medium buffered to pH 7.0 
with 0.165 M MOPS. AMB and ITZ were dissolved in DMSO and FCZ in water at a 
concentration of 3,200 mg/ml. Two fold serial dilutions of the drugs were made in RPMI -
1640 medium in order to obtain final concentrations of 0.25 to 64 mg/ml for FCZ and 
from 0.015 to 16 mg/ml for the other drugs. A drug-free well containing 0.01% DMSO 
served as the growth control for ITZ and AMB. The tests were performed in 96-well flat 
bottom microtitration plates (Corning Incorporated, N.Y., USA) which were kept at -
70ºC until the day of testing. Conidia suspensions, prepared as described above, were 
diluted 1:50 in RPMI-1640 to obtain two times the desired inoculum. After inoculation, 
the microtitration plates were incubated at 35ºC for 48 h. The MICs were read by 
spectrophotometric reader (Rosys Anthos ht3, Anthos Labtex Instruments GmbH, 
Salzburg, Austria). Background optical density (OD) was determined by 
spectrophotometric measurement of noninoculated wells processed in the same way as 
the inoculated wells. The relative ODs for each well based on measurements at 405 nm 
were calculated (in percentage) based on the following equation: [(OD of drug containing 
well – background OD)/(OD of drug-free well – background OD)] x 100%. The MIC for 
AMB was defined as the lowest concentration of the drug that showed at least 95 % 
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reduction of growth compared with that of the growth control (MIC-0) and for ITZ the 
MIC was defined as the lowest concentration of the drug that showed 50% of reduction of 
growth compared with that of the growth control (MIC-2). Off scale MICs or MFCs were 
converted to the next highest concentration.  
Minimal fungicidal concentration (MFC). The MFC was determined for each drug 
with the wild-type and the pre-incubated strains by streaking 100 ml from each well that 
showed complete inhibition of growth onto SDA plates. The plates were incubated at 
35ºC. The MFC was defined as the lowest drug concentration at which growth of less 
than two colonies was observed, which corresponds to 99.9% killing. 
PAFE assay.  The method used for determining PAFE was recently described for 
Aspergillus spp (23). PAFE was evaluated for all the drugs in different conditions: a) for 
the wild-type, b) for ISS, IRM and IRS incubated for one week, c) for ISS, IRM and IRS 
incubated for eight weeks. AMB and ITZ were dissolved in DMSO at initial 
concentrations of 400 mg/ml whereas FCZ was dissolved in water and aliquots of the 
stock solution were stored at –70 ºC until used. Then they were diluted 50 times in 
RPMI-1640 (with L-glutamine without bicarbonate) buffered to pH 7.0 with 0.165 M 
MOPS. Serial dilutions of the drugs were made in order to obtain final concentrations of 
4, 1 and 0.5  times the corresponding MIC. Control spore suspensions were made in 
RPMI-1640 without drug. The non-exposed isolates were passaged twice at an interval of 
5-7 days at 28ºC by subculturing onto SGA to obtain adequate sporulation. For the pre -
incubated strains, the conidia were taken directly from the plates with RPMI -1640 agar 
with the corresponding drug. Conidia were collected with a cotton swab and suspended in 
saline with 0.01% Tween 20. After the heavy particles were allowed to settle, the 
supernatant was transferred to another tube, vortexed for 10 sec, and 10 and 100 times 
dilutions were made. The concentration of conidia was established microscopically by 
haemotocymeter Burker Turk chambers. Then, the concentration was adjusted to obtain 4 
x 105 conidia/ml. One milliliter of this suspension was added to tubes containing 9 ml of 
RPMI-1640 alone (control) or with AMB, ITZ or FCZ in concentrations mentioned above 
resulting in a final volume of 10 ml. The final inoculum therefore was 4 x 104 CFU/ml. 
Following this procedure, each strain was exposed for 4 h with continuous shaking at 37 
ºC. 
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After incubation the conidia were washed with saline plus 0.01% Tween 20 and 
centrifuged at 3,500 x g during 15 min. After three wash cycles, 98% of the supernatant 
was completely decanted and the pellets were resuspended in a final volume of 10 ml 
RPMI-1640 with 0.01% Tween 20. Following this step, 100 ml of sample was diluted 10-
fold in sterile water and 30 ml aliquots were plated onto SGA plates for CFU 
determination, and incubated at 37ºC for 48 h. The concentration of viable CFU/ml for 
exposed conidia was determined in order to verify the concentration of viable conidia 
post drug exposure and to allow adjustment of the inoculum, if necessary, to match that 
of controls. From the resuspended suspension, 200 ml was placed in microtitration plates 
and incubated at 37ºC in a computerized spectrophotometric reader (Rosys Anthos ht3). 
Any growth was automatically monitored in terms of change in turbidity at 405 nm, at 10 
min intervals for 48 h. All assays were performed in duplicate. 
Data analysis. The repetitive OD measurements for each well resulted in a growth curve. 
PAFE was determined by comparing the growth curve of the exposed conidia with that of 
the controls. OD0  was used to calculate PAFE as was previously described (23) , by using 
the formula PAFE = T - C, where T was the time of the first significant increase in OD0 
of the exposed conidia after removal of the drug and C was the time of the first 
significant increase in OD0 of the control. Thus, PAFE was defined as the difference in 
time (Dt) between exposed and controls to reach the defined point in the growth curve 
and was expressed in hours. The time to reach this chosen point, OD0, of at least 8 
controls for each species was calculated and the mean, range, upper 95% confidence 
interval (CI) and the coefficient of variance were calculated in order to determine the 
reproducibility of the control curves at that point and to establish the reproducibility of 
the experiments. For each species the upper 95% CI of the controls was chosen as the cut -
off level that distinguished between presence or absence of PAFE.  When re-growth of 
the exposed isolates occurred within the upper 95% CI time frame of the controls, PAFE 
was considered to be absent. Alternatively, if re-growth was delayed following drug 
exposure and the lower 95% CI of the exposed isolates was delayed until beyond the 
upper 95% CI of the controls, PAFE was considered to be present. Growth curves of each 
exposed isolate were compared only with pooled controls from that same isolate. 
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Comparison of PAFE between non and pre-incubated strains of ISS, IRM and IRS were 
analyzed by analysis of variance for repeated observations followed by Bonferroni’s 
Multiple Comparison Tests. P values of < 0.05 were considered statistically significant.  
 
 
Results 
 
In this study 9 A. fumigatus strains were studied characterized by three ITZ resistance-
profiles: ITZ susceptible (ISS), ITZ resistant (IRS) and ITZ resistant mutants (IRM). 
Each of these strains were exposed to 6 pre-incubation conditions, including exposure to 
ITZ for 1 and 8 weeks; FCZ for 1 and 8 weeks and AMB for 1 and 8 weeks. For each of 
these strains and conditions three parameters were studied namely MIC, MFC and PAFE.  
Inoculum. By using a haemocytometer chamber a limited range of 2 to 4 x 104 viable 
CFU/ml was achieved. This stringent range was chosen to achieve reproducible growth 
curves.  
Viability: Exposure of conidia to the used concentrations of antifungal agents for 4 h had 
no effect on the viability in any condition tested for all the strains. In these conditions 
viability was not affected based on subculture of serial two-fold dilutions (data not 
shown).  
Microscopic morphology. Microscopic examination of the conidia before and after drug 
exposure showed that germination did not occur within the maximal exposure period of 4 
h for all species. The germination of 95% of the controls and drug-exposed conidia 
commenced after 12 h  when PAFE was absent as was demonstrated before.  
For the strains where PAFE was observed no differences in morphology was seen, the 
only difference was the time at which the germination started.  
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MIC determination. The MIC of AMB of the tested A. fumigatus isolates is shown in 
table 1. Pre-incubation with AMB, ITZ and FCZ for 1 or 8 weeks did not affect the MIC 
of AMB. 
The MIC of ITZ is shown in table 2. The ISS had low MICs of ITZ while the IRS and 
IRM had high MICs. Pre-incubation of the ISS with ITZ for 1 week had no effect on the 
MIC, while after 8 weeks of pre-incubation the MIC had risen with 2 to 6 dilution steps. 
Pre-incubation with AMB and FCZ had no effect on the MIC of ITZ. The MIC of the IRS 
and IRM strains was not affected by pre-incubation with AMB, ITZ and FCZ. For FCZ 
all the strains showed MICs > 64 mg/ml. 
MFC determination. The MFCs of AMB ranged from 4 to 8 mg/ml for the wild-type 
strains. Pre-incubation of the ISS strains with AMB, ITZ or FCZ resulted in MFC values 
ranging from 1 to > 16 mg/ml, but no differences of ³ 2 dilution steps were found 
between the wild-type and the pre-incubated strains for the same isolate. The highest 
MFC values were observed when the strains were preincubated with FCZ, with values 
ranging from 4 to > 16 mg/ml. In general no differences in MFC between any of the pre-
incubated strains was observed (Table 1 and 2). 
For the IRS and IRM the MFC was not determined.   
 
Table 1. MIC and MFC  of amphotericin B for all the A. fumigatus non-preincubated and 
incubated for 1 or 8 weeks with amphotericin B (AMB), itraconazole (ITZ) or 
fluconazole (FCZ).  
 Amphotericin B 
 MIC/MFC (mg/ml) 
Strain number-profile 
Pre-incubation condition 
 
9339 ISS 5161ISS 7820 ISS 9339 IRM 5161 IRM 7820 IRM AZG-7 IRS 58 IRS 7722 IRS 
Wild-type 1/4 0.5/2 0.5/2 1/4 0.5/4 1/4 0.5/2 0.5/2 1/2 
1 week ITZ 1/2 1/4 1/2 1/4 0.5/4 1/4 1/2 1/2 1/2 
8 weeks ITZ 2/4 1/2 2/4 1/4 1/8 2/4 1/2 1/2 1/2 
1 week AMB 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 2/8 
8 weeks AMB 0.5/2 0.5/1 1/2 1/2 0.5/1 1/2 0.5/1 0.5/1 0.5/2 
1 week FCZ 1/4 1/4 2/4 2/4 2/4 2/4 2/2 2/4 1/2 
8 weeks FCZ 1/4 1/2 1/2 1/2 1/2 1/4 1/2 1/2 1/2 
 
ISS:  itraconazole susceptible strains 
IRS: itraconazole resistant strains 
IRM: itraconazole resistant mutants strains 
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In general, PAFEs induced by AMB were always longer in the strains that had been pre-
incubated with either AMB, ITZ or FCZ compared with the wild-type strains. However,  
AMB failed to induce PAFE in all strains that had been exposed to ITZ for 1 week at a 
concentration of 1 and 0.5 times the corresponding MIC. 
PAFE assay.  The shape of the growth curves of the control and the exposed strains were 
identical and reproducible among the replicates. When PAFE was present the growth 
curve of the exposed conidia was shifted to the right compared with that of the control 
(23). 
PAFE of AMB. For the strains preincubated with AMB, AMB induced PAFE at all 
concentrations tested. The majority of PAFEs were longer compared with the non-
exposed wild-type strains. 
However, when the same strains were preincubated with ITZ for 1 or 8 weeks , at a 
concentration of 4 times the MIC, the PAFE induced by AMB was longer compared with 
the non-exposed  strains. For strains exposed to ITZ at concentrations of 1 and 0.5 times 
the MIC during 1 week, PAFE was not induced by AMB. When the exposure to these 
conditions was continued for 8 weeks AMB was again able to induce PAFE. These PAFE 
values were similar than those observed for the non-exposed strains.  
Table 2. MIC and MFC of itraconazole for all the A. fumigatus non-preincubated and 
incubated for 1 or 8 weeks with amphotericin B (AMB), itraconazole (ITZ) or 
fluconazole (FCZ). 
 Itraconazole 
 MIC/MFC (mg/ml) 
Strain number-profile 
Pre-incubation condition 
 
9339 ISS 5161ISS 7820 ISS 9339 IRM 5161 IRM 7820 IRM AZG-7 IRS 58 IRS 7722 IRS 
Wild-type 0.25/8 0.12/8 0.12/4 >16/ND 1/8 16/ND >16/ND 16/ND 16/ND 
1 week ITZ 0.5/>16 0.25/>16 0.063/>16 >16/ND >16/ND  16/ND >16/ND 16/ND 16/ND 
8 weeks ITZ 16/>16 >16/ND 2/8 >16/ND >16/ND 16/ND >16/ND 16/ND 16/ND 
1 week AMB 0.25/1 0.25/2 0.5/4 >16/ND >16/ND >16/ND >16/ND 16/ND 16/ND 
8 weeks AMB 0.25/4 0.25/>16 0.5/8 >16/ND >16/ND >16/ND >16/ND >16/ND >16/ND 
1 week FCZ 0.25/>16 0.25/>16 0.5/>16 >16/ND >16/ND >16/ND >16/ND >16/ND >16/ND 
8 weeks FCZ 0.25/>16 0.25/>16 0.25/>16 >16/ND >16/ND  >16/ND >16/ND >16/ND >16/ND 
ISS:  itraconazole susceptible strains 
IRS: itraconazole resistant strains 
IRM: itraconazole resistant mutants strains 
N.D.: no determined 
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For the strains preincubated with FCZ, PAFE was induced by AMB at all the 
concentrations tested. (Table 3). 
For ISS and IRM, statistical significant difference (p<0.05) was found between the wild-
type and the pre-incubated strains at 4 times the MIC for all the drugs after 1 and 8 weeks 
of incubation. However, no difference (p>0.05) was observed for IRS at the same 
conditions. Comparing ISS with IRS only at 4 times the MIC statistical significant 
difference (p<0.05) was obtained analysing all drugs after 1 and 8 weeks of incubation.  
PAFE of ITZ and FCZ. Both azole drugs failed to induce PAFE at any of the condition 
tested. Even concentrations of ITZ as high as 10 and 20  times the MIC failed to induce a 
PAFE (data not shown). 
The comparison of the mean MICs, MFCs and PAFEs for the ISS are given in Figure 1. 
 
 
 
 
 
Table 3. PAFE (h) after 4h exposure to amphotericin B (AMB) at 4,1 and 0.5 times the 
corresponding MIC for IS A. fumigatus strains and the corresponding IRM strains after 
incubation for1 or 8 weeks with amphotericin B (AMB), itraconazole (ITZ) or 
fluconazole (FCZ).  
 
 
  
Strain 
number-
profile 
9339 ISS 9339 IRM  5161  ISS  5161 IRM  7820  ISS  7820 IRM 
Pre-
incubation 
condition 
4x 1x 0.5x 4x 1x 0.5x 4x 1x 0.5x 4x 1x 0.5x 4x 1x 0.5x 4x 1x 0.5x 
Wild-type 11.3 9.0 6.4 9.2 6.8 5.2 6.9 5.0 2.5 10.3 7.5 5 10.2 7.7 4.5 7.8 7.1 6.7 
1 week 
ITZ 20.6 
-
4.3^ 
-
1.9^ 22.5 
-
0.5^ 
-
1.3^ 18.3 
-
0.5^ 
-
1.1^ 17.4 0.4^ 
-
2.1^ 18.5 
-
2.3^ 
-
2.7^ 20.5 1.2^ 1.1^ 
8 weeks 
ITZ 20.3 10.5 8.5 20.5 9.8 7.1 16.0 7.7 6.6 12.2 5.1 2.8 19.0 12.5 9.8 20.1 10.3 7.0 
1 week 
AMB 20 12.0 8.3 20 12.7 10.3 16.2 14.1 10.5 15 8.92 6.20 18.2 12.8 7.6 20.4 12.8 11.8 
8 weeks 
AMB 20.4 10 6 20.3 14.2 9.7 16.8 10.1 5.5 15.6 10 8 19.3 2.6 -2.0 16.2 7.3 3.2 
1 week 
FCZ 19 11 6 21 15 11 15.8 14 11 16 12 8 17 12 8 19 19.8 12.4 
8 weeks 
FCZ 18 10.0 5.5 19 13.9 10 14.9 13 9.6 15.2 11.6 8.2 16.8 12.3 7.9 18.4 19.1 11.9 
 
 
ISS:  itraconazole susceptible strains 
IRS: itraconazole resistant strains 
IMS: itraconazole resistant mutants strains 
^: No PAFE present after 1 week of pre-incubation with ITZ at concentrations of 1x and 0.5x times the 
MIC, considering the 95% CI. 
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Discussion 
 
 In this study we simulated in vitro, the in vivo situation where patients are exposed to 
antifungal agents in a prophylactic setting, followed by treatment with another drug when 
a break-through fungal infection is suspected or documented. In contrast with other 
reports we pre-incubated the strains with ITZ, FCZ or AMB during a long period of time 
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up to eight weeks, and several parameters were study that represent drug activity. Since 
there is evidence that a proportion of patients are colonized with Aspergillus on 
admission and go on to develop invasive aspergillosis, the fungus would be exposed to 
both antifungal agents.  
In contrast to other reports, none of the investigated parameters indicated that the activity 
of AMB was attenuated by pre-exposure to azoles. Although RPMI-1640 is sub-optimal 
for detecting AMB resistance, MFC and PAFE also indicated no change in AMB activity 
(9, 22). 
In a murine model of acute invasive pulmonary aspergillosis it was found that, despite the 
in vitro attenuation of AMB activity, when the isolates were recovered from infected lung 
tissue from animals which were pre-exposed to ITZ, the in vitro susceptibility of AMB 
did not change more than one dilution compared with the baseline MIC (10).  
Pre-incubation of the strains with AMB has not shown to induce variation of the MIC and 
MFC of ITZ compared with the wild -type strains, indicating that the pre-exposure to 
AMB does not attenuate the activity of azoles in vitro. In contrast, it has been 
demonstrated that pre-treatment with AMB followed by addition of azoles potentiate s 
their antifungal activity (12). 
Azoles act as ergosterol synthesis inhibitors by binding to lanosterol demethylase, a 
specific enzyme in ergosterol biosynthesis. They also may target lipids of fungal plasma 
membranes and may interact with methylsterol biosynthesis (11). 
Different potential mechanisms of azoles resistance have been proposed: alteration in 
drug influx; alteration in intracellular drug processing: alterations in the target enzyme: 
point mutations, overexpression, gene amplification, gene conversion; alterations in other 
enzymes in the ergosterol biosynthesis pathway; alteration in the efflux pumps: ATP 
binding cassette transporters (e.g., CDR1 and CDR2) and major facilitators (e.g., 
CaMDR1) (25). The mechanism of resistance for all azoles in A. fumigatus is not known, 
although there is one study in which the mechanism of resistance of posaconazole was 
shown to be a mutation in cyp51A. In A. fumigatus  resistance to posaconazole was found 
to be linked to resistance against ITZ but not against voriconazole. These observations 
suggest that different mechanisms are involved in the way that azoles bind the 14-a 
demethylase (14). Several investigators have proposed different mechanisms of resistance 
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in A. fumigatus. A possible modification of cytochrome P450 or intracellular reduction of 
the drug was suggested for ITZ in a murine model of invasive aspergillosis(4). In other 
report the ITZ resistance in A. fumigatus was suggested to be due to reduced penetration 
of the drug due to impermeability and modification of the target (13).  
In our study we found that the MIC for ITZ in the IRS (resistant) and IRM (mutants 
resistant strains) remained high but  these strains remained susceptible to AMB as has 
been shown before (13).  
In the ISS we noted that pre-incubation of the strains with ITZ initially resulted in an 
increase of MFC while the MIC remained unchanged. After 8 weeks of pre-incubation 
the MIC increased. This might suggest that an increase of the MFC could be the first sign 
for the development of resistance. The MFC of azoles was found to be higher than the 
corresponding MIC in A. fumigatus and A. terreus (6).  
Interesting to observe is that, despite no activity of FCZ against Aspergillus, the activity 
of ITZ varies in terms of MFC but not MIC in strains pre-exposed to FCZ suggesting 
again that the MFC could be a good predictor of strain susceptibility.  No differences in 
MFC between the different pre-incubated strains were observed.   It might be possible that 
the presence of FCZ induces cross resistance and activation of pumps, with a more rapid 
efflux of ITZ or another mechanisms resulting in the loss of activity of ITZ. High doses 
of FCZ were reported to have some effect to inhibit the growth of Aspergillus (17).  
PAFE studies with AMB showed that the effect was concentration dependent as was 
described previously for Aspergillus, Candida and Cryptococcus. (5, 23). In the present 
study AMB displayed PAFE against the wid-types of the ISS, IRM and IRS  as well as  
following pre-incubation with ITZ, FCZ or AMB. Exposure of all strains to azoles 
resulted in an increased PAFE compared with the unexposed controls when the strains 
were exposed to a high concentration of AMB. However, in strains incubated with ITZ 
for one week at 1 and 0.5 times the MIC, AMB induced no PAFE at low concentrations. 
For ITZ and FCZ the effect was not observed even at higher concentrations being in 
agreement with previous studies in which PAFE was absent or short when investigated 
with azoles (15, 23). 
The reason for this striking difference in PAFE is unknown and warrants further studies. 
Although multiple mechanisms of resistance to have been described and are being 
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reported that result in phenotypic resistance to azoles in A. fumigatus the effect of these 
mechanisms on the susceptibility of other antifungal drugs remains to be studied. Given 
the similar target an interaction between azoles and AMB can be anticipated. In addition, 
the interaction can evolve over time as was the case in our experiments.  
Furthermore, our results indicate that depending on the concentrations of AMB used 
different effects can be observed, which might explain the differences that have been 
reported in observations concerning interaction between azoles and AMB in fungal 
pathogens. 
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4.1. Summary 
 
The incidence of fungal infections, as well as the diversity of species involved, are 
increasing. In vitro susceptibility tests are tools to evaluate the activity of antifungal 
agents against fungi. However, despite large improvement of methodologies there may 
still be a lack of correlation between in vitro and in vivo results. 
The results of testing drugs at a constant concentration, which is the case when 
determining the minimal inhibitory concentration (MIC), minimal fungicidal 
concentration (MFC) or drug combinations might correspond better with clinical outcome 
with the addition of tests in which the action of the drug that persists despite washing is 
evaluated simulating the in vivo situation when the drug concentration falls below the 
MIC. These in vitro assays together could give more information about the activity of 
antifungal agents and correspond better with in vivo outcome. 
Therefore, Chapter 2-1 focuses on the identification and susceptibility testing of two 
new species belonging to the genus Exophiala. Black yeasts morphologically identified 
as “Exophiala spinifera” were re-analyzed on the basis of morphology, nutritional 
physiology and ITS rDNA sequencing data. SSU rDNA phylogeny data revealed that the 
strains analyzed were located at considerable distance from the E. spinifera clade 
containing the type strain. Using ITS rDNA sequencing, the strains could not be 
attributed to any existing species, and therefore two new species, E. attenuata and E. 
nishimurae were proposed. Antimycotic susceptibility data of these new species were 
generated and compared with those obtained in tests of members of the E. spinifera clade. 
E. attenuata had lower MIC values for fluconazole compared with E. nishimurae and E. 
spinifera. In contrast, amphotericin B and flucytosine were less active for E. attenuata 
than for E. nishimurae or E. spinifera. The most active drugs for the new species were 
itraconazole, voriconazole and terbinafine showing values similar to those of E. spinifera. 
In Chapter 2-2  the activity of six antifungal agents against clinical and environmental E. 
spinifera strains was evaluated applying different temperature regimens: 28 ºC, 35 ºC and 
37 ºC. We observed that the most active drug against E. spinifera was itraconazole 
against environmental as well as clinical strains regardless of the temperature of 
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incubation, with a geometric mean MIC of 0.04 and 0.06 µg/ml, respectively. 
Voriconazole and terbinafine were also active. Amphotericin B susceptibility values 
varied among the isolate classes, environmental vs clinical, with a geometric mean MIC 
at 35 ºC of 0.3 µg/ml for environmental isolates and of 0.9 µg/ml for clinical isolates. 
Differences were also seen in 5-fluocytosine MIC values which were 1.8 µg/ml for 
environmental and 5.7 µg/ml for clinical isolates respectively. In general, the activities of 
antifungal agents against environmental and clinical strains were closely comparable. 
In Chapter 2-3 , drug combinations were evaluated. Amphoteric in B was combined with 
flucytosine and ciprofloxacin, while itraconazole was combined with ciprofloxacin, 
levofloxacin, lomefloxacin and sulfadiazine against E. spinifera isolates. Synergistic 
effects were observed for the combinations of itraconazole plus  ciprofloxacin or 
levofloxacin, and amphotericin B plus ciprofloxacin and flucytosine. 
In Chapter 3-1 a novel method to evaluate post-antifungal effect (PAFE) in filamentous 
fungi was described. Due to technical problems such as the non-homogeneous growth of 
moulds in liquid media, colony count determination was not applicable for determining 
PAFE, which, in contrast, can be used for bacteria or yeasts. Therefore, for moulds, a 
spectrophotometric procedure was developed. The standard medium RPMI-1640 was 
used. Conidia were exposed to the drugs  at concentrations of 4, 1, and 0.25 times the 
MIC, each for  4, 2, and 1 h at 37°C. The same procedure was followed for  controls with 
drug-free medium. Following exposure, the conidia were washed, resuspended in RPMI -
1640 and then incubated in a spectrophotometric reader. The optical density (OD) was 
measured automatically at 10-min intervals, resulting in growth curves to quantify PAFE. 
OD0 was chosen as an arbitrary criterion due to several advantages that we observed. 
PAFE was defined as a significant delay in growth of exposed conidia compared with the 
non-exposed controls. Amphotericin B was found to induce PAFE against Aspergillus in 
a concentration dependent manner. No post drug exposure effects were observed 
following exposure to itraconazole. In Chapter 2-2 , using the method described above as 
a basis, PAFE of anfotericin B, itraconazol and terbinafine against E. spinifera was 
evaluated. PAFE was induced by amphotericin B only, with extended inhibition times 
seen at high drug concentrations. After 4 h of incubation at 4 times the MIC, 
amphotericin B induced significant PAFE against all strains with a mean of 16.2 h and a 
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range of 9.7 to 19 h. For 1 time the MIC, PAFE was induced against 7 of 11 strains tested 
with a mean of 9.8 h and a range of 1.6 to 16 h. For the other drugs PAFE was not 
observed.   
In Chapter 3-1 , the post drug exposure effects of amphotericin B and itraconazole were 
studied against fifteen clinical isolates of Aspergillus species, three isolates of A. 
fumigatus , A. flavus, A. terreus, A. nidulans, and A. ustus. PAFE was found to be 
concentration and time dependent. PAFE induced by amphotericin B was longer for A. 
fumigatus than for the other Aspergillus species, with mean PAFEs of 9.9 and 4.0 h after 
4 h and 2 h of exposure, respectively, to four  times the MIC. Itraconazole failed to induce 
a PAFE at any concentration tested and for any exposure time, even after exposure to  
concentrations  as high as 10, 20, and 50 times the MIC. 
In Chapter 3-2 , PAFE of amphotericin B and nystatin was evaluated against 30 
zygomycetes including Absidia corymbifera, Rhizopus oryzae , Rhizopus microsporus, 
Mucor spp and Rhizomucor spp., in two media: RPMI-1640 and antibiotic medium 3 
(AM3). Both drugs induced PAFE against all A. corymbifera strains at 4 and 1 times the 
MIC after 4 h exposure. However, for nystatin longer PAFEs were seen in AM3 for both 
concentrations than in RPMI-1640. PAFE was not induced by amphotericin B or nystatin 
after 1 h exposure. For Rhizopus spp. no differences in PAFE values were seen when both 
drugs were compared. Both drugs tended to induce longer PAFE in R. oryzae than in R. 
microsporus. For Mucor spp. nystatin tended to induce longer PAFE values than 
amphotericin B in the same medium. Both, amphotericin B and nystatin failed to induce 
PAFE in Rhizomucor strains. In RPMI-1640, for amphotericin B the rank order for PAFE 
was A. corymbifera > R. oryzae > Mucor sp. > R. microsporus and for nystatin the rank 
order was Mucor sp > R. oryzae > A. corymbifera > R. microsporus. 
In Chapter 3-3  the activity and PAFE of non-antifungal drugs is investigated. Two 
phenotiazines were evaluated based on their presumed antifungal acitivity against yeasts. 
The in vitro activity of chlorpromazine and trifluopherazine was evaluated against 
Aspergillus species, zygomycetes and Scedosporium species, 80 isolates in total. Both 
drugs inhibited the growth of all species tested at concentrations of 16 to 64 mg/L. 
Growth inhibition was also observed after exposure and removal of the drug (PAFE). For 
Aspergillus species the mean PAFE was 3.7 h and 4.7 h; for zygomycetes, 3.1 h and 3.4 
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h; for Scedosporium, 4.3 h and 5.3 h for chlorpromazine and trifluoroperazine, 
respectively. This observation indicates that these drugs inhibit the growth of moulds and 
might be of interest for antifungal drug discovery. 
In Chapter 3-4 , MIC, MFC and PAFE of amphotericin B , itraconazole and fluconazole  
were studied in nine clinical strains of A. fumigatus of which three were itraconazole 
susceptible (ISS), three itraconazole resistant (IRS) and three itraconazole mutants 
(IRM). The eva luation was carried out by pre-incubating all the strains at sub-inhibitory 
concentrations of itraconazole, amphotericin B and fluconazole and by comparing the 
results with those from the wild-type strains. 
The MICs and MFCs of amphotericin B were similar for the pre-incubated and wild-type 
strains. The MICs for itraconazole were similar after 1 week of pre -incubation although 
the MFC values for the ISS increased. However, after 8 weeks of pre -incubation the 
MICs of the ISS had also increased. When pre-incubated with fluconazole, the MICs of 
itraconazole for the non and pre-incubated strains were similar whereas the MFCs values 
were higher for the pre-incubated strains. Similar values in MICs and MFCs for 
itraconazole between non and pre-incubated strains was observed when the strains had 
been pre-incubated with amphotericin B. 
For the wild-type strains, PAFE was induced by amphotericin B at 4, 1 and 0.5 times the 
corresponding MIC but not by itraconazole or fluconazole. PAFE induced by 
amphotericin B against  pre-incubated strains, was observed for the ISS, IRM, IRS with 
longer values compared with the original strains, the exception was those strains pre-
incubated with itraconazole during 1 week at 1 and 0.5 times the MIC. In all cases, the 
effect was concentration dependent. In summary, the MFCs increased earlier than the 
MICs for itraconazole. For amphotericin B no differences were observed and PAFE was 
induced against both wild-type and the pre-incubated strains. 
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4.2. Samenvatting (Summary in Dutch) 
 
De problematiek van levensbedreigende schimmelinfecties neemt steeds verder toe, 
zowel in incidentie als met betrekking tot het aantal veroorzakende soorten. Een van de 
methoden om de activiteit van antifungale middelen te toetsen is de in vitro 
gevoeligheidsbepaling. Ondanks grote verbeteringen in de methodiek is er echter lang 
niet altijd een direkte correlatie tussen uitkomsten in vitro en in vivo.  
De resultaten van het testen van middelen bij een constante concentratie, zoals het geval 
is bij het bepalen van de minimale remmende concentratie (MIC), minimale fungicide 
concentratie (MFC) of combinaties van antifungale middelen, zouden beter met de 
klinische uitkomst kunnen corresponderen door het toevvegen van testen waarin de 
activiteit van het middel dat aanwezig blijft ondanks het wassen wordt geevalueerd. Dit 
bootst de in vivo situatie waarin de concentratie van het middel daalt beneden de MIC na. 
In combinatie leveren de verschillende in vitro tests meer informatie op over hun 
werkelijke activiteit, en weerspiegelen mogelijk de in vivo situatie beter.  
Hoofdstuk 2-1 behandelt identificatie en gevoeligheidsbepaling van twee nieuwe soorten 
van het geslacht Exophiala. Zwarte gisten die morfologisch werden geïdentificeerd  
als “Exophiala spinifera” werden opnieuw onderzocht op basis van morphologische 
gegevens, nutritieve fysiologie en ITS rDNA sequencing. Met fylogenie op basis van 
SSU rDNA bleek dat de onderzochte stammen op een aanmerkelijke afstand stonden van 
de E. spinifera clade, waarin zich de type-stam van de soort bevindt. Met ITS rDNA 
sequentiëring konden de stammen in geen enkele bestaande soort worden ingedeeld, en 
om die reden werden twee nieuwe soorten, E. attenuata en E. nishimurae, beschreven. 
Antimycotische gevoeligheidsbepalingen van deze nieuwe soorten werden uitgevoerd, en 
vergeleken met die van vertegenwoordigers van de E. spinifera clade. E. attenuata had 
lagere MIC waarden voor fluconazole dan E. nishimurae en E. spinifera. Amphotericine 
B en flucytosine waren daarentegen minder actief tegen E. attenuata dan tegen E. 
nishimurae of E. spinifera. De meest actieve stoffen tegen de nieuwe soorten waren 
itraconazole, voriconazole en terbinafine, met waarden die vergelijkbaar waren met die 
gevonden in E. spinifera. 
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In Hoofdstuk 2-2 werd de activiteit van zes antifungale middelen tegen klinische 
stammen van E. spinifera en stammen uit de omgeving getest bij verschillende 
temperaturen: 28 ºC, 35 ºC en 37 ºC. We stelden vast dat de stof met de hoogste activiteit 
tegen zowel omgevings- als klinische stammen van E. spinifera itraconazole was, 
onafhankelijk van incubatie-temperatuur, met geometrisch gemiddelde MICs van 
respectievelijk 0.04 en 0.06 µg/ml. Voriconazole en terbinafine waren eveneens 
werkzaam. Gevoeligheid voor amphotericin B verschilde tussen de groepen van isolaten, 
hetzij uit de omgeving of uit de kliniek, met een geometrisch gemiddelde MIC bij 35 ºC 
van 0.3 µg/ml voor omgevings-stammen en 0.9 µg/ml klinische isolaten. Verschillen 
werden ook waargenomen bij MIC waarden voor 5-flucytosine, welke 1.8 µg/ml waren 
voor stammen uit de omgeving en 5.7 µg/ml voor klinische isolaten. In het algemeen 
waren de resultaten met stammen uit de omgeving of uit de kliniek in hoge mate 
vergelijkbaar.  
In Hoofdstuk 2-3 werd amphotericine B gecombineerd toegediend met flucytosine en 
ciprofloxacin, en itraconazole met ciprofloxacin, levofloxacin, lomefloxacin en 
sulfadiazine; de combinaties werden gebruikt tegen isolaten van E. spinifera. 
Synergistisch effect werd waargenomen voor de combinaties van itraconazole met 
ciprofloxacin of levofloxacin, en amphotericin B met ciprofloxacin en flucytosine. 
In Hoofdstuk 3-1 werd een nieuwe methode geïntroduceerd om het post-antifungale 
effect (PAFE) in filamenteuze fungi te beschrijven. Door technische problemen, zoals de 
inhomogene groei van filamenteuze schimmels in vloeibaar medium, was het tellen van 
kolonies niet te gebruiken voor het vaststellen van PAFE, zoals dat wel goed te gebruiken 
is in bacteriën en gisten. Daarom werd een spectrofotometrische procedure ontwikkeld. 
Het standaard medium RPMI-1640 werd gebruikt. Suspensies van conidiën werden 
blootgesteld aan concentraties van 4, 1, en 0.25 maal de MIC, gedurende  4, 2, en 1 h bij 
37°C. Dit werd herhaald voor controles met medium zonder antifungale middelen. Na 
blootstelling werden de conidiën gewassen en werden de aantallen CFU per milliliter 
geteld. De conidiën werden vervolgens geïncubeerd in een spectrofotometer en de 
optische dichtheid (OD) werd automatisch elke 10 minuten gemeten; de resulterende 
groeicurven waren een maat voor de geconstateerde PAFE. OD0 was gekozen als een 
arbitrair citerium om verschillende redenen. PAFE werd gedefinieerd als een significante 
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remming van de groei in de blootgestelde conidiën-suspensie in vergelijking tot de niet -
blootgestelde controle-suspensies. Amphotericine B resulteerde in PAFE tegen 
Aspergillus species; de mate waarin PAFE werd waargenomen  was afhankelijk van de 
concentratie. Er werd geen effect geconstateerd na incubatie met itraconazole.  
In Hoofdstuk 2-2 werd PAFE in E. spinifera gemeten, aan de hand van de hierboven 
beschreven methode. PAFE werd alleen geconstateerd met amphotericine B, vooral als 
hogere concentraties van het middel werden gebruikt. Na 4 uur incubatie met 4 maal de 
MIC concentratie amphotericine B werd inderdaad significante PAFE waargenomen in 
alle stammen, met een gemiddelde van 16.2 uur en een spreiding van 9.7 tot 19 uur. Bij 
een concentratie gelijk aan de MIC was PAFE waarneembaar in 7 van de 11 geteste 
stammen, met een gemiddelde van 9.8 uur en een spreiding van 1.6 tot 16 uur. Bij de 
overige gesteste antifungale middelen werd geen PAFE geconstateerd. 
In Hoofdtuk 3-1 werden de post-antifungale effecten van amphotericine B and 
itraconazole bestudeerd tegen vijftien klinische isolaten van diverse Aspergillus soorten, 
namelijk drie isolaten per species van A. fumigatus, A. flavus, A. terreus, A. nidulans, en 
A. ustus. PAFE bleek afhankelijk te zijn van concentratie en incubatieduur. De door 
amphotericine B geïnduceerde PAFE was langer bij A. fumigatus dan bij andere 
Aspergillus species, met gemiddelde PAFEs van respectievelijk 9.9 en 4.0 uur na 4 en 2 
uur incubatie, tot vier maal de MIC. Met itraconazole was bij geen enkele concentratie of 
incubatietijd enige PAFE waarneembaar, zelfs niet bij blootstelling aan concentraties van 
10, 20 en 50 maal de MIC. 
In Hoofdstuk 3-2 werd PAFE van amphotericine B en nystatine geëvalueerd tegen 30 
zygomyceten, waaronder Absidia corymbifera, Rhizopus oryzae , Rhizopus microsporus, 
Mucor spp. en Rhizomucor spp. Bij beide middelen werd PAFE geconstateerd in alle 
stammen van A. corymbifera bij 4 maal resp. eenmaal de MIC na 4 uur incubatie in 
hetzelfde medium. Bij nystatine werden echter bij beide concentraties langere PAFEs 
waargenomen in antibiotisch medium 3 (AM3) dan in RPMI -1640. PAFE werd niet 
waargenomen in amphotericine B of nystatine na 1 uur blootstelling. Voor Rhizopus spp. 
werden tussen beide componenten geen verschil in PAFE waarden geconstateerd. Beide 
stoffen induceerden langere PAFE in R. oryzae dan in R. microsporus. In Mucor spp. was 
PAFE in het algemeen groter met nystatine dan met amphotericine B in hetzelfde 
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medium. Zowel amphotericine B als nystatine induceerden geen PAFE in stammen van 
Rhizomucor. In RPMI-1640 was voor amphotericine de volgorde in afnemend PAFE B 
alsvolgt: A. corymbifera > R. oryzae > Mucor sp. > R. microsporus. Voor nystatine was 
deze Mucor sp > R. oryzae > A. corymbifera > R. microsporus. 
In Hoofdstuk 3-3 werd de werkzaamheid en PAFE van minder gebruikelijke antifungale 
middelen onderzocht. Twee phenotiazines werden geëvalueerd op grond van hun 
veronderstelde activiteit tegen gisten. De in vitro activiteit van chlorpromazine en 
trifluopherazine tegen Aspergillus species, zygomyceten en Scedosporium species werd 
onderzocht aan de hand van in totaal 80 isolaten. Beide stoffen remden de groei van alle 
geteste soorten bij concentraties van 16 tot 64 mg/L. Groeiremming werd eveneens 
waargenomen na incubatie met, en na verwijdering van de componenten (PAFE). In 
Aspergillus species was de gemiddelde PAFE voor chlorpromazine en trifluoroperazine 
respectievelijk 3.7 en 4.7 uur, in zygomyceten 3.1 en 3.4 uur, en in Scedosporium 4.3 en 
5.3 uur. Deze resultaten laten zien dat de componenten inderdaad de groei van schimmels 
kunnen remmen, en dat ze dus van belang kunnen zijn bij het zoeken naar nieuwe 
antifungale middelen.  
In Hoofdstuk 3-4 werden MIC, MFC en PAFE bestudeerd voor amphotericine B, 
itraconazole and fluconazole in negen klinische isolaten van A. fumigatus, waarvan drie 
gevoelig waren voor itraconazole (ISS), drie resistent tegen dit middel (IRS), en drie 
itraconazole mutanten (IRM). Het onderzoek werd gestart met voorincubatie van alle 
stammen bij concentraties beneden MIC voor itraconazole, amphotericine B en 
fluconazole, en de resultaten werden vergeleken met die van de wild-type stammen. De 
MICs en MFCs voor amphotericine B waren vrijwel gelijk in de voorgeïncubeerde en de 
wild-type stammen. De MICs voor ITZ waren gelijk na 1 week voorincubatie, hoewel de 
MFC waarden bij de ISS stammen stegen. Na 8 weken voorincubatie stegen ook de MICs 
van de ISS stammen. Na voorincubatie met fluconazole waren de MICs voor itraconazole 
in de niet resp. wel voor-geïncubeerde stammen aan elkaar gelijk, terwijl de MFC 
waarden in de voorgeïncubeerde stammen hoger waren. Soortgelijke resultaten met MIC 
en MFC voor itraconazole tussen al of niet voorgeïncubeerde stammen wanneer de voor -
incubatie had plaatsgevonden met amphotericine B. In de wild-type stammen werd PAFE 
gestimuleerd door amphotericine B in concentraties van 4, 1 en 0,5 maal de 
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oorspronkelijke MIC, maar dat gold niet voor itraconazole en fluconazole. Het feit dat 
PAFE wordt gegenereerd door amphotericin B in voorgeïncubeerde stammen werd 
waargenomen in de ISS, IRM en IRS, waar de waarden langer waren dan in de 
oorspronkelijke stammen, met als uitzondering de stammen voor-geïncubeerd met 
itraconazole gedurende 1 week bij concentraties van 1 en 0.5 maal de MIC. In alle 
gevallen was het effect afhankelijk van de concentratie. Samengevat stijgen de MFCs 
voor itraconazole eerder dan de MICs voor dit middel. In amphotericine B werden geen 
verschillen waargenomen en werd PAFE geïnduceerd in zowel het wild-type als in de 
voorgeïncubeerde stammen.  
 
4.3. Resumen (Summary in Spanish) 
La incidencia de infecciones fúngicas se han incrementado, como así también las 
diversidad de especies involucradas. Los tests de susceptibilidad in vitro son herramientas 
para evaluar la actividad antifúngica frente a hongos. Sin embargo y a pesar de los 
adelantos y mejoras en las metodologías empleadas, sigue existiendo un problema de la 
falta de correlación de los resultados in vitro e in vivo.  
Los resultados obtenidos al evaluar concentraciones constantes de una droga, como serían 
la determinación de la concentración inhibitoria mínima (CIM), la concentración 
fungicida mínima (CFM) o las combinaciones de drogas, tal vez correlacionarían mejor 
con el resultado del tratamiento clínico,  si se adicionaran tests en donde la acción de la 
droga persista después de ser eliminada, simulando la situación in vivo , en la cual la 
concentración de la droga disminuye por debajo de la CIM. Todos éstos tests juntos 
podrían dar más información acerca de la actividad antifúngica y correlacionar mejor con 
la clínica. 
Por lo tanto, el Capítulo 2-1 , se basa en la identificación y el estudio de susceptibilidad 
antifúngica de dos nuevas especies pertenecientes al género Exophiala. Las levaduras 
negras pre-identificadas como Exophiala spinifera , fueron re-analizadas en base a 
estudios morfológicos, fisiológicos y de secuenciación (ITS rDNA). Los datos 
filogenéticos obtenidos de SSU rDNA, revelaron que las cepas analizadas se encontraban 
distanciados considerablemente respecto del grupo  Exophiala spinifera. Los datos 
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obtenidos de los estudios de secuenciación (ITS rDNA), demostraron que las cepas 
estudiadas no se podían relacionar con ninguna cepa existente, por lo que, E. attenuata y 
E. nishimurae han sido propuestas como dos nuevas especies. Paralelamente se han 
realizado estudios de susceptibilidad antifúngica de las nuevas especies mencionadas y se 
compararon los resultados con las cepas de E. spinifera. Se observó que E. attenuata 
presentaba valores de CIM más bajos para fluconazol comparándola con los obtenidos 
para E. nishimurae y E. spinifera. Por el contrario, anfotericina B y flucitocina fueron 
menos activas para E. attenuata, al compararla con los resultados observados para E. 
nishimurae o E. spinifera. 
Las drogas más activas para las nuevas especies han sido itraconazol, voriconazol y 
terbinafina con valores similares a los obtenidos para E. spinifera. 
En el Capítulo 2-2 se estudió la actividad de seis agentes antifúngicos en cepas 
ambientales y clínicas de E. spinifera, utilizándose distintos regímenes de temperaturas: 
28 ºC, 35 ºC y 37 ºC. Se observó que la droga más activa tanto para las cepas ambientales 
como para las clínicas fue itraconazol para todas las temperaturas, con una media 
geométrica de CIM de 0.04 y 0.06 µg/ml, respectivamente. 
También se observó que voriconazol y terbinafina fueron activas. En el caso de 
anfotericina B se obtuvieron algunas diferencias entre las cepas ambientales y clínicas, 
con una media geométrica de CIM a 35 ºC de 0.3 µg/ml para las cepas ambientales y de 
0.9 µg/ml para las cepas clínicas. También se observaron diferencias en el caso de 
flucitocina con valores de CIM de 1.8 µg/ml y 5.7 µg/ml para las cepas ambientales y 
clínicas, respectivamente. En general, la actividad de los agentes antifúngicos fue 
comparable entre las cepas ambientales y clínicas. 
En el Capítulo 2-3 , se estudiaron drogas en combinación. Para ello, anfotericina B se 
combinó con flucitocina y ciprofloxacina, mientras que itraconazole se combinó con 
ciprofloxacina, levofloxacina, lomefloxacina y sulfadiazina contra E. spinifera. Se 
observó efecto sinérgico para las combinaciones entre itraconazol y ciprofloxacina o 
levofloxacina y para la combinación entre anfotericina B y ciprofloxacina o flucitocina. 
En el Captítulo 3-1 , se describió un nuevo método para la evaluación del efecto post -
antifúngico (PAFE), en hongos filamentosos. Este efecto puede evaluarse tanto para 
levaduras como bacterias utilizando la técnica de recuento de unidades formadoras de 
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colonias. En el caso de los hongos filamentosos, debido a problemas técnicos como ser su 
crecimiento no homogéneo en medios líquidos, la técnica de recuento mencionada 
anteriormente no puede aplicarse. Por lo tanto, para hongos filamentosos, se desarrolló un 
método espectrofotométrico. Se utilizó el medio de cultivo estándar, RPMI -1640. Las 
conidias fueron expuestas a los agentes antifúngicos a concentraciones correspondientes a 
4, 1 y 0.25 veces la CIM. El tiempo de incubación para cada caso ha sido 4, 2 y 1 hora a 
37 ºC. El mismo procedimiento se realizó con los controles, para los cuales no se 
adicionó droga al medio de cultivo. Luego de la incubación, las conidias fueron lavadas, 
resuspendidas en el medio RPMI-1640 e incubadas en un lector espectrofotométrico, el 
cual realiza mediciones de la densidad óptica (OD) automáticamente en intervalos de 10 
minutos. La resultante de estas mediciones es una curva de crecimiento del hongo que fue 
utilizada para calcular el valor del PAFE. La OD0, fue elegida arbitrariamente como 
criterio de cálculo. El PAFE se ha definido como la diferencia en tiempo de crecimiento 
entre la OD0 de las conidias tratadas con el agente antifúngico y la OD0 del control 
correspondiente. Se observó que anfotericna B ha sido capaz de inducir PAFE en 
Aspergillus y fue concentración dependiente. Por otro lado, con itraconazol el effecto no 
fue observado.  
En el Capítulo 2-2 , se evaluó el PAFE de anfotericina B en E. spinifera, utilizando como 
base el método descripto anteriormente. El PAFE inducido por anfotericina B fue 
concentración dependiente luego de una exposición de 4 horas a 4 veces la concentración 
de la CIM. Anfotericina B indujo PAFE para todas las cepas evaluadas con una media de 
16.2 h y un rango de 9.7 a 19 h. Considerando la exposición de 1 vez la CIM, el PAFE 
fue inducido en 7 cepas de las 11 estudiadas con una media de 9.8 h y un rango de 1.6 a 
16 h. Para las otras drogas analizadas como itraconazol y terbinafina, el efecto no se 
observó.  
En el Capítulo 3-1 , se estudió el PAFE de anfotericina B e itraconazol en quince cepas 
clínicas de especies de Aspergillus , de las cuales 3 han sido cepas de A. fumigatus, 3 de A. 
flavus, 3 de A. terreus y 3 de A. ustus. Se observó también en esta ocasión que el PAFE 
fue concentración y tiempo dependiente. Anfotericna B ha inducido PAFE, más 
prolongado para A. fumigatus , al comparar esta especie con las demás, con una media de 
9.9 h y 4 h luego de 4 h y 2 h de exposición, respectivamente, a 4 veces la CIM. Para 
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itraconazol, no se ha observado PAFE aún cuando la exposición se realizó a 
concentraciones tan altas como 10, 20 y 50 veces la CIM. 
En el Capítulo 3-2 , se estudió el PAFE de anfotericina B y nistatina a 30 zygomycetes, 
utilizando dos medios de cultivos, RPMI-1640 y AM3. Se han incluído: Absidia 
corymbifera, Rhizopus oryzae, Rhizopus microsporus, Mucor spp y Rhizomucor spp. 
Analizando cada medio de cultivo, se ha observado PAFE para ambas drogas en Absidia 
corymbifera luego de 4 h de exposición a concentraciones de 4 y 1 vez la CIM. Sin 
embargo, al comparar los dos medios, se ha observado que nistatina ha inducido un 
PAFE más prolongado en AM3 que en RPMI-1640 para ambas concentraciones. Luego 
de 1 h de incubación, no se ha observado PAFE para ninguna de las dos drogas 
estudiadas. En el caso de Rhizopus spp., ambas drogas han inducido valores de PAFE 
similares. En general, el PAFE fue más prolongado para R. oryzae que para R. 
microsporus. Comparando ambas drogas en el mismo medio de cultivo, se han observado 
valores más prolongados de PAFE para nistatina en Mucor spp. Por otro lado, en 
Rhizomucor spp., no se ha observado el efecto. 
En RPMI-1640 los valores de PAFE para anfotericina B fueron en orden decreciente: A. 
corymbifera > R. oryzae > Mucor  sp. > R. microsporus y para nistatina: Mucor sp > R. 
oryzae > A. corymbifera > R. microsporus. 
En el Capítulo 3-3 , se han investigado la actividad antifúngica y el PAFE de  drogas no 
antifúngicas. Para ello, se han elegido dos fenotiazinas dada su presunta actividad 
antifúngica en levaduras. Se evaluó in vitro la susceptibilidad de clorpromazina y 
trifluperazina en 80 aislamientos incluyendo los siguientes microorganismos: Aspergillus 
species, zygomycetes y Scedosporium species. Ambas drogas inhibieron el crecimiento 
de los hongos a concentraciones de 16 hasta 64 mg/L. Se observó la presencia de PAFE 
para clorpromazina y trifluperazina en Aspergillus spp. (media de 3.7 h y 4.7 h); en 
zygomycetes (media 3.1 h y 3.4 h) y en Scedosporium spp. (media 4.3 h y 5.3 h), 
respectivamente. Estas observaciones indicarían que estas drogas son capaces de inhibir 
el crecimiento e inducir PAFE en estos hongos filamentosos, pudiendo representar drogas 
potenciales en el desarrollo de nuevos compuestos antifúngicos. 
En el Capítulo 3-4 , se evaluó la CIM, CFM y el PAFE de anfotericina B, itraconazol y 
fluconazol en nueve cepas clínicas de A. fumigatus. Entre éstas cepas, 3 fueron sensibles 
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a itraconazol (ISS), 3 fueron resistentes a itraconazol (IRS) y 3 fueron cepas mutadas en 
el laboratorio, resistentes a itraconazol (IRM). La evaluación se ha realizado pre -
incubando todas las cepas a concentraciones sub-inhibitorias de itraconazol, anfotericina 
B y fluconazol. Los resulatdos obtenidos han sido comparados con las cepas sin pre -
incubar. 
La CIM y la CFM de anfotericina B fue similar entre las cepas pre-incubadas y aquellas 
no pre-incubadas. La CIM de itraconazol para las cepas pre-incubadas luego de 1 semana 
fue similar aunque la CFM se ha elevado en las cepas ISS. Sin mebargo, la CIM en éstas 
cepas también se elevó luego de 8 semanas de incubación. En el caso de la pre -
incubación con fluconazol, los valores de CIM a itraconazol han sido similares tanto para 
las cepas pre-incubadas como para las cepas no pre-incubadas, mientras que los valores 
de la CFM se ha elevado para las cepas pre-incubadas. Por otro lado, se han observado 
valores similares tanto en la CIM como en la CFM para ambos grupos (cepas sin pre-
incubar y cepas pre-incubadas), cuando han sido incubadas con anfotericina B. 
Para las cepas no pre-incubadas, se ha observado que anfotericina B indujo PAFE a 
concentraciones de 4, 1 y 0.5 veces la CIM, mientras que, tanto itraconazol como 
fluconazol no han inducido PAFE. Anfotericina B indujo PAFE en las cepas ISS, IRM y 
IRS, se obtuvieron valores más prolongados que aquellos observados en las cepas sin pre -
incubar, a excepción de las cepas pre-incubadas con itraconazol durante 1 semana a 
concentraciones de 1 y 0.5 veces la CIM. En todos los casos, el PAFE ha sido 
concentración dependiente. En conclusión, la CFM para itraconazol, se elevó primero que 
la correspondiente CIM; en el caso de anfotericina B no se han observado diferencias y el 
PAFE fue inducido para ambos grupos de cepas: aquellas pre -incubadas y aquellas sin 
incubar.  
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4.4. Future perspectives 
 
The increment of fungal infections, the deterioration in host defenses due to 
several factors, the limited number of antifungal drugs, the adverse effects particularly 
associated with amphotericin B, the time of diagnosis, non-specific clinical 
manifestations, and site of infection makes that treatment failure is frequently observed 
highlighting the need to better understand the pathogenesis of invasive fungal infections. 
In this thesis different studies are described that investigate the in vitro activity of drugs 
with antifungal activity against fungi and methods which can be used to investigate 
antifungal activity in vitro. 
Basic to successful treatment is the correct identification of pathogenic fungi. For 
example, empiric therapy with amphotericin B might be necessary in an 
immunocompromised patient with the typical fever that persists despite antibiotic 
treatment, because of the suspicion of Aspergillus infection. Correct identification of an 
isolate from this patient is vital since other fungi resistant to amphotericin B such as 
Scedosporium could be the cause. The sole recognition of hyphae is not enough and 
culture eventually supplemented by molecular analysis is necessary for the correct 
identification.   
Taken into account the limited efficacy of antifungals available, investigations of 
conventional and new antifungal drugs are important as well as  alternative agents as 
antibiotics or other group of drugs, alone or in combination might give novel approaches 
to therapy. 
The study of post drug-exposure effects could have an impact for dosing 
regimens. Drugs that demonstrate post drug effect might require less frequent 
administration, with the consequent reduction of adverse effects. The in vitro experiments 
described in this thesis are a first step in the study of post drug exposure effects in moulds 
which needs validation in in vivo models. 
In this thesis, not only the activity of current antifungal drugs was evaluated but 
also the activity of antibiotics such as quinolones combined with conventional antifungal 
drugs was studied in black yeasts. It has been demonstrated that quinolones augment the 
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activity of amphotericin B and azoles (6, 7). In addition, the combination of fluconazole 
with ciprofloxacin was observed to be more effective in a mouse model of invasive 
candidiasis (7). Our studies demonstrate that this combination could interact 
synergistically in Exophiala. Animal models need to be performed in order to confirm the 
in vitro findings.  
Other non-antifungal drugs that exhibit antimicrobial activity are antiphychotic 
drugs which have been shown to be active against bacteria and yeasts including Candida 
or Cryptococcus. Activity was demonstrated in vitro as well as in animal models (1, 2). In 
this study, chlorpromazine and trifluoroperazine showed activity against filamentous 
fungi and also induced post antifungal effect These drugs are not suitable for treatment of 
invasive fungal infection due to the neuroleptic side effects and non-specific activity 
against eukaryotic cells. However, the mechanism of action should be explored further 
since the drug might interact with the calcium metabolism of the fungus which is new 
target. Furthermore, the existence of the cis and trans stereoisomerism in phenotiazine 
compounds is described, for which only the cis form possesses neuroleptic activity, but 
both the cis and trans forms have equal antimicrobial potency (4). 
Patients are exposed to antifungal agents in a prophylactic setting which is 
followed by treatment with another drug when a breakthrough fungal infection is 
suspected. The activity of the second antifungal agent could be augmented by exposure of 
the fungus to the first. The studies performed in this thesis indicate that exposure of 
Aspergillus to itraconazole changes the ability of amphotericin B to induce PAFE in 
vitro. Although the mechanism by which this occurs was not studied one could 
hypothesize that the ergosterol contents in the cell membrane is altered in quantity or 
quality following the exposure to itraconazole after long exposure period thereby altering 
the target for amphotericin B.  Our studies further show that resistance to itraconazole 
was first detected by increase of MFC followed by an increase of MIC. The 
appropriateness of MFC testing for detecting resistance in moulds needs further study as 
well as the correlation with clinical response. The strains with increased MIC and MFC 
need further analysis in order to establish which mechanism is related to the observed 
changes.  
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Finally, further steps are needed to confirm the post drug exposure  effects in 
different filamentous fungi, as described in this thesis . Some in vitro factors could be 
involved in the determination of PAFE such variation of pH, temperature of incubation, 
presence of serum, mechanism of action of the drug tested and others. Further studies are 
required to study the impact of these factors and other parameters on the PAFE. For 
example for Candida it was observed that the presence of serum or leucocytes enhanced 
the PAFE induced by amphotericin B (3, 5). 
The spectrophotometric system can be used to study the impact of sequential exposure of 
moulds to different antifungals or the effect of drug exposure at different stages of growth  
Finally, animal experiments should also be performed to confirm these in vitro  
findings to evaluate the impact of PAFE in filamentous fungi on dosing regimens of 
antifungal agents. The technical problems in establishing fungal burden in tissue can be 
overcome by quantitative PCR techniques.  
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